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Herpes simplex virus type 1 replicates its DNA and builds progeny nucleocapsids in the nucleus 
of the infected cell.  Replicated viral DNA is a concatemer that is cleaved to unit-length genomes 
and packaged into capsid precursors, and successful DNA packaging is required for the mature 
capsid to exit the nucleus and become incorporated into virions.  The DNA cleavage and 
packaging machinery is highly conserved across herpesvirus subfamilies; they represent novel 
targets for anti-herpesviral treatments.  Seven genes have been identified that are essential for the 
packaging reaction.  Of these, the UL25 gene product is unique because it is required for the 
completion rather than the initiation of DNA packaging.  In the absence of functional UL25, the 
nuclei of infected cells accumulate empty capsids and free, close to genome-length viral DNA.  
This phenotype differs from null mutations of the other packaging genes, which block cleavage 
of the concatemer and expulsion of the capsid scaffold protein.  While the functions of several 
members of the packaging machinery have been deduced by analogy with the dsDNA 
bacteriophages, the role of UL25 protein (pUL25) in this process is unclear. pUL25 is stably 
associated with the capsid vertices, where it forms a heterodimer with the packaging protein 
UL17.  The goal of this project is to elucidate the pUL25 capsid-binding mechanism and its 
significance for DNA packaging and virion assembly. Mutational analysis of UL25 mapped the 
capsid-binding domain to the pUL25 N-terminus. pUL25 interactions with the capsid surface 
proteins were visualized with cryo-electron microscopy and 3D image reconstructions of capsids 
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containing pUL25 fusion proteins. Finally, we demonstrated that UL25 mutants aberrantly 
cleave viral DNA before the second packaging signal. These data support a model in which 
pUL25 provides structural support to capsid vertices without interacting directly with DNA 
during the packaging reaction. 
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a lowercase “v”.  Proteins are designated by their gene name preceded by a lowercase “p”. 
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1.0  INTRODUCTION 
1.1 HERPESVIRUSES AND DISEASE 
The herpesviruses are a large group of animal viruses that infect many different vertebrate and 
one identified invertebrate species.  The prototypical herpesvirus can be recognized by its virion 
morphology, and particularly, by the shape and size of the nucleocapsid.  Negative staining and 
electron microscopy revealed that the herpesvirus virion is approximately 200 nm in diameter 
and contains an angular nucleocapsid, a protein tegument layer, and a glycoprotein-studded lipid 
envelope; the capsid is made of 162 capsomers that form an icosahedron of around 100 nm 
(238).  Inside the nucleocapsid, herpesviruses have large (124-241 kbp), linear, double-stranded 
DNA (dsDNA) genomes. Recent approaches to herpesvirus classification have relied on 
comparative genomic and structural analysis (120). In the current nomenclature, three families of 
herpesviruses infecting different classes of animal hosts—the Herpesviridae, the 
Alloherpesviridae, and the Malacoherpesviridae—constitute the order Herpesvirales (Table 1). 
In addition to sharing a common evolutionary lineage, members of Herpesvirales are also 
predicted to share ancestry with the tailed dsDNA bacteriophages due to the commonalities in 
structure of the major capsid protein and the capsid portal (10, 120). 
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TABLE 1. The order Herpesvirales. 
Family Host classes 
Herpesviridae Mammals, reptiles, birds 
Alloherpesviridae Amphibians, fish 
Malacoherpesviridae mollusk 
 
Herpesviruses are further divided into three subfamilies—the alphaherpesvirinae, the 
betaherpesvirinae, and the gammaherpesvirinae.  These classifications were initially based on 
biological similarities and later adapted to accommodate genome sequence homology (181, 182). 
Phylogenetic analyses of the sequences encoding the viral DNA polymerase have shown that the 
last common ancestor of the Herpesviridae subfamilies existed about 400 million years ago, 
indicating that viruses from the same subfamily that infect different host species are more closely 
related than viruses of different families infecting the same host (119, 120).  While acute disease 
manifestations between subfamilies vary, the herpesviruses have in common the ability to 
establish latent infections that can be periodically reactivated to the lytic cycle to cause recurrent 
disease. Eight human herpesviruses have been identified that fall into the three subfamilies 
(Table 2).  The alphaherpesviruses have a rapid lytic replication cycle and typically establish 
latency in sensory neurons.  Beta- and gammaherpesviruses are slower to replicate and target 
lymphoid tissue for latency. By serological testing for herpesvirus antibodies, it has been 
demonstrated that all of the human herpesviruses are fairly ubiquitous in the adult population 
(Table 2).   
Like most microbial infections, the severity and resolution of herpesvirus lytic infections 
are largely dependent on host immunity [reviewed in (58, 96, 210)]. The majority of healthy 
individuals resolve the acute infection without serious complications. Populations at risk for life-
threatening disease are those with undeveloped or waning immunity—neonates, the elderly, and 
immunocompromised patients with AIDS or undergoing transplantation and chemotherapy.  In 
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these individuals, recurrent and/or disseminated infections can lead to virus invasion of the 
central nervous system (CNS), resulting in lethal encephalitis or meningitis. HSV-1 and HSV-2 
invasion of the CNS is rare; CNS disease results most often from infection with CMV, but also 
with VZV, EBV, and HHV6. Less lethal but important for the elderly population are recurrent 
ocular HSV-1 infections, leading to corneal obstruction and blindness, and chronic pain 
(neuralgia) after the acute infection of HSV-1, HSV-2, or VZV is cleared.  
 
TABLE 2. Human Herpesviruses 
VirusA Common name Sub-FamilyB 
Prevalence 
(%)C Acute/Recurrent Disease Site of latency 
HHV 1 Herpes simplex virus 1 (HSV-1) α 65 
Orofacial lesions,  
ocular stromal keratitis 
Sensory 
ganglia 
HHV 2 Herpes simplex virus 2 (HSV-2) α 22-26 
Genital lesions Sensory ganglia 
HHV 3 Varicella zoster virus (VZV) α >95 
Chicken pox, shingles Sensory ganglia 
HHV 4 Epstein-Barr virus (EBV) γ >90 
Mononucleosis, 
lymphoproliferative disease Lymphocytes 
HHV 5 Cytomegalovirus (CMV) β 54-91D 
Mononucleosis CD4 T cells 
HHV 6  β >95 Roseola infantum CD4 T cells 
HHV 7  β 75-85 Roseola infantum B cells 
HHV 8 Kaposi’s sarcoma herpes virus γ 8 
Kaposi’s sarcoma,  
lymphoproliferative disease  Lymphocytes 
 
A HHV, Human herpesvirus.  
B α, β, and γ are abbreviations of alphaherpesvirinae, etc. 
C Prevalence indicates the percentage of blood donors that tested positive for antisera specific to 
each virus. Statistics are from adults in the United States (age  ≥ 30 years) in references (40, 101, 
172, 200, 243).   
D increases with age from 54 % at age 30 to 91 at age 80. 
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1.2 HSV-1 PATHOGENESIS 
The progression of HSV-1 disease follows three stages—primary infection, latency, and 
reactivation—which have been described in detail (8, 182). HSV-1 infection begins with the 
transmission of virus particles to naïve mucosa or abraded skin that are in direct contact with 
infected mucosa. The primary infection can be asymptomatic or result in the appearance of skin 
lesions at the site of virus acquisition.  The occurrence of symptoms is usually associated with   
higher viral burden and/or an immunocompromised state in the host.  Disseminated primary 
infection is rare, but it can occur in neonates that acquire HSV-1 during delivery.  In these cases, 
the spread of virus into the CNS can lead to encephalitis, serious neurological damage, and 
death.  During initial replication in the mucosal epithelium, the virus is able to infect sensory 
neurons innervating the tissue. By retrograde movement along the axon, HSV-1 spreads into the 
neuron cell body, which is located in a mass of neuron cell bodies (trigeminal ganglion) at the 
base of the skull. When virus reaches the ganglion, an initial round of virus replication is 
followed by the cessation of productive infection. The virus enters a dormant or latent state 
within the infected neuron cell body. During latency, the viral genome is maintained as a 
circular, histone-associated episome, and viral gene expression is restricted to a small set of 
latency-associated transcripts (LATs) that are not translated into protein (45, 87, 91, 203). There 
is increasing evidence that host immune surveillance of the ganglion induces and maintains 
latency (62, 63, 95).   
HSV-1 latent infection is maintained for the lifetime of the host and can periodically be 
reactivated to the lytic replicative cycle.  Reactivation is associated with physical trauma, 
environmental stress, emotional stress, or other events that downregulate host immunity (41, 153, 
185).  Some individuals may never reactivate virus replication.  In healthy individuals, 
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reactivations are transient events, but it is a prolonged state in immunocompromised patients. 
After reactivation of lytic gene expression, new virus particles are synthesized, and they travel 
anterograde down the neuron axons.  The newly synthesized virus is released from the nerve 
endings into the mucosal epithelium, which results in virus shedding, and potentially the 
recurrence of lesions, at or near the primary site of infection. Recurrent HSV-1 infection 
produces lesions around the mouth and lips (herpes labialis) and is also increasingly associated 
with genital lesions. These symptoms are usually mild and clear within two weeks.  
Immunocompromised patients are at greater risk for severe lesions and disseminated infection 
causing more serious complications in the CNS or other organs.  Other types of recurrent herpes 
infection include herpetic whitlow—lesions on the hands or fingers—and keratitis of the cornea. 
Repeated HSV-1 infection and immune infiltration of the cornea can eventually cause blindness. 
At present, all of the antiviral pharmaceuticals that are available for the treatment of 
HSV-1 target the viral DNA replication machinery (13, 58, 210). Acyclovir (ACV) is an acyclic 
nucleoside analogue that terminates DNA replication when it is incorporated into newly 
replicated DNA.  ACV is specifically phosphorylated by the viral thymidine kinase (TK), so it is 
only activated and incorporated into viral DNA in infected cells. However, ACV is a poor drug 
because it requires frequent dosage; the ACV derivatives famcyclovir and valacyclovir have 
greater efficacy. Frequently, in immunocompromised patients taking ACV regimens, the virus 
acquires ACV-resistance mutations that map to TK or the viral DNA polymerase (58).  Foscarnet 
and cidofovir are two alternative drugs, but both are very cytotoxic. Foscarnet and cidofovir 
target the viral DNA polymerase at the pyrophosphate binding site and the nucleoside-binding 
site, respectively.  Recent investigation of HSV-1 antivirals has identified potential new targets 
within the DNA replication machinery: the helicase-primase complex of the virus proteins UL5, 
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UL8, UL52; the ribonucleotide reductase kinase domain; and interaction domains of the DNA 
polymerase subunits UL30 and UL42 (13). 
1.3 THE HSV-1 PARTICLE 
The HSV-1 virion consists of a double-stranded DNA genome, nucleocapsid, tegument layer, 
and a glycoprotein-studded lipid envelope (Figure 1). The tegument is a distinctive feature of 
herpesviruses, and it is a collection of proteins—both viral and cellular—that fills the space 
between the envelope and the nucleocapsid (or “capsid”). A recent study used mass spectroscopy 
(MS) to define the polypeptide content of purified extracellular virions; each of the identified 
proteins was validated by cross-referencing previously published data or by Western blot 
analysis (112).  The host-derived lipid envelope contains 13 viral glycoproteins, and the 
tegument contains 23 viral proteins, including the viral transactivator proteins ICP0, ICP4, and 
VP16.  Additionally, the MS analysis identified 49 human cell-derived proteins in the tegument, 
which included the transcription initiation factor eIF4H and components of the cell cytoskeleton.  
The tegument is generally asymmetric but can be regularly ordered around the capsid vertices 
(73, 253).  
The capsid is 125nm in diameter and conforms to icosahedral symmetry, such that it has 
20 faces and 12 vertices (see Section 1.5 for a detailed description of capsid structure and 
formation). The 162 capsomers are arranged to produce a triangulation number (T) of 16.  Most 
of the capsomers are formed by the major capsid protein, UL19 (VP5), which is assembled into 
5- and 6-membered rings (pentons and hexons). Pentons and hexons form the vertices and faces 
of the shell, respectively.  At one vertex of the capsid, the penton is replaced with the DNA 
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portal complex, which is a dodecamer ring of UL6 protein (143, 221). The minor capsid proteins 
UL38 (VP19c) and UL18 (VP23) form a heterotrimeric complex (“triplex”) that enhances the 
connections between hexons and pentons.  Each triplex contains, on average, 2 copies of VP23 
and one copy of VP19c (145).  Another minor capsid protein, UL35 (VP26), is located at the tips 
of hexons.  
 
Figure 1. The HSV-1 virion. From Principles of Virology, 2nd ed. (59) 
 
Enclosed within the capsid is the 152 kbp, double-stranded DNA genome, which is 
highly compressed and devoid of protein (16, 253). The genome consists of two segments of 
unique sequence—the unique long (UL) and unique short (US) regions—that are flanked by 
repeat sequences (231) (Figure 2). Recombination between the terminal and internal repeat 
sequences generates four isomers in which the UL and US segments are in different orientations 
with respect to each other; the isomers are found in equal proportion in infected cells and virions 
(75, 128). The long repeat, or b sequence, is approximately 10kbp, and it contains the coding 
sequences for the viral transactivators protein ICP0 and the latency-associated transcript (LAT).  
The short repeat, or c sequence, flanks the US segment and contains the ORF for the viral 
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transactivator protein ICP4 and an origin of replication (oriS). The a sequence is present in 
multiple copies at the UL end of the genome, in one or more copies at the joint region between 
the long and short terminal repeats (b and c sequences), and in one copy at the US terminus 
(232). The a sequence contains short direct repeats (DR1, DR2, DR4) and unique sequences (Ub 
and Uc), which are organized in the following manner at the joint region: DR1-Ub-DR2-DR4-
Uc-DR1 (Figure 2). At the ends of the genome, the a sequence is inverted with respect to the a 
sequence at the joint.  The overall genome sequence can be represented as a-b-UL-b’-a’-c’-US-c-
a, in which the internal repeat sequences are in the inverse orientation to those at the genome 
termini. 
 
Figure 2. The HSV-1 genome and a sequence. A. Diagram of the HSV-1 genome, with the long (L) 
and short (S) genome segments marked.  The orientation of the a sequence with respect to the unique regions 
is depicted as the black arrow. TR, terminal repeat. IR, internal repeat. B. Diagram of the a sequence in 
“inverted” orientation (DR1-Ub-DR2-DR4-Uc-DR1) at the junction between the long and short repeats (joint 
region of the genome).  The a sequence contains three different direct repeats—DR1, DR2, and DR4—and 
two unique regions, Ub and Uc.  This figure has been modified from reference (227).  
A 
B 
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1.4 OVERVIEW OF HSV-1 LYTIC INFECTION 
The HSV-1 lytic replication cycle can be broken down into several major events that occur in 
different cellular compartments: virus attachment and entry at the plasma membrane; genome 
uncoating at the nuclear membrane; viral gene expression, DNA replication, and progeny capsid 
assembly in the nucleus; capsid egress from the nucleus to the cytoplasm; and finally, 
tegumentation, envelopment, and budding from the cell [reviewed in (182)].  The first stage of 
infection is the fusion of the virus with the host cell.  Virus attachment and entry are mediated by 
viral glycoproteins in the virion envelope (23, 197).  The initial attachment occurs via 
glycoprotein B and C (gB and gC) interaction with heparan sulfate (HS) on the cell membrane.  
gB and gC binding to HS are not absolutely required for viral entry, but they facilitate entry by 
concentrating virus particles at the cell surface.  The viral glycoprotein D (gD) binds to one of 
three cell-surface entry receptors: nectin-1, HVEM, and modified HS. Receptor-bound gD then 
brings gB, gH, and gL into a fusion complex (9). Attachment at the cell surface also induces 
structural rearrangements in the tegument compartment (122).  After the viral envelope fuses 
with the host cell plasma membrane, the envelope-associated viral glycoproteins are left at the 
cell surface (158) and the capsid plus tegument is released into the cytoplasm.   
De-enveloped capsids are actively transported along microtubules from the cell periphery 
to the nucleus, where they release viral DNA (11, 113, 114, 149, 196). Incoming capsids 
colocalize with the microtubule motor dynein (52). It is unclear which of the capsid-associated 
proteins interacts with microtubules or motor proteins during viral entry.  The small protein 
VP26 is not required for HSV-1 movement on microtubules, even though it was shown to 
interact with dynein (51, 57). The large tegument protein pUL36 is a likely candidate because it 
remains on incoming capsids and is required for their localization to the nuclear membrane (72, 
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113, 180). Copeland et al used antibodies to block several different capsid-associated proteins on 
incoming capsids; these experiments showed that pUL36—but not the tegument pUL37 or the 
capsid proteins pUL19 (VP5) and pUL18 (VP23)—was needed for docking the capsid at the 
nuclear pore (34). Depletion of the nucleoporins Nup214 and Nup358 inhibits binding of the 
capsid and delivery of viral genomes to the nucleus, and direct interaction between the capsid 
and Nup214 and Nup358 has also been demonstrated by immunoprecipitation and 
immunofluorescent localization assays (34, 156). Furthermore, the capsid-associated protein 
pUL25 interacts with Nup214, and pUL25 is required for release of the viral genome into the 
nucleus (4, 156, 169).  Thus, it is likely that a complex of the nucleoporins Nup 358 and Nup214 
form the capsid nuclear receptor, which binds to pUL36, pUL25, and/or other undefined capsid-
associated proteins. Proteolysis of pUL36 and the DNA portal protein pUL6 may also be 
necessary for release of the viral genome into the nucleus (92, 133).   When DNA is ejected, the 
US end of the genome exits the capsid first (136), so that the first viral gene exposed is ICP4. 
Release of the HSV-1 genome into the nucleus initiates viral gene expression, which is a 
complex and tightly regulated process [reviewed in (173)].  Many HSV-1 genes are arranged 
with overlapping ORFs or with common initiation or termination sites (118).  A temporal gene 
expression cascade segregates virus genes into 3 groups: immediate early (IE or α), early (E or 
β) and late (L or γ) (79, 80). Promoters that are specific to each group drive expression of the 
different gene classes.  Generally, genes expressed at early times post infection have complex 
promoters with more regulatory elements than the promoters of genes expressed late in infection.  
The IE genes ICP0, ICP4, ICP22, ICP27, and ICP47 are the first genes transcribed, and their 
expression is dependent on the viral transactivator protein UL48 (VP16).  UL48 is carried into 
the newly infected cell in the tegument compartment, and it binds to IE promoters.  Thus, IE 
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genes are expressed in the newly infected cell without any viral protein synthesis. IE genes, in 
turn, serve as transactivators of the early and late genes.  Most early genes are involved in DNA 
replication, while late genes are structural or virion proteins.  Late genes fall into two sub-
groups—γ1 (leaky late) and γ2—that have a relaxed or strict requirement, respectively, for DNA 
replication to occur before their expression. 
The HSV-1 DNA replication machinery consists of the DNA polymerase (UL30 and 
UL42), single-stranded DNA binding protein ICP8 (UL29), helicase/primase (UL5, UL8, and 
UL52), and the origin-binding protein (UL9) (14).  There are three origins of replication in the 
HSV-1 genome.  One is in the unique long segment (oriL), and two copies of the other (oriS) are 
in the c sequences located at the internal repeat and short terminal repeat (204, 236). DNA 
replication produces a highly branched, intertwined concatemer that contains many copies of the 
HSV-1 genome connected through the terminal repeat sequences (46, 189, 190).  The mechanism 
for DNA replication remains unclear. There is evidence that, similar to the dsDNA 
bacteriophages, HSV-1 utilizes a rolling-circle mechanism to produce a concatemer of head-to-
tail linked genomes (14, 195, 207).  However, the rolling-circle mechanism depends on 
circularization of the viral genome, and recent evidence suggests that the viral genome does not 
adopt the circular form during lytic infection (87). The concatemeric, branched replicative 
intermediate could also be synthesized by recombination of viral genomes during DNA 
replication (239). The viral alkaline nuclease, UL12, resolves the branched intermediate into its 
linear form (116, 163), which can be packaged subsequently into pre-assembled precursor 
capsids. Capsid assembly and the DNA packaging reaction are described in detail in Sections 1.5 
and 1.6. 
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After completion of packaging, the DNA-filled progeny capsids exit the nucleus, and 
they acquire the tegument proteins and the virion envelope en route to the host cell plasma 
membrane. Capsids in the nucleus are transported along actin filaments (60), but they cannot 
access the nuclear membrane until the viral proteins UL31 and UL34 induce breakdown of the 
nuclear lamina, probably through protein kinase C recruitment and phosphorylation of lamin B 
(65, 155, 176, 193).  Formation and localization of the UL31/UL34 complex is dependent on the 
viral kinase US3 (65, 125).  Primary envelopment of capsids involves their budding through the 
nuclear membrane into a vesicle-like structure; the primary-enveloped capsid fuses to the outer 
leaflet of the nuclear membrane and is released into the cytoplasm (124, 125, 174). The primary 
envelope contains US3, UL31, UL34 and may also contain viral glycoproteins and tegument 
proteins (126).  Conflicting reports have shown that the large tegument protein, pUL36, attaches 
to capsids in the nucleus (1, 22, 32, 106) or that pUL36 is cytoplasmic and not needed for capsid 
nuclear egress (44, 64, 129). Likewise, there is evidence for and against the addition of the 
tegument protein UL48 (VP16) to the capsid prior to its release to the cytoplasm (130, 154).  
Additional tegument proteins are added to the capsid in the cytoplasm. For secondary 
envelopment, capsids are recruited to the trans-Golgi network (TGN), where newly synthesized 
viral glycoproteins accumulate (225). During TGN envelopment, a double-layered lipid 
membrane is wrapped around the capsid.  The outer portion of this double membrane acts as a 
vesicle that transports the virion to the cell surface; it fuses to the host cell plasma membrane 
when the virion exits the cell.  The inner portion of the double membrane contains viral 
glycoproteins, and it becomes the envelope of the extracellular virion. 
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1.5 FORMATION AND MATURATION OF THE CAPSID 
The function of the nucleocapsid is to protect and transport the viral genome.  The HSV-1 capsid 
is an icosahedron with a triangulation number (T) of 16.  Like other quasi-equivalent structures, 
the capsid is made of many subunits that are identical in peptide sequence but slightly different 
in structure and conformation; the flexibility of the subunits allows a single gene product to 
assemble into a large macromolecular complex (90). In the case of HSV-1, the major component 
of the capsid is the structural protein UL19 (VP5), a large protein of 1374 amino acids and 
molecular weight 149 kDa.  VP5 is arranged into rings of five or six copies, which are visible by 
negative staining and electron microscopy of capsids (70, 145, 198, 202, 238). These capsomers 
are called hexons (6-mer rings) and pentons (5-mer rings), and they form the faces and the 
vertices of the capsid, respectively. Hexons and pentons are dissimilar not only in the copy 
number of VP5 but also in the conformation of VP5. VP5 in hexons and pentons have different 
exposed antibody epitopes, and the small capsid protein VP26 preferentially binds to hexons (17, 
223, 241).  A recent study of VP5 structure highlighted the differences in hexons and pentons 
(18). Bowman et al trypsin-digested VP5 and purified a 65 kDa fragment—the “upper” domain 
that faces the exterior of the capsid—that was used for x-ray crystallography. Folded VP5 is 
mostly α-helical and has charged faces, and it is the electrostatic interactions between these 
charged residues that likely hold the pentons and hexons together.  Furthermore, these charged 
faces are arranged differently in pentons and hexons, so that hexons have a smaller inner channel 
that is positively charged, while pentons have a smaller channel of a less acidic nature (18). 
Hexons have also been segregated into three classes based on their distance from the penton 
vertex and the edge of the capsid face, but these hexon forms do not appear to have distinct 
structures (202).  
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Between the capsomers, a heterotrimeric complex—or “triplex”—fills in the capsid 
surface. Two copies of pUL18 (VP23) and one copy of pUL38 (VP19c) make up the triplex 
(145).  VP19c and VP23 both interact with VP5, but since VP19c sits atop VP23, VP19c is 
probably more accessible to the upper domain of VP5, while VP23 interacts with the VP5 floor 
domain (184, 254). VP19c contains a nuclear localization signal (NLS) in amino acids 24-56 that 
localizes VP5 and VP23 to the nucleus (3, 179). Mutational analyses of the triplex proteins have 
identified regions that are important for the interactions between VP19c, VP23, and VP5 (150, 
179, 199).  The C-terminus (amino acids 450-465) and the region of VP19c around amino acid 
100 appear to be required for its interactions with both VP23 and VP5, and additional contacts 
with VP23 may occur at VP19c amino acids 230-347.  In VP23, mutations within several 
different regions (amino acids 22-67, 100-190, 206-239, 296-310) abrogated its interaction with 
VP19c.  
 At a single vertex of each capsid, the penton is substituted with a portal complex made of 
the DNA packaging protein UL6 (24, 26, 143).  The portal has three putative functions: it is the 
docking site for the terminase complex (consisting of the DNA packaging proteins pUL15, 
pUL28, and pUL33), it is the passageway through which DNA enters and exits the capsid, and it 
is likely the foundation upon which the procapsid is built (138, 143, 237).  The portal is made of 
twelve copies of pUL6 that are arranged into a barrel; the larger end of the barrel faces away 
from the interior of the capsid (24, 143, 221). The portal can be assembled in the absence of 
other viral proteins, but its cylindrical structure is deformed by mutations to a leucine zipper 
(LZ) motif in pUL6 (aa 409-473) (132, 143).  Deletion of the LZ motif does not prevent pUL6 or 
pUL15 inclusion to capsids, indicating that the LZ region is important for pUL6 self-interaction 
but not for its interaction with scaffold or the DNA packaging machinery (132).   
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Capsid assembly is catalyzed by interaction of the portal with scaffold proteins (138, 
144). The scaffold is composed of the viral proteins preVP22a (pUL26.5) and pUL26, which are 
both transcribed from the UL26 ORF (38, 110, 111). At the beginning of capsid assembly, a 
small region of the scaffold protein (amino acids 143-151) binds to and orients the portal so that 
its bulkier portion faces the exterior of the nascent capsid (24, 83, 194, 245). Following this 
initial event, capsomers and more scaffold proteins are added to the portal-scaffold complex. The 
scaffold forms multiple intramolecular contacts, and its C-terminus connects to the VP5 N-
terminus (81, 82, 139, 167, 233). In this way, more scaffold and capsomers are added to the 
original “wedge” and continue extending it until the spherical precursor capsid—the procapsid—
is completed (139-142, 144). The interior of the procapsid is thus filled with and supported by 
the scaffold.  The triplexes are assembled separately and are added to the assembling procapsid 
shell (199).   
As the precursor to the angularized capsid, the procapsid is porous, unstable, and requires 
several structural transformations to reach its mature form (220). Conversion of the procapsid to 
its angularized form is tightly coupled to the cleavage, disorganization, and removal of the 
scaffold (29, 36, 183). Within pUL26, there is an autocatalytic protease (VP24) that cleaves both 
scaffold proteins to form the processed scaffold, which consists of VP21 and VP22a (50, 108-
110, 160, 170, 235).  Scaffold is cleaved at its C-terminal end, near its connection to the capsid 
protein VP5 (50).  Scaffold cleavage therefore physically separates the procapsid shell from the 
scaffold (256). These biochemical events are linked to global changes in capsid structure, which 
have been observed by cryo-electron microscopy and reconstruction of a temperature-sensitive 
protease mutant at different timepoints after procapsid assembly (76).  These procapsids mature 
in “slow-motion” at the non-permissive temperature and allow collection of images at distinct 
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stages of maturation.  The first major event in procapsid maturation is formation of the VP5 
“floor” of connections between capsomers, accomplished by the rotation of VP5 in hexons. In 
both the pentons and hexons, conformational changes of VP5 close the central channels.  Finally, 
the triplexes are re-ordered to reinforce the VP5 floor. After these transitions, VP5 in hexons and 
pentons are morphologically distinct in that they have different regions exposed to the capsid 
surface (223).  These distinctions probably account for the preferential binding of the small 
capsid decoration protein VP26 to hexons (17, 222, 255).  
 
 
Figure 3. Precursor capsids mature into three different capsid forms.  Unlike the spherical procapsid, 
all mature capsid types are angular, but they contain different materials in their interior.  B-capsids are filled 
with the cleaved scaffold protein VP22a, and A-capsids are empty.  Only C-capsids contain DNA and are 
incorporated into virions.   
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Maturation of the procapsid is an inefficient process; many of the capsids formed during 
productive infection are not assembled into virions. Three types of icosahedral capsids have been 
purified from the nuclei of wt HSV-1-infected cells, and they were designated based on their 
sedimentation through sucrose density gradients (70) (Figure 3). The most dense form, the C-
capsid, contains tightly packed DNA (16, 70). C-capsids exit the nucleus and become 
incorporated into virions. A- and B- capsids are restricted to the nucleus; they are considered 
defunct by-products of the capsid maturation and DNA packaging reactions (16, 70, 139). Empty 
A-capsids have no inner core, and B-capsids contain the cleaved scaffold proteins VP21, VP22a, 
and VP24. Because DNA packaging is dependent on scaffold proteolysis and expulsion from the 
capsid (69, 117, 166, 170), A-capsids are thought to be the result of abortive packaging events, 
while B-capsids may form when DNA packaging is blocked but scaffold proteolysis proceeds 
normally.  
1.6 THE HSV-1 DNA PACKAGING REACTION 
1.6.1 Model from the dsDNA bacteriophages 
Because HSV-1 shares an evolutionary lineage with the tailed dsDNA bacteriophages (10, 120), 
the pathway for packaging of the HSV-1 capsid is presumed to resemble that observed in phage 
[reviewed in (25, 66, 89)] (Figure 4). Generally, the machinery involved are a terminase 
enzyme—so named because it generates genome termini out of a DNA concatemer—and a 
portal that provides the gateway for DNA into the procapsid.  The process of DNA encapsidation 
in bacteriophages begins when the terminase recognizes a packaging sequence at the ends of 
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genomes in the DNA concatemer.  At or near this sequence, terminase makes a double-strand cut 
to free one end of the DNA. The terminase-DNA complex then docks onto the procapsid at the 
portal vertex. Terminase acts as a motor to propel the free DNA end into the capsid through the 
central channel of the portal. As DNA enters, the procapsid is transformed into its mature 
morphology. DNA is driven into the capsid by the terminase until it senses that a full genome has 
been packaged; this can be accomplished by a head-full mechanism (i.e. a certain length or 
amount of DNA packaged) or by a second packaging site at the end of the genome.  Terminase 
cleaves the end of the genome to release it into the capsid. After the second DNA end has 
entered the capsid, head completion proteins close the portal and stabilize the capsid.  
 
Figure 4. DNA packaging in the double-strand DNA bacteriophages. Modified from (25). Initiation of 
packaging occurs when the terminase complex recognizes packaging sequences (pac) in the concatemer of 
replicated genomes.  The initial terminase cleavage frees an end of DNA.  Terminase docks on the portal and 
propels DNA into the procapsid, which triggers procapsid expansion and angularization.  Termination of 
packaging results in terminase cleavage of the end of the genome and dissociation from the filled capsid.  
Head completion proteins seal off the portal and reinforce the capsid.   
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In bacteriophage, the terminase complex is composed of multiple subunits that together 
provide the site-specificity for DNA cleavage and the force required to drive DNA into the 
capsid, by hydrolysis of ATP.  In the E. coli bacteriophage λ, the terminase is a trimer of two 
copies of the small subunit gpNu1 and one copy of the large subunit gpA (115). gpNu1 binds to 
the DNA packaging signal and recruits gpA into the complex.  The gpA subunit contains both 
endonuclease and ATPase domains that are responsible for the energy-dependent cleavage and 
translocation of DNA into the procapsid. A similar division of labor—site-specificity directed by 
the small subunit, DNA cleavage and ATP hydrolysis carried out by the large subunit—has been 
observed in the terminases of phages T4, P22, and SPP1 (25).  Association of the terminase with 
packaging sequences may require host factors that bend DNA into an appropriate conformation 
for terminase binding, as is the case for the λ terminase small subunit gpNuI and the E. coli host 
factors IHF and HU (152, 209). In all cases, the initial cleavage requires the recognition of 
specific packaging signals, for example, the cos sequence of λ phage and the pac sites of phages 
T4, P22, and SPP1 (25).   
For completion of bacteriophage DNA packaging, three events are required: 1) addition 
of accessory proteins to the capsid exterior to stabilize it against the increasing internal pressure 
of packaged DNA; 2) cleavage of DNA at the next packaging signal to release a free genome 
into the capsid; and 3) addition of head completion proteins that block off the portal to prevent 
DNA release. When the packaging reaction is nearly complete, structural proteins that reinforce 
the capsid are added to maintain capsid integrity, and thus, to allow terminase to package the 
full-length genome.  The T4 phage protein Soc is one such protein; it is present in a 
homotrimeric complex between T4 capsomers (85, 86, 201). The λ phage gpD protein also 
decorates the capsid surface, and it is only added to the expanded capsid after the initiation of 
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DNA packaging (84). In the absence of gpD, capsids are unable to retain viral DNA, and many 
empty expanded capsids are produced (244). However, truncated DNA substrates lacking the 
final 15-20% of the viral genome can be successfully packaged in the absence of gpD (249).  
Although gpD is a structural protein, these data indicate that gpD is required for the second 
cleavage reaction, inasmuch as the terminase requires the structural stability gpD provides to the 
capsid in order to reach the second cleavage site.  The second genome cleavage can occur at a 
specific DNA sequence, or terminase can cleave after it senses that a specific amount of DNA 
has been packaged, i.e. the head-full mechanism.  Most phages employ the head-full mechanism, 
with the exception being λ, which terminates packaging at a second cos sequence.  
Head completion proteins attach to the capsid portal to prevent DNA expulsion from the 
mature capsid and to build a connector complex that is the foundation for the phage tail fiber. 
The connectors typically consist of two or more proteins that attach in multiple copies to the 
portal.  Some examples include gpW and gpFII from λ phage (161) and gp4, gp10, and gp26 
from phage P22 (208). In the phage SPP1, which infects Bacillus subtilis, the structure of the 
connector has been resolved (107, 151).  The SPP1 head completion proteins gp15 and gp16 
form dodecamer rings that sit on top of the portal.  These rings are connected to each other and to 
the portal via interaction between charged faces of the multimer rings (107).  When bound to the 
connector, the portal protein gp6 has a different conformation than when unbound, suggesting 
that completion of DNA packaging triggers changes in gp6 structure that promote connector 
attachment. gp16 is the “stopper” that blocks the opening at end of the connector.  gp15 and 
gp16 null mutants produce unit-length genomes that are not encapsidated; these mutants also 
produce empty, expanded capsids (151).  
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1.6.2 HSV-1 packaging signals 
The HSV-1 genome ends are defined by the presence of the a sequence, which contains the 
signals for cleavage and packaging of DNA (43, 206). Adjacent genomes in the replicated 
concatemer share overlapping a sequences that are joined by the common DR1 element; 
cleavage between genomes occurs in this DR1 (131, 227) (Figure 5).  In the a sequence, the 
minimal packaging signals are located within the 200bp fragment containing Uc-DR1-Uc (42, 
78). Genome termini are made by two different cleavage events (229).  Accordingly, there are 
two packaging signal sequences, pac1 and pac2, which are located in the Ub and Uc portions of 
the a sequence, respectively (131).  While pac2 is required for the initial cleavage of DNA from 
the concatemer, pac1 is important for the secondary cleavage at the termination of packaging 
(78, 219). The cleavage site is not sequence-specific but is instead located at a set distance from 
the packaging signals (229).  Thus, deletions within pac1 or pac2 are more detrimental to 
packaging than substitution mutations (78, 219).  Both pac1 and pac2 have structural elements—
GC-rich elements and T tracts—that are important for DNA packaging (Figure 5).  Taken 
together, the spacing requirement between the packaging signal and the cleavage site, along with 
the inhibitory effects of substitutions in the GC and T tracts, has prompted the hypothesis that 
these DNA elements are modeled into secondary structures that are recognized by the packaging 
machinery (5, 242). 
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Figure 5. The a sequence mediates HSV-1 DNA cleavage and packaging.  A. Genomes in the DNA 
concatemer are punctuated by overlapping copies of the a sequence between the short terminal repeat (RS) 
and the long terminal repeat (RL).  Cleavage (black arrow) occurs in the direct repeat (DR1) shared by 
adjacent a sequences, leaving a single copy of the a sequence at the US terminus and multiple copies on the UL 
terminus.  Modified from (227).  B. Diagram of the Uc-DR-Ub junction between adjacent a sequences.  The 
sequences are colored green (Uc), blue (DR1), and red (Ub).  The pac2 is marked with a solid line, and pac1 is 
marked with a dashed line.  Structural features within each pac site are noted.  The cleavage site in DR1 is 
shown (black arrow). Modified from (219). 
1.6.3 HSV-1 DNA packaging machinery 
The HSV-1 packaging genes have been identified as UL6, UL15, UL17, UL25, UL28, UL32, 
and UL33 (6, 103, 104, 121, 186, 214). These genes are essential for virus replication and are 
members of a set of core genes that are conserved across herpesvirus subfamilies (120). Null 
mutations of the UL6, UL15, UL17, UL32, and UL33 genes completely eliminate DNA cleavage 
and packaging, such that the DNA concatemer is unresolved and only B-capsids are formed 
(103, 157, 175, 186, 214, 250). The observed phenotype suggests that these gene products 
catalyze the initial stages of packaging including terminase assembly, the initial cleavage of the 
concatemer, and relocation of terminase to the DNA portal.  In contrast, the packaging gene 
UL25 seems to have a unique role in packaging.  The UL25 null mutant accumulates free, 
A 
B 
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 ! !   ! !pac2!
! ! ! !          T tract  GC element!
TCCCGCGGCCCCGCCCCCCACGCC|CGCCGCGCGCGCGCACGCCGCCCGGACCGCCGCCCGCC|TTTTTT|GCGCGCGCGCGCGC|!
        DR1           ! ! ! !Ub !!
!           ! ! ! pac1!
! !      proximal GC element !            T tract   distal GC!
CCGCGGGGGGCCCGGGCTGC|CCGCCGCCGCCGCTTTAAAGGGCCGCGCGCGACCCCCGGGGGG|TGTGTTTT|GGGGGGGGCCCG|!
! ! ! ! !!
TTTTCGGGGTCTGGCCGCTCCTCCCCCCGG|!
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approximately genome-length DNA and almost equal amounts of A- and B-capsids (121, 205).  
It has been inferred from the A-capsid phenotype that UL25 is required for completion of 
packaging or retention of DNA in the capsid rather than initiation of packaging. The packaging 
machinery is localized to intranuclear centers of viral replication, which are characterized by the 
presence of the HSV-1 single-stranded DNA binding protein UL29 (ICP8). These replication 
compartments, or assemblons, are distinct areas within the nucleus where capsids and packaging 
proteins accumulate (179).  Both UL17 and UL32 have been implicated in the localization of 
capsids to assemblons (103, 211). The packaging proteins UL6 and UL25 are imported into cell 
nuclei independently of terminase, although UL25 nuclear localization requires expression of the 
triplex protein UL38 (VP19c) (148, 247). 
The putative HSV-1 terminase complex consists of three subunit proteins: UL15, UL28, 
and UL33.  The assignment of HSV-1 proteins to the terminase complex has been due to a) their 
functional and sequence similarity to terminase subunits in bacteriophage (25, 127, 171), and b) 
the mapping of resistance mutations to DNA cleavage and packaging inhibitors to the CMV 
homologues of UL15 and UL28 (100, 146, 228). The ATP-binding motifs Walker box A 
(PRRHGKT, aa 259-265) and Walker box B (LLFVDE, aa 352-357) have been identified in 
UL15, and they are common to the terminases of other herpesviruses and many bacteriophages 
(127). The importance of the ATPase domain of UL15 was demonstrated by the G263A 
mutation in Walker box A, which abrogated DNA cleavage and packaging as well as viral 
replication (171, 251). In addition to the ATPase domains, UL15 shares >70% sequence 
homology with bacteriophage terminases in at least 10 different regions of the protein (171). 
Thus, UL15 is presumed to be the motor that hydrolyzes ATP and drives DNA into the capsid. In 
UL28 protein, a highly conserved zinc finger motif is located between amino acids 197 and 225 
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(100).  Because UL28 and its homologues in CMV have been shown to bind to packaging 
signals (5, 15), UL28 is the proposed terminase endonuclease subunit, which carries out the 
cleavage of viral DNA.  Because the UL end of the genome is preferentially packaged first (46, 
136), UL28 also must distinguish between the pac2 and pac1 packaging signals, which initiate 
and terminate packaging, respectively.  UL33 is not known to have any enzymatic activity, but it 
may regulate the activity of the other terminase subunits.  Transposon insertions within two 
highly conserved regions of UL33—aa 46-77 and 101-130—inhibit the ability of UL33 to 
complement the UL33 null virus, indicating that these regions are important for UL33 function 
(12). In order to insert DNA into the procapsid, terminase must dock on the capsid portal after 
the initial cleavage of DNA at the UL terminus.  UL15 is the most likely candidate for terminase-
portal attachment because UL15 co-immunoprecipitates with the portal protein UL6 (247).  
Terminase proteins are not found in intact virions (112). Thus, after DNA is translocated, 
terminase dissociates from the capsid surface, and this dissociation may require proteolysis of 
UL15 (187, 240, 252).  
 
Figure 6. Features of the terminase subunit proteins UL15, UL28, and UL33. UL15 contains a 
nuclear localization signal (NLS) that mediates terminase complex import to the nucleus.  UL15 also contains 
two potential ATPase domains in the form of Walker box A and B (WBA, WBB) motifs. UL28 has a zinc 
finger motif that may allow it to bind to DNA.  Interaction domains between UL15, UL28, and UL33 have 
also been mapped.  
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Co-immunoprecipitation studies with UL15, UL28, and UL33 mutants have illuminated 
regions of these proteins that are important for terminase assembly (Figure 6).  In the assembled 
complex, the largest subunit UL28 hinges UL15 and UL33, which do not contact each other 
(246). Single amino acid substitutions at aa 653 of UL15 or aa 61 of UL33 disrupt their binding 
to UL28 (162, 248). It has also been demonstrated that small insertions (5 aa) in aa 46-77 of 
UL33 inhibits co-immunoprecipitation of UL28, so this region likely represents an interaction 
domain with UL28 (12). Within the UL28 protein, UL33 and UL15 binding domains have been 
mapped to aa 604-736 and 736-785, respectively (2, 88).  There is evidence of additional contact 
between UL28 and UL15 at aa 334 and 212, respectively, as the UL15 A212T mutation 
complements the UL28 linker insertion mutation 334i (88).  These interactions likely drive 
assembly of terminase in the cytoplasm of infected cells, and subsequently, the nuclear 
localization signal located in aa 183-189 of UL15 directs nuclear import of the complex (88, 99, 
247). After import to the nucleus, UL15 is required to localize the complex to replication 
compartments (77).  However, when individually expressed, UL15 retains a diffuse nuclear 
staining pattern (251), suggesting that inclusion of the terminase into replication compartments 
requires other viral proteins. 
1.7 COMPLETION OF PACKAGING AND BEYOND: ADDITION OF THE 
CAPSID-STABILIZING PROTEIN PUL25 
Completion of DNA packaging is dependent on expression of the essential gene UL25.  The 
UL25 ORF occupies bp 48813-50553 of the 152kbp HSV-1 genome (118).  By genome 
sequence analyses, UL25 gene homologues have been identified in each of the eight human 
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herpesviruses: HSV-2 (55), VZV (37), EBV (53), CMV (54), human herpesvirus 6 (56), human 
herpesvirus 7 (123), and KSHV (177) (see Table 3). The estimated similarity between the UL25 
gene products of HSV-1 and the other human alphaherpesviruses HSV-2 and varicella-zoster 
virus are 93% and 64%, respectively, while the sequence similarity of HSV-1 UL25 to UL25 
proteins in the human beta- and gammaherpesviruses drops to 40% (19). UL25 is conserved in 
members of the alphaherpesvirus family that infect other animals, such as pseudorabies virus 
(PrV) (49), herpes B virus (159), equine herpesvirus 1 (EHV-1) (213), and bovine herpesvirus 1 
(BHV-1) (47, 74). Altogether, 40 UL25 homologues have been identified and catalogued (NCBI 
Entrez Gene database).  The conservation of UL25 across virus families in humans and other 
animals is illustrative of its core function in herpesvirus replication.  
 
TABLE 3. UL25 Homologues 
Virus UL25 homologue 
Herpes simplex virus 1 UL25 
Herpes simplex virus 2 UL25 
Varicella-zoster virus Orf 34 
Epstein-Barr virus BVRF1 
Human cytomegalovirus UL77 
Human herpesvirus 6 U14 
Human herpesvirus 7 U14 
Kaposi’s sarcoma herpes virus Orf 19 
  
 
The UL25 gene is predicted to encode a protein of 580 amino acids with a molecular 
weight of 62 kDa (118). In the initial characterization of the UL25 gene product, the genome 
fragment containing UL25 was sub-cloned into an expression vector, which was transfected into 
cultured cells.  Lysates from transfected cells and cells infected with HSV-1 and HSV-2 were 
analyzed by Western blot with an antibody raised against a GST-fusion containing the predicted 
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C-terminus of UL25 protein (pUL25). A specific band running at 60 kDa reacted with the pUL25 
antibody in all three cases. This peptide could be detected in purified extracellular virions and 
could be immunoprecipitated from HSV-1 or HSV-2 infected cells (7). Thus, pUL25 does not 
appear to have post-translational modifications that significantly alter the molecular weight 
predicted from the coding sequence. The temporal range of pUL25 expression occurs between 2-
20 hours post-infection and peaks at 9-12 hours (7, 121).  pUL25 expression is partially blocked 
by the addition of phosphonoacetic acid, an inhibitor of viral DNA replication (7).  Because 
expression of pUL25 is somewhat dependent on DNA synthesis, it is classified as a γ1 or leaky 
late HSV-1 protein.  
UL25 null mutant viruses exhibit a variety of phenotypes that distinguish them from wt 
virus and from other packaging gene mutants.  Similar to the other packaging genes, UL25 is 
essential to viral replication, and the null mutant produces many B-capsids.  Unlike the other 
packaging mutants, the UL25 null mutant also accumulates a large number of empty A-capsids 
in infected cell nuclei (30, 121). In this aspect, the UL25 null phenotype is identical to the 
bacteriophage SPP1 mutants gp15- and gp16-; gp15 and gp16 act as head completion proteins 
that seal off the portal after DNA is packaged (151). Due to the similarity in phenotype, pUL25 
is presumed to be the equivalent of a head completion protein that is required for the completion 
but not the initiation of packaging. The UL25 homologue in BHV-1 is similarly required for 
completion of packaging, while in PrV, UL25 does not appear to be needed for formation of C-
capsids (48, 102).  Secondly, the UL25 null mutant produces near-to-full-length viral genomes 
that are (a) sensitive to DNase digestion and (b) missing, or are significantly reduced in, the US 
genome terminus (30, 121, 205).  These data suggest that in the absence of UL25, the packaging 
machinery can process viral DNA from the concatemer, but the DNA is not stably packaged into 
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capsids.   Furthermore, these observations suggest that UL25 null mutations impair the second 
terminase cleavage at the US terminus, but not the first cleavage event at the UL terminus.  This 
phenotype is similar to that observed for the λ phage gpD mutant (249).  Lastly, several UL25 
mutations can also impair capsid trafficking and genome uncoating (4, 98, 147, 169). These 
deleterious effects occur after successful DNA packaging and effect cell-to-cell spread of virus. 
As demonstrated by multiple studies in which capsids containing pUL25 were 
immunogold-labeled, pUL25 is incorporated into the exterior surface of capsids at their vertices 
(33, 121, 137, 148, 192, 216, 224).  At the capsid vertex, pUL25 is a member of a proposed 
heterodimer with pUL17 (224).  This heterodimer—termed the C-capsid specific component, or 
CCSC—was observed by cryo-electron microscopy; it is present on wt but not UL25-null 
capsids.  The assignment of pUL17 to the heterodimer was based on the observation that pUL17 
is necessary for the attachment of pUL25 to capsids (216).  Densitometric analyses of Western 
blots showed that in the absence of pUL17, the amount of pUL25 associated with the capsid 
dropped to 10% of wt (216).  Conversely, pUL17 occupancy was only reduced by 50% in the 
UL25-null mutant. These data indicate that pUL17 attaches to the capsid prior to pUL25, but the 
addition of pUL25 stabilizes the CCSC. pUL25 attachment to the capsid surface is most likely 
influenced also by its interactions with the capsid proteins pUL19 (VP5) and pUL38 (VP19c), 
which have been demonstrated by co-immunoprecipitation of these proteins with pUL25 from 
infected cells and by far-Western assays in which pUL25 was attached to a membrane containing 
immobilized pUL19 and pUL38 (148, 188). pUL25 may also bind the portal protein,  pUL6 
(156).  Pasdeloup et al. demonstrated that transiently co-expressed pUL6 and pUL25 could be 
co-immunoprecipitated, but they could not determine if pUL6 was in monomers or in its ring 
structure as the assembled portal.  This result prompted the suggestion that pUL25 has a second 
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site of attachment near the portal.  At the portal, pUL25 may adopt a different conformation or 
different interaction partners, as the dodecameric portal is structurally distinct from the pentons 
containing five-mer rings of VP5.  To date, there is no indication in capsid reconstructions that 
pUL25 associates with the portal. However, the reconstructions are limited by the imposition of 
icosahedral symmetry, which conceals the unique portal vertex, and it is also possible that 
pUL25 at the portal could dissociate from capsids during their preparation for cryo-electron 
microscopy.  
Capsid-associated pUL25 has several functions. Most importantly, pUL25 provides 
structural reinforcement for the capsid (183).  Because pUL25 occupancy on the capsid surface 
increases during maturation of the capsid from procapsid to the C-capsid (137, 192), pUL25 
addition to the capsid is probably used to counteract the increasing internal pressure of packaged 
DNA, but it could also be an indirect signal to the terminase that DNA packaging should be 
completed. If pUL25 is present at the DNA portal, it could also be used to seal off the portal, in 
the manner of a bacteriophage head completion protein.  After packaging, pUL25 is required for 
the egress of capsids from the nucleus (98, 102, 147).  It has been estimated that more pUL25 is 
in the virion (239 copies) than in intranuclear C-capsids (178 copies), suggesting that a threshold 
amount of pUL25 on the capsid is a requirement for nuclear egress (217, 224).  pUL25 initiates 
tegumentation of the cytoplasmic capsid via its interaction with the large tegument protein, 
pUL36 (VP1/2) (32, 156). The pUL25-pUL36 interaction organizes tegument around capsid 
vertices (253).  pUL36 has two independent pUL25-binding domains located at pUL36 aa 2037-
2353 and 3104-3164 (156). Finally, capsid-associated pUL25 has roles in virus entry. In PrV, 
pUL25 associates with microtubules in the absence of other viral proteins (93), but in the context 
of HSV-1 infection, this association is probably mediated by pUL36, which is known to interact 
 30 
with microtubules during capsid transport (191).  A temperature-sensitive mutation that maps to 
pUL25 aa 233 causes incoming capsids to aggregate at the nuclear periphery and prevents 
release of viral DNA into the nucleus (169). In reciprocal co-immunoprecipitation experiments, 
transiently-expressed pUL25 was shown to pull down the nucleoporins CAN/Nup214 and hCG1; 
this interaction was supported by pUL25 interaction with nucleoporins in a yeast-2-hybrid assay 
(156).  pUL25 interaction with the nuclear pore would complement that of pUL36, which binds 
to the nucleoporin Nup358 (34). Thus, pUL25 helps to dock the incoming capsid at the nuclear 
pore prior to uncoating of the viral genome. 
 
Figure 7. pUL25 structure. (Top) UL25 protein secondary structure was determined by x-ray 
crystallography (19).  Flexible loops are shown as dashed lines. (Bottom) Diagram of linear UL25 protein. 
White boxes are regions of the protein that form the folded core.  The gray line represents unstructured 
regions.  Loop domains and surface clusters identified by Bowman et al (19) are indicated.  The regions 
marked as surface clusters are not contiguous sets of residues, but instead represent the general area of each 
cluster.  The specific residues in each cluster are noted in Table 4.    
 
The structure of a truncated version of pUL25 has been determined by x-ray 
crystallography (19). During protein expression and crystallization, pUL25 was proteolytically 
cleaved between aa 116 and 130, with subsequent analysis finding that the first ordered residue 
was aa 134.  Thus, the structural prediction effectively includes pUL25 aa 134-580.  Bowman et 
Loop domain                         1                2           3     4     5               6 
Surface cluster      2       3              1     4   
580 1 
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al. described the structure of folded pUL25 as a core of packed α-helices with an overall unique 
α plus β folding pattern that has not been previously observed (Figure 7) (19). Six unstructured 
loops and a long flexible N-terminus extend from the pUL25 core, and based on the charge 
distribution of the surface residues, pUL25 has two polar faces, one positively charged and one 
negatively charged.  Comparison of 38 pUL25 homologues revealed four evolutionarily 
conserved clusters of residues on the protein surface. The location of these structural features in 
the pUL25 sequence are listed in Table 4 and illustrated in Figure 7.  
 
AAdapted from (147). n.d. not determined.  +, no effect. -, inhibitory effect.  
 
The surface cluster and loop domains are the most accessible regions of pUL25 and are 
predicted to be the sites of pUL25 interaction with other proteins. Recently, mutational analysis 
of pUL25 tested the importance of the unstructured loop domains and conserved surface clusters 
TABLE 4. Mutational analysis of pUL25 structural features.A   
   Phenotype 
Structure Amino Acid Sequence Mutation 
Virus 
replication 
DNA 
Packaging 
Capsid 
egress 
Loop domain 1 249-AADDSD-254 ∆249-254 + n.d. n.d. 
                      
2 
335-RDASTHVNPDG-345 ∆335-345 + n.d. n.d. 
                      
3 
417-PSEAIARGA-425  ∆417-425 - + - 
                      
4 
479-PVGST-483  ∆479-483 + n.d. n.d. 
                      
5 
511-RTN-513 ∆511-513 - - n.d. 
                      
6 
578-SAV-580 ∆578-580 - + + 
Surface cluster 1 G225, R288, R305, P327, 
G331, H348, R362, G363, 
N365 
n.d. n.d. n.d. n.d. 
                       
2 
R148, D150, N152, D156, 
L214, N508 
n.d. n.d. n.d. n.d. 
                       
3 
G169, S170, G172, R180, 
G202, R203, K206, P413 
G169A, S170A, 
G172A, G202V, 
R203A, K206A 
- - 
n.d. 
                       
4 
R390, N396, Y398, D400, 
L402, R552 
N396A, Y398A, 
D400A, L402A - + - 
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for virus replication, DNA packaging, and capsid trafficking (147). With UL25 supplied in trans 
from a plasmid vector, the mutations deleted each of the loop domains and substituted point 
mutations at each of the surface cluster residues of pUL25.  Mutant UL25 plasmids were 
transfected into cells that were subsequently infected with the UL25-null virus.  Several different 
mutant phenotypes were generated, as summarized in Table 4.  Interestingly, three of the loop 
domains (1, 2, and 4) could be removed without deleterious effects on virus replication. Loop 
domain 5 and surface cluster 3 mutants were defective in DNA packaging, while mutants of loop 
domains 3 and 6 and surface cluster 4 successfully packaged viral DNA.  Ultrastructural analysis 
of the latter three mutants showed that two produced C-capsids that were sequestered to the 
nucleus (loop domain 3 and surface cluster 4), and one (loop domain 6) produced extracellular 
virions that were not infectious. These results led the authors to conclude that residues 417-425 
and 396-402 were important for capsid nuclear egress, while aa 578-580 were involved in entry 
of the capsid to the newly infected cell.  
In studies of herpesviral protein interactomes by yeast-2-hybrid screens, pUL25 
homologues in VZV and KSHV were found to interact with the orthologues to HSV-1 pUL15 
and pUL31—proteins that are implicated in the terminase complex and in capsid nuclear egress, 
respectively (61, 94, 97, 124, 226, 251).  Although pUL25 interaction with pUL15 and pUL31 
have not been tested directly, it could be hypothesized that the DNA packaging and capsid egress 
null phenotypes generated by O’Hara et al. affected pUL25 interaction with one or both of these 
proteins.  A summary of the predicted interactions of pUL25 with other viral and cellular 
proteins is presented in Table 5. 
In sum, UL25 is involved in a diverse array of events in the virus replication cycle, 
beginning with DNA packaging and including capsid nuclear egress, tegumentation, and 
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uncoating of the genome from the capsid in the newly infected cell.  These features are all 
intrinsically linked to the unique structure of pUL25—which allows it to participate in dynamic 
interactions with different binding partners—and pUL25 attachment to the capsid surface, which 
provides access to those binding partners.   
 
 
TABLE 5. Summary of predicted pUL25 interactions with viral and cellular proteins. 
Predicted 
binding partner Function 
Confirmation of 
interaction References 
pUL6 Capsid portal IPA (156) 
pUL15 Terminase complex No (226) 
pUL17 DNA packaging IP (188, 216, 224) 
pUL19 Major capsid protein (VP5) IP; far-Western assay (148, 188) 
pUL31 Capsid nuclear egress No (226) 
pUL35 Small capsid protein (VP26) No (105) 
pUL36 Large tegument (VP1/2) IFB (32, 156, 226) 
pUL38 Triplex protein (VP19c) IP; far-Western assay (148, 188) 
CANCt/hCG1 Nucleoporin IP (156) 
A IP, Immunoprecipitation 
B IF, co-localization by immunofluorescence 
1.8 SPECIFIC AIMS AND RATIONALE 
The goal of this project is to elucidate the biological functions of UL25 protein through (a) 
analysis of its interactions with the HSV-1 capsid and (b) determination of the importance of 
 34 
pUL25 capsid-attachment for DNA packaging. To address these goals, the specific aims focused 
on the protein-protein interactions that drive pUL25 incorporation to the capsid, the effects of 
UL25 mutations on HSV-1 genome retention in the capsid, and the effects of UL25 mutations on 
genome cleavage. These studies explain the role of UL25 in the HSV-1 DNA packaging reaction 
and generally improve our knowledge of herpesvirus virion assembly. 
1.8.1 Specific aim I: To map the pUL25 capsid-binding domain. 
UL25 protein is added to the capsid exterior during the DNA packaging reaction.  It has been 
postulated that accumulation of UL25 stabilizes the capsid and promotes completion of DNA 
packaging.  In this aim, the UL25 capsid-binding domain(s) were identified by mutational 
analysis of UL25. To address the importance of UL25 capsid attachment, UL25 null mutants 
were examined for changes in DNA packaging phenotype. These studies defined functional 
domains of pUL25 that are important for capsid binding and DNA packaging. 
1.8.2 Specific aim II: To identify UL25 protein interactions by structural analyses 
UL25 protein is predicted to contact multiple proteins on the capsid surface.  To identify these 
connections, capsid-associated pUL25 was visualized by cryo-electron microscopy and 3D 
image reconstruction of capsids.  pUL25-fusion proteins were used to add extra density to the 
capsid surface and to facilitate prediction of pUL25 location(s). 
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1.8.3 Specific aim III: To investigate the potential role of UL25 in stabilizing secondary 
DNA cleavage or in direct DNA-binding. 
Equimolar amounts of both long and short genome termini (TRL and TRS) are produced by DNA 
cleavage and packaging during wild-type HSV-1 infection. TRS has been reported to be 
truncated or missing in the UL25 null virus. We characterized the effect of UL25 mutations on 
the cleavage of viral genome termini. Additionally, purified UL25 protein has been bound to 
HSV-1 DNA immobilized on a membrane (148), but is not known if this observation reflects a 
similar phenomenon in HSV-1-infected cells.  In this study, pUL25 was purified from infected 
cells and used for an in vitro DNA-binding assay. 
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2.0  UL25 PROTEIN ATTACHES TO CAPSIDS THROUGH A SMALL N-
TERMINAL DOMAIN 
 
2.1 ABSTRACT 
The herpes simplex virus type 1 (HSV-1) UL25 protein (pUL25) attaches to the external vertices 
of capsids and is required for the stable packaging of viral DNA. To define regions of the protein 
important for viral replication and capsid attachment, the 580 amino acid (aa) UL25 open 
reading frame was disrupted by transposon mutagenesis. The UL25 mutants were assayed for 
complementation of a UL25 deletion virus, and in vitro-synthesized protein was tested for 
binding to UL25-deficient capsids. Of the 11 mutants analyzed, 4 did not complement growth of 
the UL25 deletion mutant, and analysis of these and additional mutants in the capsid-binding 
assay demonstrated that UL25 aa 1 to 50 were sufficient for capsid binding. Several UL25 
mutations were transferred into recombinant viruses to analyze the effect of the mutations on 
pUL25 capsid binding and on DNA cleavage and packaging. Studies of these mutants 
demonstrated that aa 1 to 50 of UL25 are essential for its stable interaction with capsids. A short 
region of the putative capsid-binding domain (aa 26-39) is highly conserved throughout the 
alphaherpesviruses.  To investigate the importance of these residues for pUL25 capsid-
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attachment and DNA packaging, recombinant viruses were generated that expressed pUL25 with 
point mutations and small deletions in the highly conserved region. With the exception of the 
deletion of aa 40-50, deletions within the N-terminus of pUL25 prevented viral replication and 
DNA packaging.  The paired point mutations F26A I27A and F35A W36A partially supported 
viral replication and DNA packaging but did not allow cell-to-cell spread of virus.  
Immunoblotting of purified capsids determined that pUL25 amino acids 1-36 were required for 
capsid attachment, and amino acids 37-50 were dispensable for capsid attachment but not for 
virus replication. To account for the possibility that N-terminal truncations prevented nuclear 
import of pUL25, indirect immunofluorescence assay was used to observe pUL25 protein in 
Vero cells infected with the N-terminal truncation mutant, vΔ1-50. The Δ1-50 protein was 
present in infected nuclei, indicating that deletion of the capsid-binding domain did not 
mislocalize pUL25.  Taken together, these data suggest that pUL25 attaches to capsids with a 
small N-terminal domain and that capsid attachment is required but not sufficient for completion 
of the DNA packaging reaction. 
2.2 INTRODUCTION 
The herpes simplex virus type 1 (HSV-1) virion consists of a 152 kbp double-stranded DNA 
genome, an icosahedral capsid (T=16), an amorphous protein layer called the tegument, and a 
lipid envelope containing viral glycoproteins. The HSV-1 genome contains several kbp of repeat 
sequences that flank and separate the unique long (UL) and unique short (US) regions, which 
contain most of the ORFs for viral genes. Viral DNA is replicated as a concatemer of head-to-tail 
genomes in the nucleus of the infected cell (189, 190).  DNA replication is concurrent with the 
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expression of the HSV-1 capsid structural proteins VP5 (UL19), VP19c (UL38), VP23 (UL18), 
and VP26 (UL35) [reviewed in (173)].  Using a protein scaffold—made of the viral proteins 
VP22a and pUL26.5—these structural proteins self-assemble into a spherical capsid precursor, 
or procapsid (139, 215, 220). Packaging of viral genomes into procapsids requires several tightly 
coupled events: 1) proteolysis and expulsion of the scaffold proteins, 2) recognition and cleavage 
of viral genome termini by the terminase complex, 3) docking of the terminase-DNA complex on 
the capsid portal, and 4) insertion of DNA into the procapsid. Terminase preferentially cleaves 
and packages the UL end of the genome first; conversely, the US end is ejected first from the 
progeny capsid (46, 133).  The product of DNA packaging is an angular capsid that contains 
tightly packed viral DNA (16, 70).  This mature capsid, also known as a C-capsid, exits the 
nucleus and is incorporated into virions.   
In the absence of successful packaging, two capsid by-products accumulate in nuclei.  B-
capsids contain the cleaved scaffold proteins VP21, VP22a, and VP24; A-capsids are empty (70). 
The three types of capsids are distinguishable in electron micrographs, and they can be separated 
from each other preparatively by sucrose density gradient ultracentrifugation. B- and A-capsids 
are thought to form when DNA packaging is terminated prior to or after insertion of DNA, 
respectively.  DNA packaging can be blocked by null mutations of the UL6, UL15, UL17, UL25, 
UL28, UL32, and UL33 genes (6, 103, 104, 121, 157, 186, 214).  For most of the packaging 
genes, deletion or null mutation completely eliminates DNA cleavage and packaging, such that 
the DNA concatemer is unresolved and only B-capsids are formed. UL25 mutants, however, 
have a dissimilar phenotype to that of the other packaging gene mutants.  Deletion of UL25 
results in the formation of A-capsids and nearly unit-length genomes that are aberrantly cleaved 
at the US end of the genome (30, 121, 205).  
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The UL25 gene product is a 580 amino-acid, 62 kDa protein that contains an unstructured 
N-terminal tail and core of packed alpha helices (19). UL25 protein (pUL25) attaches to the 
external vertices of HSV-1 capsids (30, 137, 224). Based on the crystal structure of a truncated 
pUL25 lacking the N-terminal 134 amino acids, pUL25 was predicted to occupy the penton-
distal region of the UL25-UL17 heterodimer (CCSC), which is present in five copies at each 
capsid vertex (224). pUL25 interaction with the capsid structural proteins has been tested directly 
by immunoprecipitation and far-Western assays (148, 188).  Formation and stability of the 
CCSC is dependent on its interaction with the major capsid protein pUL19 (VP5) and the triplex 
protein pUL18 (VP23) (188), and pUL25 may also bind to the triplex protein pUL38 (VP19c) 
(148). Much like the accessory proteins of the double-stranded DNA bacteriophages, 
accumulation of UL25 protein may reinforce the capsid to prevent loss of DNA (121, 137). 
pUL25 has been shown to interact with pUL6, which forms a dodecameric ring that serves as the 
portal of entry for DNA into the procapsid and the docking site for the terminase complex (143, 
156, 221, 237). In structural studies, pUL25 has not yet been observed around the portal.  
However, because pUL25 prevents aberrant cleavage of viral genome termini (205), pUL25 
could be involved in stabilizing the terminase complex on the portal while DNA is being actively 
packaged, or in sealing off the portal for DNA retention after completion of packaging. 
Its flexible nature and accessibility on the capsid surface has implicated pUL25 in 
interactions required for trafficking capsids through infected cells. Quantification of pUL25 copy 
numbers on intranuclear C-capsids and those in virions revealed that more pUL25 is present on 
capsids that leave the nucleus, suggesting that capsid-associated pUL25 is required for nuclear 
egress (98, 217, 224); UL25 involvement in nuclear egress has been confirmed in HSV-1 and 
pseudorabiesvirus (98, 102, 147, 169). It has been suggested that conformational changes of the 
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capsid proteins induced by DNA packaging expose pUL25 binding sites at the capsid surface, 
such that accumulation of pUL25 serves as a signal for nuclear egress (224). pUL25 recruits the 
large tegument protein pUL36 to virus assembly compartments, and it is the pUL25 interaction 
with pUL36 that initiates tegumentation around the capsid pentons (27, 32, 156, 253).  The 
pUL25/pUL36 complex may also contact microtubules and the nucleoporins; these interactions 
would transport capsids from the cell periphery to the nucleus and dock them on the nuclear pore 
before the viral genome is released (93, 156, 169). Finally, UL25 is required at a very early stage 
in infection, in the uncoating of the viral genome (169).  
In this study, we completed a mutational analysis of UL25 to define regions of UL25 
protein important for viral replication and capsid attachment. The pUL25 capsid-binding domain 
is located in the N-terminal 50 amino acids and is essential for successful viral replication and 
DNA packaging in vivo. The capsid-binding domain of pUL25 was further defined by making 
small deletions and point mutations within the N-terminal 50 amino acids. In addition, UL25 
mutants that bind capsids in vivo without promoting the formation of infectious particles were 
isolated. These mutations may span regions of UL25 protein that are required for capsid 
maturation from the nucleus or other downstream events in virion assembly.  
2.3 MATERIALS AND METHODS 
2.3.1 Cells, viruses, and antibodies 
African green monkey kidney cells (Vero; American Type Culture Collection, Rockville, MD) 
and UL25-transformed 8-1 cells (121) were propagated in 5% FBS/DMEM with penicillin 
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(10U/ml) and streptomycin (10µg/ml) at 37° and 5% CO2. HSV-1 wild-type KOS strain and 
UL25-null virus KUL25NS have been previously described (121). The rabbit polyclonal 
antibody NC1 (31) was used in Western blots to detect the HSV-1 major capsid protein, pUL19 
(VP5).  Baculovirus-expressed UL25 protein (121) was purified and used to prepare a UL25 
monoclonal antibody, 25E10, that was provided by W. Newcomb, University of Virginia (33). 
2.3.2 Transposon mutagenesis 
The transposition reaction was done following the GPS-LS protocol (New England Biolabs). The 
GPS-LS system is an in vitro method for random insertion of a 1.7 kbp transposon (Tn7-based 
transprimer) that encodes a kanamycin resistance gene, KanR. The mutagenesis is accomplished 
by introduction of a transposon that contains the 8 bp PmeI site; the majority of the transposon is 
then removed by restriction digestion with PmeI. Religation results in a 15 bp insertion, which 
retains the unique PmeI site. Plasmid pAPV-UL25 contains the UL25 gene expressed from the 
HSV-1 ICP6 promoter and was used as the template for the transposition (121). Following 
transposition, the plasmid was transformed into bacteria and plated on selective agar containing 
kanamycin and ampicillin. DNA extracted from individual colonies was analyzed using a 
restriction enzyme (PmeI) to map the site of the transposition. Plasmids with insertions that 
mapped within the UL25 open reading frame were digested with PmeI to remove transposon 
sequences, religated, and transformed into bacteria. The mutants were sequenced (University of 
Pittsburgh DNA sequencing core laboratory) to confirm the positions and residues inserted as a 
result of the transposition. 
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2.3.3 Construction of UL25 mutants 
UL25-expressing plasmids were made by PCR using pAPV-UL25 as a template followed by 
Topo cloning of the gel-purified PCR products into pcDNA3.1/V5/His-TOPO (Invitrogen) such 
that the UL25 gene was under the transcriptional control of the cytomegalovirus (CMV) 
promoter. PCR primers contained BamHI and EcoRI restriction sites that were used for further 
subcloning. UL25 plasmids pFH274, pFH284, pFH368, and pFH379 contained the coding 
sequences for UL25 amino acids 37 to 580, 1 to 580, 1 to 50, and 51 to 580, respectively. The 
primers used to amplify these regions of UL25 are listed in Table 9 (Appendix A). The UL25 
Topo clones were digested with BamHI, and UL25 sequences were then ligated into the BamHI 
site of plasmid pFH118. pFH118 expresses proteins (using the CMV promoter) with a C-
terminal tandem affinity purification (TAP) tag and was constructed from plasmid pZOME-1-C 
(obtained from EUROSCARF, Institute of Microbiology, University of Frankfurt, Germany) 
(178). pZOME-1-C was digested with BamHI and EcoRI, and a 540-bp fragment containing the 
TAP ORF was cloned into pcDNA3 at the BamHI and EcoRI sites to generate pFH118. Plasmids 
pFH290, pFH373, and pFH392 expressed UL25-TAP fusion proteins 1-580-TAP, 1-50-TAP, 
and 51-580-TAP, respectively. 
2.3.4 Complementation assay 
Vero cells (1.0 x 105 cells/well in a 24-well plate) were transfected with 0.5 µg of plasmid DNA 
and 1 µl of Lipofectamine 2000 (Invitrogen) diluted in 100 µl of serum-free medium. The DNA-
lipid complexes were allowed to form at room temperature for 20 min, added to the cells, and 
incubated overnight at 37°C. The next day, the cells were infected with UL25-null virus 
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(v∆UL25) at a MOI of 5 PFU/cell. After 90 min at 37°C, the medium was removed and 
unabsorbed virus was inactivated by washing the cells three times with citrate buffer (pH 3). The 
cultures were incubated for an additional 18 h, after which the cells were scraped from the plate 
and rinsed with PBS. A 10% aliquot of total cells was frozen and used to determine virus titers 
on 8-1 cells and Vero cells. The remainder of the cell pellet was resuspended in 20 µl PAGE 
loading buffer (Invitrogen) and used for Western blot analysis. 
2.3.5 In vitro binding of pUL25 to capsids 
Binding was performed with capsids lacking pUL25 that were prepared from Vero cells infected 
as described below with the UL25-null mutant virus, v∆UL25. Synthesis of [35S]-methionine-
labeled UL25 was carried out in a rabbit reticulocyte lysate using a coupled transcription and 
translation system (TNT T7Quick; Promega) according to the manufacturer’s instructions using 
pGEM-4z, pcDNA3.1/V5-HIS-TOPO, or pFH118 vectors expressing wild-type or mutant UL25 
genes. The [35S]methionine-labeled UL25 (45 µl of the 50 µl in vitro translation reaction) was 
mixed with 50 µl of pooled A- and B-capsids plus 400 µl of phosphate-buffered saline (PBS), 
and the mixture was incubated for 90 min at room temperature with constant rotation. Capsids 
were isolated from the reaction mixture by centrifugation on a gradient of 20% to 50% sucrose in 
TNE (500 mM NaCl, 10 mM Tris, 1 mM EDTA [pH 7.5]) on an SW41 rotor at 24,000 rpm for 1 
h at 4°C. After centrifugation, capsids were harvested from the gradient, precipitated by addition 
of an equal volume of 16% trichloroacetic acid, and analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). Gels were stained with Coomassie blue and 
dried onto Whatman 3M filter paper prior to autoradiography. 
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2.3.6 Construction of recombinant BACs 
Production and characterization of a bacterial artificial chromosome (BAC) containing the entire 
HSV-1 (KOS-37 strain) genome was described previously (71). The KOS BAC clone (bFH439) 
containing a deletion that removed the entire UL25 ORF was produced with a counter-selection 
BAC modification kit (Genebridges). Briefly, the Red/ET expression plasmid pSC101-BAD-
gbaA (Genebridges) was transformed into EPI300 bacteria containing the wild-type KOS-37 
BAC. After induction of Red/ET expression, cells were transformed with a PCR product 
consisting of the rpsL-neo antibiotic selection cassette flanked by sequences homologous to 50 
bp immediately upstream and downstream of the UL25 ORF. Recombinant clones were isolated 
on selective agar medium, and deletion of UL25 from BAC DNA was confirmed by PCR with 
primers external to the recombination locus. To create specific UL25 mutations, the KOS BAC 
clone was transferred to GS1783 bacteria (gift from G. Smith) and mutagenesis was performed 
using the two-step bacteriophage Red-mediated homologous recombination system described by 
Tischer et al. (218). PCR was used to produce a construct that contained the KanR gene (alphAI 
from plasmid p-EP-Kan-S) flanked by UL25 homologous sequence repeats containing the 
desired mutation or deletion. Integration of this construct into the BAC was followed by a second 
recombination that removed alphaAI and left the seamless mutation within the UL25 gene. The 
list of primers for production of PCR amplicons that were used for isolation of the UL25 deletion 
and insertion mutants can be found in Tables 10 and 11 (Appendix A). To confirm mutations in 
UL25 mutant viruses, viral DNA was amplified by PCR with the primers 5’-
GCAGAAGGTCTCCGGTAATATCACC-3’ and 5’-GGTGATCAGGTACAACAGGCGCTC-
3’.  The 2.9 kb PCR product was extracted from agarose gels and used for restriction digest and 
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for sequencing with primers 5’-GCGGCGGCCGCAAGACTCATTTGGATCCG-3’ and 5’-
TCTCCGCGACGGCCAGAC-3’ (GeneWiz sequencing core). 
2.3.7 Virus generation and propagation 
To recover mutant viruses, BAC DNA (5 µg) was transfected into 8-1 cells with Lipofectamine. 
Recombinant viruses harvested from transfected cell lysates were plaque purified on 8-1 or Vero 
cells. The third round plaque isolate was used to generate a mini-stock of virus in a T25 flask of 
Vero or 8-1 cells.  Cell lysates were freeze-thawed, and virus mini-stock concentrations were 
determined by plaque assay on 8-1 cells.  To prepare a large stock of virus, 1.5 x 108 Vero or 8-1 
cells were infected at a MOI of 0.01.  At 3 days post-infection, cell lysates were harvested by 
freeze-thaw.  Clarified cell lysates were centrifuged at in a Sorvall SS34 rotor at 10000 RPM for 
2 hours to pellet virions from the media. The virion pellet was resuspended in 10% 
glycerol/DMEM overnight on ice.  The resultant virus stock was titrated on Vero and 8-1 cells.   
2.3.8 Preparation of viral DNA 
Viral DNA was prepared essentially as described in (21), with the following modifications.  A T-
175 flask (3 x 107) of Vero cells was infected with virus at a MOI of 1 PFU per cell. At 48 h 
post-infection, the medium was removed and the cells were washed in 1x PBS, scraped off the 
plate, and pelleted. The cells were resuspended in TE and lysed in Triton X-100 (1.5%) on ice 
for 15 minutes.  Nuclei were pelleted by centrifugation at 2000 rpm for 10 minutes and 
subsequently discarded. Virus was lysed by incubation at 50°C with SDS (0.5%) and Proteinase 
K (0.5µg/µl) for 1 h.  DNA was extracted with phenol once and chloroform twice before being 
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precipitated with 1/10 volume sodium acetate and 2 volumes ethanol.  Pelleted DNA was dried 
and resuspended in TE or sterile ddH2O with RNAse A. 
2.3.9 Southern blot and hybridization analysis 
Viral DNA (10µg) was digested with BamHI and PmeI to confirm the transposon mutations. 
DNA was separated by agarose gel electrophoreses and transferred in alkaline buffer to a 
positively-charged nylon membrane. The 1.8 kbp fragment of plasmid pFH283 containing UL25 
was recovered by BamHI digest and agarose gel extraction.  The UL25 fragment was 
radiolabeled by nick translation reaction (GE Biosciences) with 32P-dCTP (PerkinElmer). 
Unincorporated nucleotides were removed from the probe by CentriSep gel filtration columns 
(Princeton Separations). Southern blots were pre-incubated with hybridization buffer (5X SSC, 
5X Denhardt solution, 1% SDS, 100µg/ml denatured salmon sperm DNA) at 68°C for 3h.  The 
probe was boiled, quick-cooled on ice, added to hybridization buffer, and incubated with blots 
overnight at 68°C. The next day, blots were washed twice in 2X SSC/0.1% SDS and once in 
0.1X SSC/0.1% SDS at 68°C before autoradiography.  
2.3.10 Immunoblotting 
Protein extracts were separated on a 5 to 12% SDS–polyacrylamide gel, and proteins were 
transferred to nitrocellulose. The nitrocellulose was washed twice in Tris-buffered saline (TBS) 
and blocked overnight in TBS-T (20 mM Tris, 0.5 M NaCl [pH 7.5] plus 0.5% Tween 20) 
supplemented with 10% nonfat dry milk. The UL25 monoclonal antibody, 25E10, and the VP5 
rabbit polyclonal antibody, NC1, were diluted to 1:5000 in blocking buffer. The diluted 
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antibodies were reacted with the blocked nitrocellulose for 2 h at room temperature, washed, and 
reacted with horseradish peroxidase-conjugated anti-goat or anti-mouse immunoglobulin G 
(IgG) diluted at 1:5000 in TBS-T plus 10% nonfat dry milk. The bound Igs were revealed by 
enhanced chemiluminescence (Pierce ECL kit). 
2.3.11 Capsid preparation 
Vero cells (1.5 x 108) were infected overnight (18 h at 37°C) at a MOI of 5 PFU/cell. Infected 
cells were harvested, rinsed with PBS, and resuspended in 20 mM Tris (pH 7.5) plus protease 
inhibitors (Roche), adjusted to 1% Triton X-100, and incubated for 30 min on ice. The resulting 
nuclei were harvested by low-speed centrifugation at 2000 rpm, resuspended in 10 ml TNE (500 
mM NaCl, 10 mM Tris, 1 mM EDTA [pH 7.5]), and then sonicated to lyse the nuclei. The 
nuclear lysate was adjusted to 20 mM MgCl2 and incubated with DNase I (100 µg/ml) at room 
temperature for 30 min. The lysate was then cleared by low-speed centrifugation, and the 
resulting supernatant was layered on top of a 10-ml cushion of 35% sucrose (SW28 rotor; 23,000 
rpm for 1 h). The pellets were suspended in 3 ml TNE and adjusted to 1 mM dithiothreitol, and 
capsids were separated by centrifugation on 20 to 50% sucrose (in TNE) gradients (SW41 rotor 
at 24,000 rpm for 1 h). The positions of A-, B-, or C-capsids were observed as light-scattering 
bands, with A-capsids being found highest (least dense) on the gradient and C-capsids found 
lowest (dense fractions) on the gradients. The different capsid fractions can also be identified 
based on the presence or absence of the scaffold protein, VP22a, since only B-capsids contain 
the scaffold protein. The fractions were collected using a Beckman fraction recovery system 
(Beckman catalog no. 34890). The apparatus has a mechanism to puncture the bottoms of the 
tubes, and fractions are collected from the bottom to top. Fractions (0.75 ml) were collected, and 
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protein was precipitated by adding an equal volume of 16% trichloroacetic acid. Pellets were 
resuspended in 35 µl of 2x PAGE loading buffer (Invitrogen) supplemented with 0.4 M Tris-
base. Gradient fractions were run on 5 to 12% SDS-PAGE, and the gels were either stained with 
Imperial blue (Pierce) to visualize capsid proteins or analyzed by immunoblotting with the UL25 
(25E10) antibody. 
2.3.12 Indirect immunofluorescence assay 
2 x 105 Vero cells grown on coverslips were infected at a MOI of 5 for 1 h on ice.  Cells were 
washed twice with DMEM to remove unattached virus, then incubated in DMEM at 37°C to 16 h 
post-infection.  Coverslips were rinsed twice in PBS, and cells were fixed in 2% PFA in PBS for 
15 minutes.  Coverslips were rinsed 3x in PBS and 5x in 0.5% BSA/PBS (PBB).  Cells were 
blocked in 20% goat serum/PBB for 30 minutes, then incubated with the 25E10 antibody (1:200 
in blocking buffer) for 1 h.  After rinsing 5x with PBB, coverslips were incubated with Cy3-
conjugated secondary antibody (1:1800) for 1 h.  Cells were rinsed 5x in PBB, stained with 
DAPI, washed 3x in PBS, and mounted on glass slides with Immunomount medium.  
Fluorescence was visualized on a Leica DMI4000B microscope.  Images were captured with the 
Leica application software and imported to Adobe Photoshop for cropping and resizing. 
2.3.13 Thin section electron microscopy 
Vero cells (2 x 106) were infected overnight (18 h at 37°C) at a MOI of 5 PFU/cell.  Cells were 
rinsed in 1X PBS, fixed in 2.5% glutaraldehyde for 1 h at RT, and rinsed several times with 1X 
PBS to remove the fixative.  The samples were stained (1% OsO4/1% potassium ferricyanide), 
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sectioned, and prepared onto carbon grids for transmission electron microscopy by Mara 
Sullivan of the Center of Biologic Imaging, University of Pittsburgh. Images were captured with 
a T12 electron microscope with the assistance of Katerina Toropova (University of Pittsburgh 
Department of Structural Biology).  
2.4 RESULTS 
2.4.1 Transposon mutagenesis and functional assessment of UL25 mutants 
In order to identify regions of UL25 protein that are important for viral replication and for 
attachment to capsids, the UL25 ORF was randomly disrupted by linker scanning mutagenesis. 
A plasmid vector (pAPV-UL25) containing the UL25 gene was subjected to Tn7 transposon-
mediated insertion of a 15 bp fragment that contained a PmeI restriction site. Eleven clones with 
unique DNA insertions in the coding region of the UL25 gene were mapped by restriction 
digestion and DNA sequencing. The resulting amino acid insertions into the UL25 protein are 
shown in Figure 8. The mutations were scattered across the UL25 ORF with a clustering of three 
insertions between amino acids 143 and 155. Three of these mutants contained in-frame stop 
codons after amino acids 12, 212, and 560.  
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Figure 8. Diagram of UL25 transposon mutations. (Top left) Physical map of the HSV-1 genome 
showing the location of the UL25 gene. UL and US refer to the long and short unique region sequences.  
(Bottom left) Schematic representation of the 580 amino acid UL25 protein. White boxes are the folded 
protein core, and gray boxes are the flexible, unstructured regions, as determined by characterization of the 
UL25 crystal structure (19). Numbers above the line indicate the amino acid location where 15 base pairs 
were inserted into the UL25 open reading frame resulting in either the insertion (i) of five amino acids or an 
in-frame stop codon (s).  (Right) The location of the insertions and the predicted amino acid changes are 
shown along with the predicted molecular weight for each mutant. *, stop codon. This figure was used with 
permission from reference (30). 
 
 
The ability of the UL25 transposon mutants to support virus replication was tested using 
a genetic complementation assay. Vero cells were transfected with wild-type and mutant 
plasmids, and the next day the cells were infected with the UL25 deletion virus, v∆UL25. 
Following another day of incubation, the cell lysates were harvested, tested for UL25 protein 
expression by Western blot analysis, and assayed for virus progeny yield by plating the lysates 
on UL25-complementing cells (8-1 cells). With the exception of the 12s mutant, all of the 
plasmids produced proteins of the expected sizes (Figure 9A). Eight of the transposon mutants 
expressed a UL25 protein that was similar in size to the wild-type UL25 protein. For these 
mutants, a size difference would not be apparent since only five amino acids were added to the 
mutant UL25 proteins. The two nonsense mutants 212s and 560s produced proteins of 23 and 60 
kDa, respectively. No immunoreactive proteins were observed for the 12s mutant, but this 
plasmid was predicted to make only a small peptide that would probably not be recognized by 
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the UL25 antiserum. Using the HSV-1 major capsid protein (UL19) as a loading control, all of 
the mutants except the 12s mutant were found to express similar amounts of pUL25 (Figure 9A). 
The ability of the UL25 mutants to complement growth of the UL25-null mutant was determined 
by titrating the cell lysates on 8-1 cells. Figure 9B shows that, with the exception of the three 
truncation mutants (12s, 212s, and 560s) and the 143i mutant, the remaining mutants were able 
to complement the UL25-null virus, although the 155i and 403i mutants complemented at less 
than 10% of the wild-type UL25 protein. 
 
 
Figure 9. Complementation assays of the UL25 transposon mutants. The UL25 transposon mutants 
were examined for their ability to complement the growth of the UL25 null virus. A. Western blots for UL25 
protein and major capsid protein, UL19.  Molecular weight standards in kDa are shown at left. B. The 
progeny virus was titrated on the UL25 complementing cell line, 8-1, and the results shown are averages of at 
least six experiments.  Error bars represent the standard deviation.  The data listed at the bottom is the 
percentage of complementation relative to the wild-type UL25 protein. This figure was used with permission 
from reference (30). 
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2.4.2 The N-terminus of pUL25 is required for capsid attachment in vitro 
Previously, we showed that [35S]-methionine-labeled UL25 synthesized in a coupled in vitro 
transcription-translation system attached to the surface of UL25-deficient capsids during in vitro 
incubation (137). To determine if mutations that eliminated complementation also affected 
pUL25 capsid attachment, the 12s, 143i, 212s, and 560s mutants were tested for in vitro capsid 
binding. In vitro translation of plasmids containing the 143i, 212s, and 560s mutants produced 
proteins corresponding to their predicted molecular weights (Figure 10A). Unexpectedly, in vitro 
translation of the 12s mutant produced a nearly wild-type-size protein (Figure 10A). Capsid 
binding was determined by adding an aliquot of the [35S]-methionine-labeled UL25 to pooled A- 
and B-capsids derived from the nuclei of cells infected with the UL25-null mutant, v∆UL25 
(Table 6). After incubation to allow pUL25 attachment, the capsids were separated from other 
reaction components by centrifugation on a sucrose gradient, and gradient fractions were 
analyzed by SDS-PAGE followed by autoradiography. Capsid attachment was indicated by 
comigration of UL25 protein with capsids in the sucrose gradient (Figure 10B and C).  
The 143i, 212s, and 560s proteins attached to capsids. Although the 212s protein was 
found to be primarily associated with the fractions containing A- and B-capsids, significant 
levels of the protein were found in fractions denser than capsids. This was probably the result of 
aggregation of the truncated UL25 protein, as evidenced by the observation that this protein is 
found in the same dense fractions when the in vitro-translated protein was run on the gradient in 
the absence of A- and B-capsids (Figure 10C). In contrast to the 143i, 212s, and 560s mutants, 
the 12s translation product did not attach to capsids, although we cannot rule out that there may 
be some low-level binding since the amount of radiolabeled 12s protein was reduced compared 
to the amounts of the other UL25 proteins.  
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Figure 10. Capsid binding by UL25 transposon mutants. A. Autoradiograph of [35S]Met-labeled 
UL25 protein after SDS-PAGE.  The sizes of the 143i, 212s, and 560s proteins were consistent with predicted 
molecular mass for each protein, while the 12s mutant unexpectedly produced a near wild type sized UL25 
protein.  B, C. In vitro capsid-binding assay.  In vitro-translated protein was incubated with pooled A- and B-
capsids isolated from Vero cells infected with the UL25 null virus, vΔUL25, and then purified by sucrose 
gradient centrifugation.  The sucrose gradients were fractionated and analyzed by SDS-PAGE followed by 
Coomassie staining (top panel, representative gel) and autoradiography (bottom panels). The fractions 
containing A- and B-capsids are indicated. The capsid proteins visible in the stained gel are listed at right. 
Capsid-binding was demonstrated by co-migration of the UL25 protein with A- and B-capsids. Aggregation 
of the truncated 212s protein may explain the presence of this protein in the same dense fractions as in the 
gradient lacking A- and B-capsids (bottom of panel C). IVT, in vitro transcription-translation; M, molecular 
weight markers (from top, 194, 104, 60, 41, 27, 21, 16, 7 kDa).  Lane 1 is the bottom and lane 10 is the top of 
the gradient. This figure was amended with permission from reference (30).  
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Examination of the UL25 coding sequence revealed that after the first AUG, the next in-
frame AUG start codon was located 120 bp downstream. This start site corresponded to UL25 
amino acid 37. To determine if the 12s mutant was initiating at this downstream start site, the 
codons for amino acids 1 to 36 were deleted from the UL25 expression plasmid (Figure 11A). 
The resulting in vitro synthesized protein, containing UL25 amino acids 37 to 580, was identical 
in size to the 12s mutant in vitro translation product (Figure 11B).  
Similar to the result with the 12s protein, the UL25 N-terminal truncation (37 to 580) 
mutant did not bind capsids when tested in the in vitro capsid-binding assay (Figure 11C). In 
addition, this mutant did not complement the UL25-null virus (data not shown). These results 
demonstrated that the sequences within the N-terminus of the UL25 protein are required for 
capsid binding. To determine if the UL25 N-terminus was sufficient for capsid binding, three 
plasmids were generated that expressed portions of UL25 protein fused at its C-terminus to a 
tandem affinity purification (TAP) tag (Figure 11A). The TAP tag consists of the IgG-binding 
peptide protein A, the cleavage site for the tobacco etch virus protease, and the calmodulin 
binding domain; the tag adds 178 amino acids (20 kDa) to the C-terminus of the UL25 fusion 
protein (178). The three constructs 1-580-TAP, 51-580-TAP, and 1-50-TAP contained the full-
length UL25 protein, UL25 amino acids 51 to 580, and UL25 amino acids 1 to 50 fused to the 
TAP tag, respectively (Figure 11A). In vitro translation produced proteins corresponding to their 
predicted size, and each protein was tested for binding to UL25-deficient A- and B-capsids 
(Figure 11A to C). Like the 12s and 37-580 mutants, the UL25 fusion protein 51-580-TAP did 
not attach to capsids. In contrast, the full-length 1-580-TAP and truncated 1-50-TAP fusion 
proteins were able to bind capsids. When incubated with A-, B-, and C-capsids purified from 
KOS-infected cells, the 1-50-TAP but not the 51-580-TAP was found to bind all three capsid 
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types by binding to unoccupied sites on the capsids and/or competitively displacing wild-type 
protein from capsids (Figure 11D). These results demonstrated that UL25 amino acids 1 to 50 
mediate capsid attachment in the in vitro capsid-binding assay. 
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Figure 11. Capsid binding by UL25 N-terminal mutants.  A. UL25 N-terminal truncation and TAP 
fusion constructs are shown.  The numbers listed on the left indicate the UL25 amino acids included in each 
construct. The TAP constructs contained the tandem affinity purification (TAP) tag fused to the C-terminus 
of UL25.  The predicted MW of each protein is listed in parentheses.  B. Autoradiograph of in vitro 
translation products after SDS-PAGE.  Molecular weight markers in kDa are shown at left.  Each protein 
showed appropriate MW either due to addition of the TAP tag or deletion of the UL25 N-terminal amino 
acids. C.  In vitro capsid-binding assay.  In vitro-translated protein was incubated with pooled A- and B-
capsids isolated from Vero cells infected with the UL25 null virus, v∆UL25, and then purified by sucrose 
gradient centrifugation. A representative Coomassie stained gel of the gradient fractions is shown (top panel). 
Autoradiographs of dried gels demonstrated the binding of the proteins 1-580-TAP and 1-50-TAP, but not 
the 51-580-TAP or the 37-580-TAP, to the two capsid types (bottom panel). D. In vitro-translated protein was 
incubated with pooled wild type KOS A-, B-, and C-capsids and then purified by sucrose gradient 
centrifugation.  A representative stained gel of the gradient fractions is shown (top panel).  Autoradiographs 
of dried gels demonstrating the binding of the 1-50-TAP but not the 51-580-TAP to all three capsid types 
(bottom panel).  The fractions containing A-, B-, and C-capsids are indicated. The capsid proteins visible in 
the stained gel are listed at right. IVT, in vitro transcription-translation; M, molecular weight markers (from 
top, 194, 109, 59, 30, 22, 13, 6 kDa). Lane 1 is the bottom and lane 10 or 11 is the top of the gradient. This 
figure was amended with permission from reference (30). 
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2.4.3 Introduction of UL25 mutations to the viral genome 
Several of the UL25 mutations were introduced into the viral genome through the genetic 
manipulation of an HSV-1 (KOS) genome maintained in a recombinant bacterial artificial 
chromosome (BAC). The genotypes of the viruses used in these studies are listed in Table 6. 
Virus v∆UL25 contains the rpsLneo antibiotic resistance genes, which replace the entire UL25 
ORF. Recombinant viruses v143i, v155i, v212s, and v560s contain the indicated UL25 linker 
insertion mutations (Figure 5A). Recombinant virus v∆1-50 contains a deletion that removed the 
coding sequences for UL25 amino acids 1 to 50, which were replaced with an ATG start codon. 
The BACs used to generate each virus were confirmed by digesting them with BamHI and PmeI. 
The UL25 ORF is contained within the HSV-1 2.3 kbp BamHI U fragment (118, 164) (Figure 
12A). Since there are no PmeI sites in the HSV-1 genome, the presence of the PmeI linker in the 
UL25 gene of the HSV-1 BACs 143i, 155i, 212s, and 560s resulted in the loss of the 2.3 kbp 
BamHI U fragment, which was shifted to a smaller fragment that comigrates with other HSV-1 
BamHI fragments (Figure 12B). The HSV-1 BAC ∆1-50 contained the deletion of 150 bp in 
UL25, which was detected as a shift in the BamHI U fragments (Figure 12B). The BACs were 
transfected onto UL25-complementing 8-1 cells, and the recovered viruses were plaque purified 
on Vero or 8-1 cells. Each mutant was titrated on Vero and 8-1 cells to determine the effects of 
UL25 mutations on viral replication (Table 6). Vero cells were nonpermissive for the replication 
of v∆UL25, v143i, v212s, v560s, and v∆1-50. The virus v155i displayed an intermediate 
phenotype with a six fold reduction of growth on Vero cells as compared to the UL25-
complementing cell line. To verify the presence of the mutations in the progeny virus, viral DNA 
was digested with BamHI and PmeI and subjected to Southern blot analysis with the 32P-labeled 
UL25 probe (Figure 12C). As seen in the restriction enzyme digestion analyses of the individual 
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BAC preparations, a prominent 2.3 kbp fragment was detected in the KOS lane, which was 
reduced to two smaller fragments in v143i, v155i, v212s, and v560s and one smaller fragment in 
v∆1-50. The 400 bp fragment for v560s was observed on longer exposure (not shown). The 2.3 
kbp fragment containing the UL25 ORF was not detected in the UL25 deletion virus v∆UL25. 
These results demonstrated that that the UL25 mutants had the desired insertions or deletions. 
TABLE 6. Virus stock titers: Transposon insertion and N-terminal truncation mutants 
 UL25 protein expressed PFU/ml in: 
Virus strain (amino acid positions) Vero cells 8-1 cells 
KOS Wild type (1–580) 2 x 108 2 x 108 
KUL25NS Null (1–107) 3 x 104 2 x 108 
v∆UL25 Null <1 x 102 9 x 107 
v143i 143i (1–580) <1 x 102 3 x 107 
v212s 212s (1–212) <1 x 102 1 x 107 
v560s 560s (1–560) <1 x 102 2.7 x 107 
v155i 155i (1–580) 1 x 107 6 x 107 
v∆1-50 ∆1-50 (51-580) <1 x 102 3 x 108 
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Figure 12.  Characterization of BAC DNA and HSV-1 infected cell DNA.  A. Schematic 
representation of the BamHI region located between nucleotides 48635-50929 of the HSV-1 genome that 
contains the UL25 ORF.   The sites where unique PmeI restriction sites are found in the UL25 gene and the 
resulting BACs and viruses (143i BAC, 155i BAC, 212s BAC, 560s BAC) are listed on top. Δ1-50 BAC 
contained a deletion that removes the coding sequences for UL25 amino acids 1-50 and inserts a new ATG 
start codon. B. BAC DNA was digested with BamHI and PmeI and run on a 1.2% agarose gel.  The wt 2.3 
kbp BamHI fragment is present in the KOS BAC lane (arrow).  This fragment was cleaved to smaller 
fragments by PmeI in 143i BAC, 155i BAC, 212s BAC, and 560s BAC.  The UL25 fragment of  Δ1-50 BAC is 
shifted to 2.1 kbp , which comigrates with another viral band. C. Southern blot of viral DNA.  Viral DNA was 
purified from cells infected with the indicated viruses. Viral DNA (10µg) was digested with BamHI and PmeI 
and run on 1.2% agarose gel.  DNA was blotted to a nylon membrane, and the blot was hybridized with the 
32P-labeled UL25 probe. The wt BamHI fragment containing UL25 is visible at 2.3 kbp in the KOS lane and 
was cleaved to smaller fragments by PmeI in v143i, v155i, v212s, and v560s.  The UL25 fragment of vΔ1-50 is 
shifted to 2.1 kbp. M, DNA markers in kbp. This figure was amended with permission from reference (30). 
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2.4.4 Association of pUL25 with capsids in vivo 
Intranuclear capsids were purified from Vero cells infected with wild-type KOS or UL25 mutant 
viruses. The nuclear lysates were subjected to sucrose gradient centrifugation, and capsids were 
viewed as visible light-scattering bands (Figure 13). In cells infected with wild-type KOS or 
v155i, which replicate on Vero cells, all three capsid forms were observed. The KOS gradients 
contained nearly equal amounts of both B- and C-capsids, with only minor amounts of A-
capsids. In contrast, the gradient for the v155i mutant contained less C-capsids and more A- and 
B-capsids, and the C-capsid band was barely detectable in the v155i gradient. The lysates of the 
UL25 mutants that did not replicate on Vero cells (v∆UL25, v143i, v212s, v560s, v∆1-50, and 
KUL25NS) contained approximately equal numbers of A- and B-capsids but no DNA-containing 
C-capsids. The high proportion of A-capsids found along with the absence of C-capsids in all of 
these UL25 mutants is identical to what was previously described with the UL25-null mutant 
KUL25NS (121).  
 
 
Figure 13. Capsid phenotypes of UL25 mutant viruses.  Vero cells infected at a MOI of 5 with KOS 
or the indicated virus were harvested at 18 h post infection. Nuclear lysates were layered onto 20 to 50% 
sucrose gradients and centrifuged at 24,000rpm (SW41 rotor) for 1 h. The position of A-, B-, and C-capsid 
bands are indicated. This figure was amended with permission from reference (30). 
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To determine whether the UL25 protein was present in these capsids, the sucrose gradient 
fractions were analyzed by Western blot (Figure 14). The KOS gradient showed that pUL25 was 
found in the fractions that contained A-, B-, and C-capsids. The 155i mutant was found to 
associate with A- and B-capsids, but since there were so few C-capsids present on the gradient, 
there was little if any of this protein detected with these DNA-containing capsids. The UL25 
linker insertion mutant 143i and the nonsense mutants 212s and 560s were found associated with 
A- and B-capsids isolated from cells infected with viruses expressing those proteins. The v∆1-50 
mutant expressed a truncated UL25 protein that was missing residues 1 to 50, and although this 
protein could be detected in the cell extract, it failed to bind either the A- or B-capsids. This 
result demonstrates the importance of the N-terminus of pUL25 for its capsid association. These 
data also demonstrate that similar to the result of the in vitro capsid-binding assay (Figure 11), 
the pUL25 capsid-binding domain resides within its first 50 amino acids. Furthermore, the 
studies with the UL25 mutant viruses demonstrate that the pUL25 capsid-binding domain is 
essential but not sufficient for production of infectious virus, as both virus progeny and C-
capsids were significantly reduced in non-complementing cells infected with the 155i mutant 
(Table 6). 
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Figure 14. Analysis of capsid bound pUL25. (Top panels) The protein composition for each gradient 
fraction was determined by SDS-PAGE (stained gel). Lane 1 is the bottom and lane 10 is the top of the 
gradient. Gradient fractions that contained A-, B-, and C-capsids are indicated. The positions of the capsid 
proteins (major capsid protein, VP5; triplex proteins, VP19C and VP23; scaffold protein, VP22a; smallest 
capsid protein, VP26) are indicated at far right. The stained gel in the right panel contains capsids isolated 
from the UL25 null virus ΔUL25, which is representative of the mutants (vΔ1-50, v143i, v212s, v560s) that fail 
to replicate on Vero cells. (Bottom panels) Gradient fractions were analyzed by SDS-PAGE followed by 
immunoblotting for pUL25 using the 25E10 antibody. Lane CL: KOS, cell lysate from KOS-infected cells. 
Lane CL: mut, cell lysate from UL25 mutant-infected cells.   Molecular mass standards are visible in lane M 
(from top, 194, 109, 59, 30, 22, 13, 6 kDa). This figure was amended with permission from reference (30). 
 
2.4.5 Deletion of the pUL25 N-terminus does not inhibit pUL25 nuclear localization 
The virus-expressed UL25 protein deleted of amino acids 1-50 is present in infected cell lysates 
but is not associated with capsids purified from infected cell nuclei (30). It is possible that this 
truncated protein is structurally unstable and consequently, sequestered in the cytoplasm. In this 
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case, the nuclear exclusion of Δ1-50 protein would prevent contact with intranuclear capsids and 
could have led us to erroneously conclude that the capsid-binding domain was located in amino 
acids 1-50.   
 
 
Figure 15. The truncated UL25 protein Δ1-50 localizes to infected cell nuclei.  Vero cells were mock-
infected or infected with ΔUL25, wt KOS, or vΔ1-50.  Cells were fixed at 16 hpi and stained for pUL25 with 
the monoclonal antibody 25E10, the Cy3-congugated secondary antibody, and DAPI.  The following 
parameters were used for image capture: exposure time 0.9-1.3 seconds, gain 1x, and gamma 1-1.4.  
 
Mock     v!UL25           KOS (wt)          v!1-50 
DAPI 
Cy3 
Overlay 
DAPI         Cy3           Overlay 
KOS (wt) 
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To rule out this possibility, indirect immunofluorescence was used to track pUL25 in 
infected cells. Vero cells were mock-infected or infected at a MOI of 5 with KOS, vΔUL25, or 
Δ1-50 viruses and fixed at 16 hours post-infection.  Cells were stained with the pUL25 
monoclonal antibody, 25E10, the Cy3-conjugated secondary antibody, and DAPI.  In mock-
infected cells, nuclei retained clearly defined nucleoli and roughly spherical symmetry, while 
infected cells had distorted nuclei with marginalized host DNA. The Δ1-50 UL25 protein was 
visible in infected cells, and it was predominantly located in cell nuclei (Figure 15).  Like the wt 
protein, Δ1-50 protein was visible in compartments segregated from the host DNA.  These 
compartments have been described as assemblons or replication compartments (234).  We 
conclude that the Δ1-50 UL25 protein is stably expressed and trafficked to the nucleus, and the 
observed defects in virus replication and DNA packaging are specifically due to the inability of 
the truncated protein to attach to capsids.   
2.4.6 Characterization of viruses expressing pUL25 with small deletions and point 
mutations in the highly conserved N-terminal region 
Several residues within the putative capsid-binding domain are highly conserved throughout the 
alphaherpesviruses, particularly through amino acids 26-39 of HSV-1 (Fig 16A).  We 
hypothesized that these highly conserved residues represented the essential amino acids required 
for pUL25 interaction with capsid proteins.  In order to determine the effects of small deletions 
within the UL25 N-terminus on in vivo capsid attachment and virus replication, recombinant 
viruses were generated by manipulation of the HSV-1 KOS strain genome maintained in a 
bacterial artificial chromosome (BAC), as previously described (30, 71, 218). These deletions 
spanned the highly conserved region within amino acids 1-50 and removed amino acids 1-36, 
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27-37, 40-50, and 27-50 (Figure 16B).  Point mutations of the most conserved residues—F26, 
I27, F35, and W36—were also made in pairs (F26 and I27, F35 and W36) or in quadruplet (F26, 
I27, F35, and W36). For each of the alanine substitution mutants, a restriction site was embedded 
into the primers used for BAC recombination (see Methods, Tables 10 and 11).  These mutations 
inserted a unique restriction site while making only conservative changes to the codons 
surrounding the mutated residues. 
 
Figure 16. Generation of HSV-1 mutant viruses containing small deletions or point mutations in the 
highly conserved region of the pUL25 N-terminus.  A.  Alignment of pUL25 amino acids 1-50 from eight 
alphaherpesviruses including human herpesviruses 1, 2, and 3 (HHV1, 2, 3); chimpanzee herpesvirus 1 
(CHV1), suid herpesvirus 1 (SHV1); bovine herpesvirus 1 (BHV1); equine herpesvirus 1 (EHV1); and gallid 
herpesvirus 1 (GHV1).  Sequences were acquired from the NCBI website (GenBank).  The alignment was 
generated with VectorNTI software.  Similar or conservative residues are highlighted in gray; identical 
residues are highlighted in black.  The highly conserved region comprises HSV-1 amino acids F26-P39. B. 
UL25 recombinant viruses.  The highly conserved residues in the WT sequence are shown in bold.  Deletions 
are shown as dashes (-), and alanine substitutions are underlined.   
 
1        10        20        30        40        50 
|        |         |         |         |         || WT  MDPYCPFDALDVWEHRRFIVADSRNFITPEFPRDFWMSPVFNLPRETAAEQ 
!1-36  ------------------------------------MSPVFNLPRETAAEQ 
!27-37  MDPYCPFDALDVWEHRRFIVADSRNF-----------SPVFNLPRETAAEQ 
!40-50  MDPYCPFDALDVWEHRRFIVADSRNFITPEFPRDFWMSP-----------Q 
!27-50  MDPYCPFDALDVWEHRRFIVADSRNF------------------------Q 
F26A I27A  MDPYCPFDALDVWEHRRFIVADSRNAATPEFPRDFWMSPVFNLPRETAAEQ 
F35A W36A  MDPYCPFDALDVWEHRRFIVADSRNFITPEFPRDAAMSPVFNLPRETAAEQ 
F26A I27A F35A W36A  MDPYCPFDALDVWEHRRFIVADSRNAATPEFPRDAAMSPVFNLPRETAAEQ 
B 
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BACs were transfected onto Vero cells and the UL25 complementing cell line, 8-1, and 
the recovered viruses were plaque-purified on Vero or 8-1 cells. Viral DNA was prepared and 
used in PCR with primers flanking the UL25 locus (Figure 17A). In order to detect very small 
deletions in UL25, the PCR products were digested with SacI, which cleaved within the wt UL25 
gene near its 5’ end.  SacI digestion of the wt PCR product liberated DNA fragments of 2.1 and 
0.8 kb; the 0.8 kb fragment is shifted to a lower molecular weight by the small deletions in 
viruses v∆1-36, v∆27-37, v∆40-50 and v∆27-50 (Figure 17B). This method allowed observation 
of the small (≤ 100 bp) shifts in the UL25 gene, which would have been difficult to detect by 
Southern blot.  PCR-amplified DNA from viruses vF26A I27A, vF35A W36A, and vF26A I27A 
F35A W36A was digested with the restriction enzymes XbaI, BcgI, or BsmI in order to detect the 
inclusion of these unique restriction sites in the recombinant viruses.  For additional confirmation 
that the anticipated mutations were in place, the 2.9 kb PCR product from each virus was 
sequenced through the region of the mutations. Each mutant virus was titrated on Vero and 8-1 
cells (Table 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 7. Virus stock titers: Small N-terminal deletion and point 
mutants 
 PFU/ml in: 
Virus strain Vero cells 8-1 cells 
KOS (wild type) 2 x 108 2 x 108 
v∆UL25 <1 x 102 9 x 107 
v∆1-36 < 103 5.9 x 108 
v∆27-37 < 103 3.8 x 108 
v∆40-50 1.9 x 108 2.5 x 108 
v∆27-50 < 103 2.7 x 107 
vF26A I27A < 103 7.5 x 108 
vF35A W36A 3 x 107 1.5 x 108 
vF26A I27A 
 F35A W36A 
< 103 
 
7.1 x 107 
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Figure 17. Confirmation of UL25 mutations in viral DNA.  A. Diagram of the HSV-1 genome 
showing the 2.9 kbp region amplified from viral DNA by PCR. Forward and reverse primers are shown as 
black arrows. The SacI restriction site is shown. B. PCR products were digested with the restriction enzymes 
SacI, XbaI, BcgI, or BsmI. These unique restriction sites were embedded in the primers used for BAC 
recombination (Tables 10 and11).  Digested PCR products were run on 2.2% agarose in TAE and stained 
with ethidium bromide.  The expected restriction fragments are listed below the gel.  Molecular weight 
markers are indicated in kbp. 
 
 
Although the vF35A W36A virus produced plaques on Vero cells, the plaques were very 
small and difficult to quantify by plaque assay. Likewise, the titer of the vF26A I27A F35A 
W36A virus was difficult to quantify because infected cells tended to fuse into syncytia.  To 
assay the changes in virus replication due to UL25 mutations, single-step growth curves were 
calculated for each UL25 mutant (Figure 18).  Briefly, Vero and 8-1 cells were infected at a MOI 
of 3 with each virus. At 0, 6, and 24 hours post-infection (hpi) (deletion mutants) or 0, 6, 12, 22, 
and 30 hpi (point mutants), viral progeny in the cell lysates was harvested and quantified by 
titration on 8-1 cells. While the aa 40-50 deletion had no effect on virus growth, other small 
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deletions (∆1-36, ∆27-37, ∆27-50) inhibited virus replication on Vero cells. All point mutants 
exhibited growth defects on Vero cells. Surprisingly, replication of the F35A W36A mutant on 
Vero cells was not comparable to wt virus at 24 hpi, which was unexpected given the virus stock 
formed plaques on Vero cells (Table 7).  This result indicates that F35A W36A replication in its 
initial stages is slowed compared to wt but continues through several rounds of virus replication, 
unlike the UL25 deletion virus, which is unable to replicate on Vero cells.   
 
 
 
Figure 18. Analysis of viral replication. 1 x 106 Vero or 8-1 cells were infected with each virus at a 
MOI of 3 on ice for 1 h, rinsed twice with DMEM, and incubated in DMEM at 37°C to the indicated 
timepoints.  Cells were lysed by freeze-fracture, and viral progeny in cell lysates was quantified by titration 
and plaque assay on 8-1 cells. The results shown are averages of duplicate experiments.  (Top) Small deletion 
mutants. (Bottom) Point mutants. 
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2.4.7 The minimal capsid-binding domain is located within pUL25 amino acids 1-36 
Purified capsids from Vero cells infected with each mutant were assayed for the presence of 
pUL25 by Western blot. Viruses that did not replicate on Vero cells were deficient in DNA 
packaging, as demonstrated by the absence of C-capsids (Figure 19, bottom panels). Of the 
deletions within aa 1-50, only the aa 40-50 deletion did not preclude formation of C-capsids.   
The UL25 mutant proteins ∆27-37 and ∆27-50 were found associated with capsids although 
these mutations to UL25 inhibited replication of the virus. Only the ∆1-36 mutant protein was 
undetectable on A- and B-capsids purified from cells infected with that mutant virus.  This result 
was similar to that observed in the mutant virus v∆1-50.  These data indicate that within the 
putative capsid-binding domain of UL25, amino acids 1-36 were absolutely required for capsid 
attachment, while amino acids 27-50 were dispensable for capsid attachment but not for DNA 
packaging and viral replication. 
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Figure 19. Deletion of amino acids 1-36 prevents pUL25 capsid attachment. Lane 1 is the bottom of 
the gradient, and lane 10 is the top. Gradient fractions that contained A-, B-, and C-capsids are indicated; the 
different capsid fractions can also be identified by the presence or absence of the scaffold protein, VP22a, 
since only B-capsids contain the scaffold protein. The positions of the capsid proteins (major capsid protein, 
VP5; triplex proteins, VP19C and VP23; scaffold protein, VP22a) are indicated. CL: cell lysate from KOS or 
UL25 mutant. The representative stained gels shown contain capsids isolated from KOS and the UL25-null 
virus v∆27-50, respectively. Of the deletions within aa 1-50, only the aa 40-50 deletion did not preclude 
formation of C-capsids. (Bottom panels) Gradient fractions were analyzed by immunoblotting for UL25.  
 
 
Gradients prepared with capsids from both the double point mutants vF26A I27A and 
vF35A W36A contained faint but visible bands of C-capsids, although the majority of capsids 
produced were the A- and B-types (data not shown).  In each case, the gradient fractions 
containing C-capsids were positive for pUL25 by Western blot (Figure 20). The quadruple 
mutant vF26A I27A F35A W36A only produced A- and B-capsids. Immunoblots of the vF26A 
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I27A F35A W36A gradient fractions showed that these capsids contained very reduced amounts 
of pUL25 (Figure 20).  
 
 
Figure 20. pUL25 point mutant capsid phenotypes. Capsids were prepared as previously described 
and observed as light-scattering bands on sucrose density gradients. Fractions from gradients were run on 
SDS-PAGE and tested for pUL25 by Western blot. Lane 1 is the bottom of the gradient, and lane 10 is the 
top. Gradient fractions that contained A-, B-, and C-capsids are indicated; the different capsid fractions can 
also be identified based on the presence or absence of the scaffold protein, VP22a, since only B capsids 
contain the scaffold protein. The positions of the capsid proteins (major capsid protein, VP5; triplex proteins, 
VP19C and VP23; scaffold protein, VP22a) are indicated. CL: cell lysate from KOS or UL25 mutant.  
2.4.8 Point mutations of pUL25 aa26 and 27 or 35 and 36 block nuclear egress of capsids 
The viruses vF26A I27A and vF35A W36A clearly exhibited defects in viral replication (Figure 
18), but the production of C-capsids by these viruses was inconsistent with a null DNA 
packaging phenotype.  Very small plaques were observed on Vero cells during titering of the 
vF35A W36A virus stock (data not shown), suggesting that the reduced viral replication may 
have been due to a defect in cell-to-cell spread. We postulated that the point mutations at amino 
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acids 26, 27, 35, and 36 interfered with capsid transport after packaging, causing an 
accumulation of C-capsids in infected nuclei or in other sub-cellular compartments. 
To investigate the possibility that the point mutations F26A I27A and F35A W36A 
inhibited primary or secondary envelopment of capsids after DNA packaging, Vero cells were 
infected with either point mutant, fixed, and prepared for imaging by thin-section electron 
microscopy. The location of capsids in these infected cells was compared to those found in wt 
KOS-infected cells or cells infected with the viruses vΔUL25 and vF26A I27A F35A W36A, 
which are both deficient in DNA packaging.  In wt-infected cells, scaffold-containing B-capsids 
and DNA- containing C-capsids were visible in the nuclei of infected cells (Figure 21, dashed 
and black arrows).  Wt C-capsids were also observed as unenveloped particles in the cytoplasm, 
in enveloped inclusions in the cytoplasm, and in virions in the extracellular space. The UL25 
deletion mutant produced A- and B-capsids—and an occasional C-capsid—that were all 
contained in the nucleus (Figure 21E).  In the replication-defective but DNA packaging-
competent point mutants vF26A I27A and vF35A W36A, A-, B-, and C-capsids were visible in 
the nucleus but not the cytoplasm (Figure 21A and B). During infection of Vero cells with the 
quadruple point mutant vF26A I27A F35A W36A, many of the cells fused to form syncytia that 
were visible under the light microscope. In thin-sections, multi-nucleated cells were observed in 
which up to five nuclei were adjacent to each other. We observed many C-capsids in the nuclei 
of cells infected with this virus (Figure 21C). This result was surprising because we could not 
purify C-capsids from Vero cells infected with vF26A I27A F35A W36A, and the A- and B-
capsids that were present in the gradients contained very reduced amounts of pUL25 (Figure 20). 
These data suggest that point mutations within the highly conserved region of the pUL25 N-
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terminus destabilize the pUL25 connection to the capsid, leading to detachment of the protein 
and destruction of C-capsids during purification. 
 
  
 
Figure 21. Thin-section electron microscopy. Vero cells were infected at a MOI of 5 and incubated to 
18 hpi.  Cells were fixed, sectioned, and embedded on carbon grids for imaging.  White arrows, A-capsids. 
Dashed arrows, B-capsids.  Black arrows, C-capsids. The nucleus and cytoplasm are marked with N and C, 
respectively.  A-D. 4400x magnification, scale bar 0.5um. E. 6500X magnification, scale bar 0.2 um. Insets 
show C-capsids (1), B-capsids (2), and A-capsids (3). 
2.5 DISCUSSION 
The HSV-1 UL25 protein is one of seven viral proteins that are required for DNA cleavage and 
packaging. pUL25 is found near of the vertices of DNA-containing C-capsids. The capsid-bound 
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pUL25 appears to be a multifunctional protein required (i) to stabilize capsids after DNA is 
packaged; (ii) to trigger nuclear egress of the capsid once a stable DNA-containing capsid is 
formed; (iii) to anchor VP1/2, the major tegument protein to capsids; and (iv) to uncoat the 
incoming viral genome early during infection (32, 121, 137, 169, 205, 224). Random 
mutagenesis of the HSV-1 UL25 gene was used to identify regions of UL25 protein important 
for virus replication and for pUL25 capsid attachment. Although the five amino acid insertions 
disrupted core portions of the folded protein, most UL25 transposon mutants were able to 
complement the UL25 deletion virus. Four mutants (12s, 143i, 212s, 560s) were defective in the 
complementation assay. Insertion of stop codons after amino acids 212 and 560 resulted in the 
expression of nonfunctional truncated proteins that attached to capsids in vitro and when 
expressed from a recombinant virus. Similarly the 143i insertion mutant expressed a 
nonfunctional protein that failed to complement the UL25-null virus but retained the ability to 
bind capsids. The 12s mutant was predicted to encode a small UL25 peptide, but in vitro 
translation of the 12s plasmid produced a nearly wild-type-size protein that did not bind to 
capsids. Examination of the UL25 DNA sequence indicated that the resulting protein was 
probably the result of translation initiation at an internal start codon (M37) in the UL25 gene. 
This result was confirmed by constructing a UL25 mutant in which the codons for amino acids 1 
to 37 were deleted and replaced with an ATG codon. In vitro translation of this construct 
produced a protein the same size as the 12s mutant that also failed to bind capsids. Deletion of 
the UL25 N-terminus to amino acid 50 eliminated in vitro capsid binding; conversely, the UL25-
TAP fusion protein containing UL25 amino acids 1 to 50 was able to bind capsids in vitro. A 
recombinant virus expressing the UL25 51–580 protein was replication defective and produced 
capsids lacking the virus-expressed mutant protein, suggesting that the capsid binding domain 
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resides solely within amino acids 1 to 50. This conclusion was supported by the capsid-binding 
studies in which the UL25 1-50-TAP protein was shown to bind capsids (Figure 11C). Taken 
together, these data indicate that amino acids 1 to 50 are necessary and sufficient for pUL25 
capsid binding and therefore comprise the pUL25 capsid-binding domain. In order to rule out the 
possibility that deletion of the N-terminus caused aberrant localization of pUL25, indirect 
immunofluorescence was used to track pUL25 in infected cells.  Δ1-50 pUL25 was properly 
localized to the nucleus, indicating that while the deletion blocked attachment to capsids, it did 
not prevent the interactions required for transport of the protein to the nucleus. Furthermore, 
binding of pUL25 to the capsid through the N-terminal capsid-binding domain is not sufficient 
for virus production. The two truncation mutants v212s and v560s both express proteins that 
associate with capsids, but these mutants do not produce infectious virus, indicating that the final 
19 amino acids of UL25 are also essential for function. 
Within the putative capsid-binding domain, the most highly conserved residues lie 
between HSV-1 aa 26-39. Small deletions and point mutations were made through amino acids 
1-50 in order to further define the capsid-binding domain and to determine the importance of the 
highly conserved residues for pUL25 function. While deletion of aa 1-36 prevented capsid 
attachment, deletion mutants missing aa 27-37 or 27-50 were capsid-associated. Point mutations 
of four of the highly conserved residues—aa 26, 27, 35, and 36—generated mixed phenotypes.  
These mutants did not replicate well on Vero cells, as determined by single-step growth curves. 
The double point mutants vF26A I27A and vF35A W36A produced C-capsids that were positive 
for pUL25, but the quadruple mutant vF26A I27A F35A W36A appeared to be a typical UL25 
null virus, in that only A- and B-capsids could be purified from infected cells. On Western blots 
of these A- and B-capsids, only a very faint pUL25 immunoreactive band was observed. 
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Although we did not test each of the smaller deletion mutants in the indirect 
immunofluorescence assay, we expect that mutations within aa 1-50 that prevented capsid 
attachment—Δ1-36 and F26A I27A F35A W36A—represent disruptions of pUL25 interaction 
with the capsid but not its localization to the nucleus, since deletion of amino acids 1-50 did not 
mislocalize pUL25. Unexpectedly, we found that cells infected with vF26A I27A F35A W36A 
contained many intranuclear C-capsids. These data suggest that the F26A I27A F35A W36A 
mutation renders the pUL25 connection to the capsid—and hence, the packaging of viral DNA—
very tenuous. Purification of vF26A I27A F35A W36A capsids caused detachment of pUL25 
and conversion of unstably packaged C-capsids to A-capsids. Interestingly, thin-sections of cells 
infected with the deletion mutant v∆27-37 contained only intranuclear A- and B-capsids (data 
not shown); pUL25 was detected on these purified capsids by Western blot. Therefore, it appears 
that deletion—but not substitution—of the hydrophobic residues between pUL25 aa 26-36 was 
tolerated with respect to pUL25 capsid attachment.   
Atomic force microscopy has been used to measure the force required to puncture A-, B-, 
and C- capsids (183).  A- and C-capsids exhibit almost the same resistance to disruption, but B-
capsids are broken with much less force. These results suggest that although scaffold proteolysis 
and DNA packaging are thought to be concomitant, it is scaffold removal, and not DNA 
insertion, that catalyzes the structural transformation and stabilizes the capsid. Furthermore, 
removal of the penton vertices of all capsid types by treatment with guanidine hydrochloride 
equalized the force required to disrupt the capsid, suggesting that the distinguishing structural 
features of the angularized capsid are the vertices containing the pUL17/pUL25 heterodimer. It 
would be interesting to use this assay to test pUL25 null mutants that do not support DNA 
packaging but do remain able to bind capsids.  It is possible that these mutations inhibit pUL25 
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ability to buttress the vertex by interrupting its attachment to pUL17 or other capsid proteins.  
Thus, we would expect that A-capsids of mutants v∆27-37, v∆27-50, vF26A I27A, vF35A 
W36A, and vF26A I27A F35A W36A would break with less force than the wild type A-capsid.   
Analysis of the crystal structure of pUL25 (amino acids 134 to 580) showed that UL25 
protein consists of numerous flexible loops extending from a rigid core composed of several 
tightly packed alpha helices (19). We expected that mutations disrupting any of the alpha helices 
located in the core would alter the overall structure of the protein and hence inhibit its function. 
However, most of the transposon mutants isolated in this study contained insertions in the 
pUL25 core that did not reduce function of the plasmid-expressed mutant protein. For example, 
the 354i and 538i mutations were both located in internal alpha helices, but neither of these 
mutations caused significant reduction in complementation of the UL25-null virus. The 143i, 
151i, and 155i insertion mutations occur within a region where the predicted amino acid 
sequence is strongly conserved within homologues of the UL25 gene of other herpesviruses. In 
the folded protein, this region is part of a loop that bridges the unstructured N-terminus (residues 
1 to 45) with the highly structured C-terminus (residues 133 to 580); there are two small 
antiparallel beta sheets located between amino acids 133 and 155 (19). The 143i insertion maps 
to the turn between the two beta sheets, and the 151i insertion occurs shortly after the end of the 
second beta sheet. The 155i insertion is located within the first alpha helix found in the core 
structure. Interestingly, the 143i and 155i insertions altered virus replication, but the 151i 
insertion did not. Our results suggest that this region does not contribute to capsid binding but is 
important for UL25 function, possibly as a bridge from the flexible capsid- binding region 
(residues 1 to 50) of UL25 to the more structured C-terminus. Other structural features of UL25 
protein include electropositive and electronegative faces and clusters of conserved surface 
 78 
residues (19). The 151i and 155i mutations are located in the electropositive face of UL25, while 
the other mutations occur along the periphery or in the interior of the folded protein. The 151i 
and 155i mutations also fall within one of the conserved surface clusters identified by Bowman 
et al. (19).  
A recent report detailed the significance of the loop domains and conserved surface 
clusters of pUL25 for DNA packaging and capsid incorporation into virions (147).  O’Hara et al. 
reported that point mutations between aa 396-402 or deletion of aa 417-425 of pUL25 allowed 
DNA packaging but inhibited nuclear egress of capsids; this defect was characterized by an 
accumulation of C-capsids in nuclei. We observed a similar phenotype in our point mutants 
vF26A I27A and vF35A W36A. C-capsids produced by vF26A I27A and vF35A W36A were 
stable and could be purified from cells. The double point mutations appeared to inhibit capsid 
egress from the nucleus without significantly reducing pUL25 capsid attachment or DNA 
packaging. Thus, the residues at pUL25 positions 26, 27, 35, and 36 also may be involved in 
egress of capsids from the nucleus. Another interesting mutant described by O’Hara et al. was 
deleted of aa 578-580 and released virions that were defective in propagating infection into the 
extracellular space (147). In contrast, our v560s mutant, deleted of aa 561-580, completely 
eliminated DNA packaging and accumulated A-capsids that were visualized in micrographs of 
infected cells (not shown). Taken together, these data indicate that both the N- and C-termini of 
pUL25 are important for capsid stability and transport.  
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3.0  STRUCTURAL ANALYSES OF CAPSIDS CONTAINING PUL25 FUSION 
PROTEINS DEMONSTRATE THAT THE PUL25 N-TERMINUS CONTACTS HEXONS 
AND TRIPLEXES ADJACENT TO THE PENTON 
3.1 ABSTRACT 
The HSV-1 virion is a large macromolecular complex that is engaged in a dynamic set of 
interactions.  These interactions coordinate the attachment, removal, rearrangement, and 
deconstruction of virion components in a precise temporal manner in order to propagate the virus 
lytic cycle.  Studies of virion composition and structure have elucidated many aspects of the viral 
replication process, including virus attachment and entry, capsid assembly, and tegumentation. 
The DNA packaging protein pUL25 is located on the exterior surface of HSV-1 capsids on their 
vertices.  Previous reports have shown that pUL25 interacts with the capsid structural proteins 
pUL19 (VP5) and pUL38 (VP19c) and that it incorporates the packaging protein pUL17 into 
capsids. Because definition of pUL25 location on the capsid surface—and consequently, 
identification of the interactions required for that placement—are important for elucidating the 
mechanisms by which pUL25 supports DNA packaging, we have visualized the connections 
between the pUL25 capsid-binding domain and the capsid.  Cryoelectron microscopy and 3D 
image reconstructions were performed with capsids containing pUL25 fused at or near its N-
terminus to GFP or to a tandem affinity purification (TAP) tag.  In the composite image of 
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NTAP-UL25 and GFP-UL25 capsids, the precise location of pUL25 was visualized.  The pUL25 
capsid-binding domain appears to make contact with the triplexes and hexons adjacent to the 
penton vertex. 
3.2 INTRODUCTION 
The HSV-1 virion consists of 44 different viral proteins and many host cell proteins, and it can 
be segregated into three major compartments: the host-derived lipid envelope, the tegument 
protein layer, and the nucleocapsid (112).  The first structural analysis of HSV-1 was completed 
by negative staining and transmission electron microscopy of purified virions. From these 
micrographs, it was determined that the HSV-1 capsid is angular with icosahedral symmetry, and 
its 162 subunits, or capsomers, are composed of 5- and 6-membered rings (pentons and hexons) 
(238).  The capsid structural proteins were identified by SDS-PAGE analysis of infected cells 
and purified virions.  Following sequencing and annotation of the complete HSV-1 genome, the 
gene products that constituted these structural proteins were designated (70, 118, 198).  The 
major constituent of capsids is pUL19 (VP5), which forms the hexameric and pentameric 
capsomers. The other predominant structural proteins are pUL18 (VP23) and pUL38 (VP19c)—
which together form a heterotrimer termed the “triplex” that lodges between capsomers—and 
pUL35 (VP26), which decorates the outer surfaces of hexons.  Other minor components of 
capsids—including the DNA packaging proteins pUL6, pUL25, and pUL17—were discovered 
by Western blot analysis of purified capsids (192, 216, 252). 
Several strategies have been used to define the arrangement of the capsid proteins.  In the 
initial attempts, capsids were reacted with antibodies raised against individual capsid proteins.   
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Electron microscopy and biochemical analyses of these antibody-coated capsids proved that the 
capsomers were made of the largest capsid protein, pUL19, and that pUL19 adopted distinct 
conformations in hexons and pentons (31, 223, 230).  More recently, EM mapping studies with 
monoclonal antibodies have located the portal protein, pUL6, and the packaging proteins, pUL17 
and pUL25, at capsid vertices (24, 137, 143, 148, 216).  Other methods for resolving the 
organization of capsid proteins involved chemical extraction of parts of the capsid, with 
visualization and biochemical identification of the proteins that remained (17, 134, 135, 145).  
Extraction of capsid components was achieved by exposing B-capsids to an ionized argon beam, 
guanidine hydrochloride (GuHCl), or urea, and the composition of the depleted capsids was 
ascertained by SDS-PAGE. Treated capsids retained their overall structure so that changes in 
capsid morphology could be observed by electron microscopy.  Plasma etching of capsids 
revealed that pUL18, pUL19, and pUL38 were the first proteins removed, suggesting that these 
components were readily accessible on the capsid surface; removal of the scaffold proteins 
pUL26 and pUL26.5 required longer exposure times and probably occurred after the capsid was 
stripped of the outer proteins (135).  In contrast, B-capsids treated with guanidine hydrochloride 
or urea lost most of the pUL26 and pUL26.5 while pUL18, pUL19, and pUL38 remained mostly 
intact (134, 145). Subsequent cryo-electron microscopy and 3D reconstruction of these capsid 
structures showed that GuHCl or urea treatment removed the vertices, allowing pUL26 and 
pUL26.5 to escape.  In sum, these studies defined the internal scaffold as consisting of pUL26 
and pUL26.5, while pUL18, pUL19, and pUL38 formed the external capsid lattice.  
Furthermore, the stoichiometry of the capsomers was elucidated; changes in the mass and protein 
composition of treated capsids could only be accounted for if both the pentons and hexons were 
made of pUL19 and the triplexes were made, on average, of two copies of pUL18 and one copy 
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of pUL38.  Using similar methods, the small capsid protein pUL35 was traced to the outer tips of 
hexons but not pentons (17). More recently, genetic deletion of capsid components has allowed 
assignment of structural features to the capsid proteins that form them without destruction of the 
native capsid (27, 184, 255). Difference imaging techniques have been used also to describe the 
contacts between the capsid and the tegument and the asymmetry of the tegument within the 
virion (27, 73, 253).  Finally, in vitro assembly studies have been carried out with HSV-1 capsid 
proteins expressed from Baculovirus and purified from infected insect cells (138-141, 143, 144, 
220) (see Section 1.5).  In vitro studies of pUL6 showed that the capsid portal is a dodecamer 
ring of pUL6; formation of the portal precedes the accumulation of scaffold proteins into the 
procapsid.  Additionally, these studies elucidated the transition between procapsid and mature 
capsid forms, including the rearrangements of pUL19 and the addition of the triplex proteins 
onto the procapsid floor.  
The HSV-1 UL25 gene product is a 580 amino acid, 62 kDa protein that contains an 
unstructured N-terminal tail and core of packed alpha helices (19). UL25 protein (pUL25) 
attaches to the external vertices of HSV-1 capsids with a capsid-binding domain that is located 
within its first 50 amino acids (30, 137, 224) (see Chapter 2). Based on comparative structural 
and biochemical analyses of wt and UL25-null capsids, pUL25 is predicted to form a 
heterodimer with the packaging protein pUL17 (216, 224).  The putative pUL25-pUL17 
complex—called the C-capsid specific component (CCSC)—is present in up to five copies at 
each capsid vertex and contacts the two triplexes and the hexons adjacent to the penton. While 
formation of the pUL25-pUL17 complex is independent of interactions with other structural 
proteins (188), pUL25 has several other potential binding partners at the capsid vertex: the major 
capsid protein pUL19 in pentons and hexons, and the triplex proteins pUL18 and pUL38. 
 83 
Immunoprecipitation and far-Western assays have shown that pUL25 interacts directly with 
pUL19 and pUL38, suggesting that the CCSC connection to pUL18 is mediated by UL17 (148, 
188). Additionally, transiently expressed pUL25 immunoprecipitates pUL6, which forms a 
dodecameric ring that serves as the portal of entry for DNA into the procapsid (143, 156, 221).  
It has yet to be determined if and how pUL25 binds to the capsid-integrated portal, or what 
importance this potential interaction might have for DNA packaging.  
In this study, recombinant viruses were generated that expressed UL25 protein fused to 
either green-fluorescent protein (GFP) or a tandem affinity purification (TAP) tag.  Each of these 
fusions served a dual purpose.  First, tagged pUL25 could potentially be isolated from other viral 
proteins in infected cells. While GFP-fused pUL25 could be tracked in cells by fluorescence 
microscopy, TAP-tagged pUL25 could be purified by affinity chromatography.  Secondly, the 
tags added extra density to the pUL25 N-terminus in cryo-electron micrographs, facilitating 
pUL25 location in 3D reconstructions of capsids. Based on the crystal structure of truncated 
pUL25, pUL25 was predicted to occupy the penton-distal region of the CCSC (224).  Using the 
GFP and TAP tags as markers of the pUL25 N-terminus in capsid reconstructions, the location 
and orientation of pUL25 on the capsid surface has been mapped.  pUL25 is present in the 
penton-distal region of the CCSC, as previously suggested, and its N-terminal capsid-binding 
domain makes contact with hexons and triplexes adjacent to the penton vertex. 
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3.3 MATERIALS AND METHODS 
3.3.1 Cells, viruses, and antibodies 
African green monkey kidney cells (Vero; American Type Culture Collection, Rockville, MD) 
and UL25-transformed 8-1 cells (121) were propagated in 5% FBS/DMEM with penicillin 
(10U/ml) and streptomycin (10µg/ml) at 37°C and 5% CO2. HSV-1 wild-type KOS virus has 
been previously described (121). Baculovirus-expressed UL25 protein (121) was purified and 
used to prepare a UL25 monoclonal antibody, 25E10, that was provided by W. Newcomb, 
University of Virginia (33). 
3.3.2 Introduction of GFP and the TAP tag into the virus genome 
To create specific UL25 mutations, the HSV-1 KOS BAC clone was transferred to GS1783 
bacteria (gift from G. Smith), and mutagenesis was performed using the two-step bacteriophage 
Red-mediated homologous recombination system described by Tischer et al. (218). PCR with 
template plasmids p-EGFP-in or p-EP-TAP-in (gift from P. Kinchington) was used to produce a 
construct that contained the KanR gene (alphAI) flanked by UL25 homologous sequences and 
repeat sequences containing the desired insertion. Integration of this construct into the BAC was 
followed by a second recombination that removed alphaAI and left the seamless insertion within 
the UL25 gene. Resolution of the integrated PCR product resulted in insertion of the GFP gene 
between UL25 codons 50 and 51 and the TAP sequence before UL25 codon 1. The list of 
primers for production of PCR amplicons that were used for isolation of the UL25 insertion 
mutants can be found in Table 10 (Appendix A). To confirm mutations in UL25 mutant viruses, 
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viral DNA was amplified by PCR with the primers 5’-GCAGAAGGTCTCCGG 
TAATATCACC-3’ and 5’-GGTGATCAGGTACAACAGGCGCTC-3’.  The PCR product was 
extracted from agarose gels and used for restriction digest and for sequencing with primers 5’-
GCGGCGGCCGCAAGACTCATTTGGATCCG-3’ and 5’-TCTCCGCGACGGCCAGAC-3’ 
(GeneWiz sequencing facility). 
3.3.3 Virus generation and propagation 
To recover mutant viruses, BAC DNA (5 µg) was transfected into 8-1 cells with Lipofectamine. 
Recombinant viruses were harvested from transfected cell lysates and were plaque purified three 
times on Vero cells. The third round plaque isolate was used to generate a mini-stock of virus in 
a T25 flask of Vero cells.  Cell lysates were freeze-thawed, and virus mini-stock concentrations 
were determined by plaque assay on Vero cells. Briefly, serial dilutions of virus preparation were 
absorbed to cells for 1 h, then incubated on cells three days under methylcellulose.  Plaques were 
counted after staining cells with crystal violet (0.1% in 50% ethanol). To prepare a large stock of 
virus, 1.5 x 108 Vero cells were infected at a multiplicity of infection (MOI) of 0.01.  At 3 days 
post-infection, cell lysates were harvested by freeze-thaw.  Clarified cell lysates were centrifuged 
at in a Sorvall SS34 rotor at 10000 RPM for 2 h to pellet virions from the media. The virion 
pellet was resuspended in 10% glycerol/DMEM overnight on ice.  The resultant virus stock was 
titrated on Vero and 8-1 cells.   
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3.3.4 Preparation of viral DNA 
Viral DNA was prepared essentially as described in (21), with the following modifications.  A T-
175 flask of Vero cells (3 x 107 cells) was infected with virus at a MOI of 1 PFU per cell. At 48 h 
post-infection, the medium was removed and the cells were washed in 1x PBS, scraped off the 
plate, and pelleted. The cells were resuspended in TE and lysed in Triton X-100 (1.5%) on ice 
for 15 minutes.  Nuclei were pelleted by centrifugation at 2000rpm for 10 minutes and 
subsequently discarded. Virus was lysed by incubation at 50°C with SDS (0.5%) and Proteinase 
K (0.5µg/µl) for 1 h.  DNA was extracted with phenol twice and chloroform once before being 
precipitated with 1/10 volume sodium acetate and 2 volumes ethanol.  Pelleted DNA was dried 
and resuspended in TE or sterile ddH2O with RNAse A. 
3.3.5 Immunoblotting 
Protein extracts were separated on a 5 to 12% SDS–polyacrylamide gel and transferred to 
nitrocellulose. The nitrocellulose was washed in Tris-buffered saline (TBS) and blocked 
overnight or 1 h at room temperature in T-TBS (20 mM Tris, 0.5 M NaCl [pH 7.5] plus 0.5% 
Tween 20) supplemented with 10% nonfat dry milk. The UL25 monoclonal antibody, 25E10 was 
diluted to 1:5000 in blocking buffer. The diluted antibody was reacted with the blocked 
nitrocellulose for 1 h at room temperature, washed 6 times in T-TBS, and reacted with 
horseradish peroxidase-conjugated anti-mouse immunoglobulin G (IgG) diluted at 1:5000 in 
blocking buffer. The bound Igs were revealed by enhanced chemiluminescence (Pierce ECL kit).  
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3.3.6 Capsid preparation 
Vero cells (1.5 x 108) were infected overnight (18 h at 37°C) at a MOI of 5 PFU/cell. Infected 
cells were harvested, rinsed with PBS, and resuspended in 20 mM Tris (pH 7.5) plus protease 
inhibitors (Roche), adjusted to 1% Triton X-100, and incubated for 30 min on ice. The resulting 
nuclei were harvested by low-speed centrifugation, resuspended in 10 ml TNE (500 mM NaCl, 
10 mM Tris, 1 mM EDTA [pH 7.5]), and then sonicated to lyse the nuclei. The nuclear lysate 
was adjusted to 20 mM MgCl2 and incubated with DNase I (100 µg/ml) at room temperature for 
30 min. The lysate was then cleared by low-speed centrifugation, and the resulting supernatant 
was layered on top of a 10-ml cushion of 35% sucrose (SW28 rotor; 23000 rpm for 1 h). The 
pellets were suspended in 3 ml TNE and adjusted to 1 mM dithiothreitol, and capsids were 
separated by centrifugation on 20 to 50% sucrose (in TNE) gradients (SW41 rotor at 24000 rpm 
for 1 h). The positions of A-, B-, or C-capsids were observed as light-scattering bands, with A-
capsids being found highest (least dense) on the gradient and C-capsids found lowest (dense 
fractions) on the gradients. The fractions were collected using a Beckman fraction recovery 
system (Beckman catalog no. 34890). The apparatus has a mechanism to puncture the bottoms of 
the tubes, and fractions are collected from the bottom to top. Fractions (0.75 ml) were collected, 
and protein was precipitated by adding an equal volume of 16% trichloroacetic acid. Pellets were 
resuspended in 35 µl of 2x PAGE loading buffer (Invitrogen) supplemented with 0.4 M Tris-
base. Gradient fractions were run on 5 to 12% SDS-PAGE, and the gels were either stained with 
Imperial blue (Pierce) to visualize capsid proteins or analyzed by immunoblotting with the UL25 
(25E10) antibody. On the stained gel, the different capsid types were identified based on the 
presence or absence of the scaffold protein, VP22a, since only B-capsids contain the scaffold 
protein. 
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To isolate capsids for cryo-electron microscopy, capsid bands were collected from 
sucrose gradients, diluted 1:4 in TNE, and pelleted for 1hr (SW41 rotor, 24000 rpm). Capsid 
pellets were resuspended overnight in a low volume (50µl) of low salt TNE (150 mM NaCl). 
Samples were prepared for cryo-electron microscopy (cryo-EM) by James Conway and Katerina 
Toropova (University of Pittsburgh, Department of Structural Biology) as described (33).  Cryo-
EM and image analysis was performed by James Conway (UL25-GFP) and Katerina Toropova 
(NTAP-UL25 and composite images).   
3.4 RESULTS 
3.4.1 Generation of viruses expressing GFP-UL25 and NTAP-UL25 fusion proteins 
In order to facilitate the location of pUL25 on the capsid surface, viruses were generated that 
expressed pUL25 fused to either GFP or a tandem affinity purification (TAP) tag.  The 234bp 
TAP sequence encoded a calmodulin-binding peptide, linker, and streptavidin-binding peptide 
(Figure 22). Insertions to the UL25 ORF were recombined into a HSV-1 (KOS) genome 
maintained in a bacterial artificial chromosome (BAC).  BAC recombination resulted in targeted 
insertion of the GFP gene in-frame between codons 50 and 51 of the UL25 gene (Figure 23A).   
The TAP tag was inserted into the UL25 ORF in-frame before UL25 codon 1.  Thus, each 
insertion was adjacent to the putative capsid-binding domain of pUL25 (aa 1-50).   
To confirm insertion of these sequences, BAC DNA was digested with BamHI and 
analyzed by agarose gel electrophoresis.   The UL25 ORF is contained within the 2.3 kbp BamHI 
U fragment of HSV-1 DNA (118, 164), and in the restriction enzyme digestion of the KOS-BAC 
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preparation, a prominent 2.3 kbp fragment was observed (Figure 23B, black arrows). The UL25-
GFP BAC contained an additional 726 bp in UL25, which was detected as an upward shift in the 
mobility of the BamHI U fragment (Figure 23B). Likewise, the NTAP-UL25 BAC BamHI U 
fragment was shifted to a molecular weight consisted with insertion of the 234 bp TAP sequence. 
These results demonstrated that that the UL25 mutant BACs had the desired insertions.  
 
 
 
 
Figure 22. Amino acid sequence of the N-terminus of NTAP-UL25 protein. The TAP tag (Stratagene) 
is inserted between pUL25 amino acids 1 and 2.  Bold, calmodullin-binding peptide; italic, linker peptide, 
underline, streptavidin-binding peptide.  
 
 
 
To recover viruses, BACs were transfected onto UL25-complementing 8-1 cells.  
Transfected cell lysates were freeze-thawed and re-plated on Vero cells.  Single plaques were 
isolated during three subsequent rounds of virus purification on Vero cells.  From these clonal 
plaques, virus stocks of vUL25-GFP and vNTAP-UL25 were prepared as described in Materials 
and Methods.  To determine the concentration of virus particles in each stock, virus preparations 
were titrated on Vero and 8-1 cells.  The virus stock concentrations, expressed as plaque-forming 
units (PFU) per ml, are listed in Table 8.  The virus yield calculation was similar for both cell 
lines tested (Vero and 8-1) for both the vUL25-GFP and vNTAP-UL25 viruses. 
NTAP-UL25 1 MKRRWKKNFIAVSAANRFKKISSSGALGSGSGTMDEKTTGWRGGHVEGLA 50 
         51 GELEQLRARLEHHPQGQREPSGGCKLGMDPYCPFDALDVWEHRRFIVADS 100 
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Figure 23. Insertion of GFP and TAP sequences to BAC DNA. A. (Top) Schematic representation of 
the HSV-1 genome and the UL25 locus at kbp 48813-50555. (Bottom) Diagram of the UL25 gene in UL25-
GFP BAC and NTAP-UL25 BAC.  Numbers above each box represent codon positions; numbers below the 
line are the nucleotide position within the viral genome. The UL25 gene is  located within the BamHI U 
fragment that contains nucleotides 48635-50929. The pUL25 capsid binding domain is encoded by codons 1-
50 and is shown as a gray box. UL25-GFP BAC contained an in-frame insertion of the 726 bp GFP coding 
sequence after the codon for UL25 amino acid 50. NTAP-UL25 BAC had the 234 bp TAP sequence inserted 
in-frame before UL25 codon 1. B. BAC DNA was digested with BamHI and run on a 1.2% agarose gel. The 
wild-type 2.3 kbp BamHI fragment is present in the KOS BAC lanes (black arrows). The UL25 fragments of 
UL25-GFP BAC and NTAP-UL25 BAC are shifted to 3.2 kbp (white arrow) and 2.6 kbp (gray arrow), 
respectively. M, DNA markers in kbp.   
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TABLE 8. Virus stock titers: UL25-fusion mutants 
 UL25 protein expressed PFU/ml in: 
Virus strain (amino acid positions) Vero cells 8-1 cells 
KOS Wild type (1–580) 2 x 108 2 x 108 
vUL25-GFP UL25-GFP (1-50-GFP-51-580) 4 x 107 4 x 107 
vNTAP-UL25 NTAP-UL25 (TAP-1-580) 3.4 x 107 3.2 x 107 
 
 
The presence of the mutations in the progeny virus was verified by PCR and restriction 
digest.  Viral DNA was prepared from infected cells and was amplified by PCR with primers that 
were external to UL25 (Figure 24A). Wt KOS, vUL25-GFP, and vNTAP-UL25 PCR products 
were then digested with the restriction enzymes NotI or SacI, which cleaved within the wt UL25 
gene near its 5’ end.  NotI digestion of the wt PCR product produced fragments of 0.9 and 1.9 kb 
(Figure 24B).  Insertion of the GFP sequence in vUL25-GFP shifted the smaller fragment to 1.7 
kb.  Likewise, SacI digestion of wt and vNTAP-UL25 PCR products showed that the smaller wt 
fragment (0.8 kb) is shifted to a higher molecular weight (1.1 kb) by the TAP sequence.  Thus, 
both GFP and TAP sequences were present in the UL25 gene within the coding sequence for the 
N-terminus.  These results were confirmed by sequencing of the PCR products through the 5’ 
region of UL25. 
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Figure 24. Confirmation of UL25 insertions in viral DNA.  A. Diagram of the HSV-1 genome showing 
the 2.9 kb region amplified from viral DNA by PCR. Black arrows indicate the forward and reverse primers. 
The SacI and NotI restriction sites are shown. B. PCR products were run on 1% agarose in TAE and stained 
with ethidium bromide.  The GFP and TAP sequences added 0.8 kb and 0.3 kb to the PCR products of 
vUL25-GFP and vNTAP-UL25, respectively. PCR products were digested with the restriction enzymes SacI 
or NotI, which cleaved near the coding sequence for the pUL25 N-terminus. The expected restriction 
fragments are listed below the gels. The shift in molecular weight of the 5’ region of UL25 indicates that both 
insertions were at the N-terminus of the UL25 protein. Molecular weight markers are indicated in kbp. 
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Single-step growth curves were calculated for both viruses to determine if addition of 
GFP or TAP tags interfered with virus replication on Vero cells. Briefly, Vero cells were 
infected at a MOI of 3 with each virus. At 0, 2, 4, 8, 12, 24 and 30 hours post-infection, viral 
progeny in the cell lysates was harvested and quantified by plaque assay on Vero cells. Virus 
titers at times after the initial infection were then plotted to form a graphical representation of 
viral replication.   Replication of vUL25-GFP was very similar to wt KOS (Figure 25).  
Additionally, vUL25-GFP plaques were observed to be fluorescent. These results indicated that 
the internal insertion of GFP to pUL25 aa 50-51 did not inhibit the expression or function of the 
protein.   
 
 
 
Figure 25. Analysis of vUL25-GFP viral replication. 1 x 106 Vero cells were infected with each virus 
at a MOI of 3 on ice for 1 h, rinsed twice with DMEM, and incubated in DMEM at 37°  to the indicated 
timepoints.  Cells were lysed by freeze-fracture, and viral progeny in cell lysates was quantified by titration 
and plaque assay on Vero cells. The results shown are averages of duplicate experiments. This figure was 
amended with permission from reference (33).  
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In contrast, replication of vNTAP-UL25 was diminished compared to wt beginning at 12 
hours post infection, leading to a 100-fold reduction in viral progeny yields at 30 hours post 
infection (Figure 26A). The reduced growth of vNTAP-UL25 was also apparent in its plaque 
morphology. vNTAP-UL25 developed very small plaques on Vero cells that were difficult to 
ascertain by crystal violet staining (Figure 26B).  The plaque size was on average 45% of wt, 
suggesting a deficiency in cell-to-cell spread.  
 
 
 
 
Figure 26. Analysis of vNTAP-UL25 viral replication. A. Single-step growth curve. 1 x 106 Vero cells 
were infected with each virus at a MOI of 3 on ice for 1 h, rinsed twice with DMEM, and incubated in DMEM 
at 37°C to the indicated timepoints.  Cells were lysed by freeze-fracture, and viral progeny in cell lysates was 
quantified by titration and plaque assay on Vero cells. The results shown are averages of duplicate 
experiments. B. Comparison of vNTAP-UL25 and KOS plaque size at 3 days post-infection.  Plaques were 
imaged at 50x magnification, and the diameter of each plaque was measured by Leica application software. 
The vNTAP-UL25 plaques were on average 45% of wt size (n=100).  The scale bar is equal to 400 µm.   
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3.4.2 Association of tagged pUL25 with capsids. 
The insertions were cloned into the UL25 ORF such that they flanked the pUL25 capsid-binding 
domain (aa 1-50; see Chapter 2). The TAP tag was at the amino-terminal end (aa 1) of the 
capsid-binding domain, and GFP was at the carboxy-terminal (aa 50).  While the GFP insertion 
appeared to have no negative impact on pUL25 function, the diminished replication of vNTAP-
UL25 could have been due to a disruption of the pUL25 capsid-binding domain.  To ascertain if 
the capsid attachment of the UL25-GFP and NTAP-UL25 proteins were disrupted, intranuclear 
capsids were prepared from Vero cells infected with each mutant virus. Capsids were viewed as 
visible light-scattering bands on sucrose density gradients. The capsid preparations consisted 
mainly of C- and B-capsids, with a faint but observable A-capsid band. To determine whether 
the UL25 proteins were incorporated into these capsids, the sucrose gradient fractions were run 
on SDS-PAGE and analyzed by Western blot (Figure 27).  Each of the tags was expected to shift 
the apparent molecular weight of pUL25.  The GFP fusion protein contains an additional 239 aa, 
which corresponded to a 27 kDa molecular weight shift of pUL25 present in infected cell lysates 
(Figure 27). NTAP-UL25 protein ran with a smaller shift of 8.5 kDa (78 aa).  Both GFP- and 
NTAP-UL25 proteins were observed on all capsid types, indicating that the capsid-binding 
domain of pUL25 was not obstructed by the GFP or TAP insertions (Figure 27, lower panels).  
Thus, while insertion of the TAP tag at the pUL25 N-terminus had negative effects on virus 
replication, it did not appear to alter the DNA packaging phenotype or the ability of the protein 
to attach to the capsid.  
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Figure 27. UL25-GFP and NTAP-UL25 proteins are capsid-associated. A. vUL25-GFP.  B. v NTAP-
UL25. Capsids purified from infected cells were separated on sucrose density gradients. (Top panels) Stained 
gels containing infected cell lysates and fractions from capsid gradients. Lane 1 is the bottom of the gradient, 
and lane 12 or 10 is the top. Gradient fractions that contained A-, B-, and C-capsids are indicated; the 
different capsid fractions can also be identified based on the presence or absence of the scaffold protein, 
VP22a, since only B-capsids contain the scaffold protein. The positions of the capsid proteins (major capsid 
protein, VP5; triplex proteins, VP19C and VP23; scaffold protein, VP22a) are indicated. CL: cell lysate from 
KOS, vUL25-GFP, or vNTAP-UL25. (Bottom) Gradient fractions were immunoblotted for pUL25. GFP adds 
239 aa to pUL25, shifting the molecular weight by approximately 27 kDa. The TAP tag adds 78 aa (8.5 kDa) 
to pUL25. 
3.4.3 Structural analysis of vGFP-UL25 capsids 
To visualize the UL25-GFP protein on the capsid surface, purified B- and C-capsids of vGFP-
UL25 were used for cryo-electron microscopy and 3D reconstruction.  Cross-sections of C- and 
B-capsids produced by vUL25-GFP were then compared to the wt C-capsid (Figure 28, top 
panels).  The C-capsid specific component (CCSC), which was previously identified on the wt 
C-capsid (224), is visible on the vUL25-GFP C-capsid as well; the vUL25-GFP B-capsid does 
not contain the CCSC. The vUL25-GFP C-capsid contains an extra density above the CCSC that 
was attributed to the GFP fusion in pUL25 (Figure 28A). In the surface views of these capsid 
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forms, the overall capsid morphology is similar, but there is no CCSC around the B-capsid 
penton (Figure 28, lower panels). 
At the vGFP-UL25 C-capsid penton vertex, GFP is present as a globular domain that 
extends from the CCSC (Figure 29). The CCSC touches the proximal and distal triplexes and the 
hexon adjacent to the penton, and the GFP density contacts the underlying CCSC at its penton-
distal region. Thus GFP localizes pUL25 within this region of the CCSC, confirming the 
placement by Trus et al. (224). GFP placement also allows prediction of the orientation of 
pUL25. Because the point of contact between pUL25 and GFP is at pUL25 amino acids 50-51, it 
appears that the pUL25 N-terminus makes contact with the capsid surface at the distal triplex, 
and another part of the CCSC touches the triplex proximal to penton. The exact orientation 
of pUL25 within the CCSC cannot yet be determined because the crystal structure of this portion 
of pUL25 is not available (19).  In the model, GFP appears to occupy a larger volume of space 
than would be expected from its molecular weight. As shown in Figure 29D, GFP may adopt 
different positions as it pivots around its point of contact with pUL25.  The larger-than-expected 
density in the reconstruction, therefore, is interpreted as being to the averaging of different 
positions of this flexible molecule.   
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Figure 28. Density maps calculated from capsid micrographs.  (a) C-capsids with UL25-GFP, (b) C-
capsids with wt UL25 and (c) B-capsids that appear to lack the CCSC density as well as packaged DNA. 
Central sections are shown at top, and surface views along the 2-fold axis below. Capsomers, triplexes and the 
CCSC molecules are colored as indicated although the exact boundaries are not known in detail. The inset 
shows the positions of the four kinds of capsomers and six kinds of triplex on one triangular facet. The CCSC 
density common to both C-capsid samples (marked in red in a, b, and the inset) binds both the triplex (Ta) 
adjacent to the penton and the next closest (Tc) that are indicated in (c), as well as appearing to contact one of 
the two adjacent hexons. We attribute the additional density above the CCSC (green in a and the inset lower 
left) to the GFP protein inserted between residues 50 and 51 of UL25. Bar = 200Å.  This figure was 
contributed by James Conway, Department of Structural Biology, University of Pittsburgh, and is published 
in reference (33). 
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Figure 29. Close-up views of the UL25-GFP density. (a) The estimated boundaries for UL25 and GFP 
densities are shown as a purple and a green mesh, respectively. The scale bar represents 20 Å. (b) An 
alternative view revealing contacts (black arrows) between a hexon and the CCSC density (with GFP 
removed to aid visibility), at left, and between a hexon and the GFP density, at right. The scale bar represents 
20 Å. (c) Ribbon representation of the GFP atomic model with termini and amino acid 11 (valine) marked, 
along with the sequence of GFP amino acids 2–11 (below). When inserted into UL25, the N- and C-termini of 
GFP may be closer together, possibly by refolding the 11 N-terminal amino acids moving the N-terminus as 
indicated (white arrow). The scale bar represents 5 Å. (d) Atomic models for UL25 (PDB ID: 2F5U, dark blue 
ribbons) and GFP (PDB ID: 1EMA, rainbow and green ribbons) positioned within the cryo-EM density. The 
UL25 atomic model (residues 134–580) is positioned so that the 133 missing N-terminal residues would 
occupy the distal region (black arrow) where contact with GFP appears most likely. The GFP model may be 
placed in two non-overlapping orientations to fill the green mesh, as indicated at left (position I) and at right 
(position II). These locations place the termini midway along the GFP density that closely approaches the 
CCSC density (arrowhead). The scale bar represents 20 Å. The inset shows the two GFP positions, 
represented by light and dark green models, superimposed on the CCSC density. The C-termini of the GFP 
are placed in the GFP density where it most closely approaches the UL25 density (arrowhead). This figure 
was contributed by James Conway, Department of Structural Biology, University of Pittsburgh, and is 
published in reference (33). 
 
3.4.4 Reconstruction of capsids containing NTAP-UL25 protein 
vNTAP-UL25 C-capsids were analyzed by cryo-EM, and surface maps for vNTAP-UL25 and wt 
C-capsids were calculated.  Both vNTAP-UL25 and wt C-capsids contain the CCSC around the 
penton vertices (Figure 30).  The NTAP-UL25 CCSC contains an additional small density 
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midway along the CCSC and adjacent to the hexon.  This density is ascribed to the TAP tag.  
The region of the CCSC directly adjacent to the TAP tag (and more distal to the penton) makes 
contact with the hexon.  The connection between the CCSC and the hexon is also observed on 
the wt capsid.  Because the extreme N-terminus of pUL25 is fused to the C-terminus of the TAP 
tag, the region of the CCSC adjacent to the TAP tag must be occupied by the pUL25 N-terminus.  
Thus, we infer that the connection between the CCSC and the hexon is mediated by the extreme 
N-terminus of pUL25.  
 
Figure 30. Comparison of the CCSC on vNTAP-UL25 and wt C-capsids.   In this close-up view of the 
capsid vertices, the CCSC is colored dark pink.  The blue penton is labeled 5, as it represents the five-fold 
axis of symmetry.  Black arrows indicate the density attributed to the TAP tag, which is present in the 
vNTAP-UL25 CCSC but is missing from wt (right).   A region of the CCSC to the right of the TAP tag makes 
contact with the hexon in both images. The penton-distal triplex is colored yellow.  This figure was 
contributed by Katerina Toropova, Department of Structural Biology, University of Pittsburgh, and is 
unpublished material. 
 
 
A composite view of the vUL25-GFP and vNTAP-UL25 CCSC molecules clarifies the 
boundaries of the pUL25 capsid-binding domain, located in aa 1-50 (Figure 31).  In the 
composite CCSC, the TAP tag flanks pUL25 aa 1, and GFP connects to aa 50.  The portion of 
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the CCSC between these two molecules touches both the hexon and the penton-distal triplex.  
These data suggest that the capsid-binding domain of pUL25 is able to bind both hexons and 
triplex proteins. 
 
 
 
Figure 31. Composite image of the GFP and TAP labels. (i) Top view of the composite CCSC (gray), 
shown beside to the hexon (light pink) adjacent to the penton vertex. The GFP density is green, and the TAP 
tag is dark pink. The pUL25-hexon connection is obscured by GFP.  (ii) Rotation of the image in (i) shows the 
side view from the surface of the capsid. The yellow region of the triplex makes contact with pUL25. (iii) View 
from underneath the hexon, looking out from the interior of the capsid. The region of pUL25 between the 
TAP and GFP densities makes contact with the hexon (pink arrow) and the triplex (yellow arrow). This 
figure was contributed by Katerina Toropova, Department of Structural Biology, University of Pittsburgh, 
and is unpublished material. 
3.5 DISCUSSION 
pUL25 is a minor component of HSV-1 capsids that is attached to their external surface.  Based 
on immunogold labeling studies and difference imaging maps of wt and pUL25-deficient 
(i)                 (ii)               (iii) 
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capsids, pUL25 was predicted to bind the packaging protein, pUL17, to form a heterodimer that 
occupies 5 sites around each penton vertex.  In order to verify this hypothesis and to discern the 
orientation of pUL25 in the pUL25-pUL17 complex, we generated viruses expressing pUL25 
fused at its N-terminus to exogenous peptides—GFP or a tandem affinity purification (TAP) tag. 
While the TAP tag was inserted at the extreme N-terminus of pUL25 preceding aa 1, GFP was 
an internal fusion between aa 50 and 51.  Hence, each tag was adjacent to the pUL25 capsid-
binding domain in aa 1-50. Capsids containing the UL25-GFP and NTAP-UL25 fusion proteins 
were purified and analyzed by cryo-electron microscopy.  Because GFP and the TAP tag add 
approximately 27 and 8.5 kDa of extra density to pUL25, respectively, the fusions were a 
convenient way to distinguish the location of pUL25 on the capsid surface. They also allowed 
visualization of a region of pUL25 that was not included in the crystal structure or the previous 
model of pUL25 in the CCSC. First, the reconstructions confirmed the predicted location of 
pUL25 in the CCSC.  Furthermore, the tagged capsid reconstructions showed that the pUL25 N-
terminus connects to the penton-distal triplex and the hexon adjacent to the penton. These data 
support the reports that pUL25 interacts with pUL19 (VP5) and pUL38 (VP19c), which are 
present in hexons and triplexes, respectively (148, 188). Finally, we postulate from the positions 
of the TAP and GFP molecules that the extreme N-terminus of pUL25 (aa 1) connects to the 
pUL19 in the hexon, while the region of the capsid-binding domain nearest to GFP (aa 50) binds 
to pUL38 in the triplex.  
Preliminary quantitative analyses of pUL25 copy number on C-capsids indicates that 
pUL25 occupies more locations on the capsid than can be accounted for by its inclusion in the 
five CCSCs at each penton vertex (224).  Recently, pUL25 was found to precipitate the portal 
protein pUL6 when the two were co-expressed in transfected cells (156).  In structural studies, 
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pUL25 has not yet been observed around the portal.  Interestingly, yeast-2-hybrid screens of 
UL25 homologues in KSHV and VZV predict that pUL25 also interacts with the putative 
terminase subunit, pUL15 (226). Because capsid-associated pUL25 prevents aberrant cleavage of 
viral genome termini (see Chapter 4), a potential role for pUL25 may be to stabilize terminase at 
its docking site on the portal while DNA is being actively packaged (237).  A transient 
interaction between portal-associated pUL25 and pUL15 in the terminase complex could allow 
pUL25 to act as a tether that keeps terminase at the portal until the genome is completely 
packaged.  
Its flexible nature and accessibility on the capsid surface has implicated pUL25 in 
interactions required for trafficking capsids through infected cells. Quantification of pUL25 copy 
numbers on intranuclear C-capsids and those in virions revealed that more pUL25 is present on 
capsids that leave the nucleus, suggesting that capsid-associated pUL25 is required for nuclear 
egress (98, 217, 224). UL25 involvement in nuclear egress has been confirmed in HSV-1 and 
pseudorabiesvirus (98, 102, 147, 169). pUL25 has been predicted to interact with pUL31, a viral 
protein involved in nuclear egress (124, 226).  This interaction has not been tested in HSV-1, but 
if proven, could demonstrate the mechanism by which pUL25 capsid attachment promotes 
nuclear egress.  Finally, pUL25 recruits the large tegument protein pUL36 to virus assembly 
compartments; in the virion, pUL36 likely connects to capsid pentons (27, 32, 156, 253).  The 
studies presented here have confirmed that pUL25 is present on the capsid near the penton.  
Thus, indirectly, capsid-associated pUL25 drives maturation of the virion from the cell by the 
first addition of the inner tegument protein at the penton vertices. The pUL25/pUL36 complex 
may also contact microtubules and the nucleoporins; these interactions would transport capsids 
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from the cell periphery to the nucleus and dock them on the nuclear pore before the viral genome 
is released (93, 156, 169).  
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4.0  CAPSID-ASSOCIATED UL25 PROTEIN IS REQUIRED FOR SECONDARY 
CLEAVAGE OF THE VIRAL GENOME  
4.1 ABSTRACT 
The HSV-1 DNA packaging machinery cleaves unit-length genomes from a replicated DNA 
concatemer and packages them into preformed nucleocapsid precursors.  Null mutations to the 
packaging gene UL25 promote the nuclear accumulation of two dead-end packaging products—
empty A-capsids and unencapsidated, cleaved DNA—that are notable because they are not 
observed in other packaging mutants. In this study, pulsed field gel electrophoresis demonstrated 
that the UL25 deletion virus produced both genome-length DNA and a form that ran at a lower 
molecular weight.  Southern blot analysis of viral DNA showed that in the absence of functional 
UL25, the US genome terminus was underrepresented with respect to the internal joint and UL 
terminal fragments. In contrast to the discrete band observed in wt DNA, the UL25 mutant US 
terminus was detected as a smear of DNA that ran at lower molecular weight than wt, indicating 
that the US end of the genome was present but was shortened compared to the wt genome. These 
results suggest that in the UL25 mutants, aberrant cleavage takes place at the US end of the viral 
genome, producing truncated viral genomes that are not retained in capsids. Additionally, an in 
vitro binding assay tested the ability of soluble pUL25 prepared from infected cells to attach to 
DNA.  pUL25 eluted from the DNA-cellulose resins at a low molarity of salt, suggesting that it 
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did not have a strong non-specific affinity for double-stranded or single-stranded DNA. Taken 
together, these data support a role for capsid-associated pUL25 in stabilizing the termination of 
cleavage and packaging without a direct interaction with viral DNA.    
4.2 INTRODUCTION 
In the HSV-1 virion, the linear, 152kbp, double-stranded DNA (dsDNA) genome is compressed 
into a nucleocapsid, where it is under immense pressure but not associated with any protein (16).  
The genome consists of two unique segments—UL and US—that are flanked by the repeat 
sequences a, b, and c.  The general arrangement of the genome is a-b-UL-b’-a’-c’-US-c-a; each 
of the repeat sequences is inverted at the joint region between the unique segments. After the 
genome enters the nucleus of the newly infected cell, viral DNA is replicated into a concatemer 
of new genomes.  Currently, there is a debate over the structure of the parent DNA and the 
mechanism of DNA replication.  The concatemer may be generated by a rolling-circle 
mechanism, if the input DNA template is circular, or concatemerization may occur by 
recombination of linear DNA molecules, which is likely if the template itself is linear (87, 207, 
239).  Regardless of the mechanism of DNA replication, the concatemer is processed to single, 
unit-length genomes and packaged into precursor nucleocapsids by an ATP-driven terminase 
complex.  
The cleavage and encapsidation of DNA requires specific packaging signals—pac1 and 
pac2—that are located in the a sequences present at the genome termini (128, 131, 206, 229). 
While pac2 is important for the initial cleavage that frees the UL end of DNA, pac1 is required 
for the second cleavage, which frees the full-length genome from the concatemer and terminates 
 107 
packaging (78).  Within the pac1 and pac2 sites, GC or T-rich tracts are essential for DNA 
cleavage and packaging (219).  In the overlapping a sequences of adjacent genomes in the 
concatemer, pac2 and pac1 are separated by a small (20 bp) direct repeat, DR1.  Cleavage 
between genomes occurs within DR1 and leaves a single copy of the a sequence and a 3’ 
overhang at the US terminus (128).  In bacteriophage, the second cleavage of the concatemer can 
occur at a second packaging signal (phage λ) or after a headfull of DNA has been injected into 
the capsid (phages T4, P22, SPP1) (25).  Although HSV-1 employs the pac1 site for secondary 
cleavage, there is evidence that there may also be a headfull component to HSV-1 DNA 
packaging.  First, the packaging signals are in the multiple copies of the a sequence present at the 
joint region between the UL and US segments, yet those pac sites are not cleaved in wild-type 
infection. Secondly, when the packaging signals were inserted into an amplicon of 4 kbp, tandem 
copies of the amplicon—measuring between 53 and 106 kbp—were stably packaged (78).  These 
observations suggest that termination of packaging is coupled to a threshold amount of DNA 
inside the capsid, which is sensed by the terminase or some other component of the packaging 
machinery. 
In the tightly coupled processes of DNA cleavage and packaging, some proteins must 
have direct contact with DNA, while others have indirect roles—or helper functions—in 
packaging.  Several proteins that are assumed to contact DNA include the nuclease that cleaves 
near the packaging signals; architectural proteins that hold DNA in a particular conformation, 
much like the single-stranded DNA binding proteins of the DNA replication machinery; and 
proteins that hold DNA in place inside the capsid. Numerous examples of these DNA-binding 
mechanisms can be found in the DNA packaging machinery of the dsDNA bacteriophages 
[reviewed in (25)].  In λ phage, the terminase consists of two sub-units—gpNu1 and gpA—that 
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are the site-specific DNA binding component and endonuclease, respectively. Assembly of the 
terminase onto phage DNA concatemer requires the E. coli host cell proteins IHF and HU, which 
bind near the packaging signal and manipulate DNA into the conformation needed for gpNu1 
binding (39, 115, 152, 209).  In most phages, termination of packaging is followed by addition of 
head completion proteins, which seal the portal and form a connector that links the portal with 
the tail fiber. In the filled capsid of the bacteriophage SPP1, a short segment of packaged genome 
extrudes through the portal, probably making contact with the head completion proteins gp16 
and gp15 (107, 151, 212).  Some phages utilize decoration proteins that bind to the exterior of 
the partially packaged capsid to counteract the internal pressure of DNA; these include λ gpD 
and the Soc protein in phage T4 (86, 201, 249).  Although these helper proteins do not contact 
DNA, they are required for the stable packaging of full-length genomes.   
In HSV-1, some of the DNA packaging machinery with analogous functions to those in 
phage have been identified.  UL6 forms the DNA entry portal at one vertex of the procapsid 
(143, 221).  UL15, UL28, and UL33 presumably form the terminase complex (88, 246, 247).  
There is evidence that UL28 binds to HSV-1 packaging signals.  Adelman et al used purified 
UL28 in electromobility shift assays with probes spanning the pac1 and pac2 sites (5).  When the 
probes were tested as non-denatured dsDNA, no binding could be detected.  However, pUL28 
formed a nucleoprotein complex with both pac 1 and pac2 when they were used as boiled, 
ssDNA probes.  It was also observed that pUL28 preferentially binds to the upper strand of the 
pac1 sequence and that GC-rich stretches are important for UL28 binding. These data confirmed 
a previous report (242) that like λ phage DNA, HSV-1 DNA needs to be in a specific 
architecture for cleavage. Thus, the HSV-1 packaging reaction may require DNA-bending 
proteins, but to date, none have been identified.   Other HSV-1 proteins that have been 
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hypothesized to bind to the packaging signals include the viral nuclease UL12, the tegument 
protein UL36 (VP1/2), the disputed tegument US11 (ICP48), US12 (ICP47), and an unknown 
peptide of 140 kDa (28, 35).  Of these, only UL12 has tangential relevance to packaging, as it is 
required to resolve branched intermediates in the DNA concatemer (116, 190).   
The DNA packaging protein pUL25 plays an important role during the later stages of 
DNA packaging, prior to the release of capsids into the cytoplasm (205). Although pUL25 is 
primarily thought to reinforce the capsid (see Chapters 2 and 3), several features of pUL25 
structure and function have encouraged the prediction that pUL25 associates with viral DNA 
during the packaging reaction: (i) the folded protein has a positively-charged face (19), (ii) 
purified pUL25 binds to immobilized HSV-1 DNA but not to Baculovirus DNA (148), (iii) 
pUL25 interacts with pUL6, the portal of viral DNA entry to the capsid (156), and (iv) capsid-
associated pUL25 ensures retention of packaged DNA (30, 121). These observations have 
prompted suggestions that pUL25 seals the portal after the completion of packaging, much like 
the head completion proteins of bacteriophage [(151); reviewed in (25)]. Thus, UL25 could bind 
the viral genome (i) to remodel or maintain DNA in an appropriate structure that facilitates 
terminase cleavage or (ii) to anchor DNA within the portal for its retention within the capsid, but 
to date, neither of these functions has been experimentally determined.  It is also possible that 
pUL25 could provide a platform for other proteins that interact directly with DNA.  In the 
converse process of genome delivery to the nucleus of the newly infected cell, pUL25 is 
important for docking the capsid at the nuclear pore and for viral genome release (156, 169). If 
pUL25 is associated with viral DNA, it is possible that conformational changes in pUL25 during 
viral entry remove the constraint that pUL25 places on packaged DNA, allowing either pUL25 
or other structural proteins to dissociate from the packaged genome. Furthermore, the UL25 null 
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mutant virus was shown to package shorter than unit-length genomes that were missing the US 
terminus (205); this observation conflicted with the initial characterization of the virus, when 
genomes of apparent full-length were detected (121).  Since the UL terminus is generated by the 
first concatemer cleavage (46), UL25 may have a role in the second site cleavage of DNA during 
packaging.   
We have shown that the late defect in packaging in the UL25 null virus is due to the 
premature cleavage of the viral genome as it is being packaged, resulting in truncated genomes 
that failed to be retained in capsids. Thus, capsid-associated pUL25 stabilizes the secondary 
cleavage of DNA.  Finally, in contrast to a previous report, we found that UL25 protein does not 
bind to DNA in vitro.  These data suggest that pUL25 does not directly interact with DNA, but 
instead plays an accessory role in packaging.  
4.3 MATERIALS AND METHODS 
4.3.1 Cells, viruses, and antibodies 
African green monkey kidney cells (Vero; American Type Culture Collection, Rockville, MD) 
and UL25-transformed 8-1 cells (121) were propagated in 5% FBS/DMEM with penicillin 
(10U/ml) and streptomycin (10µg/ml) at 37°C and 5% CO2. HSV-1 wild-type KOS strain virus 
has been previously described (121). The UL25 mutant viruses vΔUL25, v143i, v212s, v560s, 
vΔ1-50, vΔ1-36, vΔ27-37, vΔ27-50, vΔ40-50, vF26A I27A, vF35A W36A, and vF26A I27A 
F35A W36A were described in Chapter 2.  The UL28 null virus gCB is deleted of UL28 amino 
acids 78-706, and it serves as a negative control for DNA cleavage and packaging (214). 
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Baculovirus-expressed UL25 protein (121) was purified and used to prepare a UL25 monoclonal 
antibody, 25E10, that was provided by W. Newcomb, University of Virginia (33). Mouse 
monoclonal antibody 25E10 (αUL25) (33), rabbit polyclonal antibody NC1 (αUL19) (31), and 
mouse monoclonal antibody MAB8672 (αICP8; Millipore) were diluted to 1:5000, 1:10000, and 
1:5000, respectively, in blocking buffer for immunoblotting. HRP-conjugated secondary 
antibodies goat anti-mouse or goat anti-rabbit (BioRad) were used at 1:5000 dilutions. 
4.3.2 Preparation of total cell DNA 
A T-175 flask of 8-1 or Vero cells was infected with virus at a MOI of 5 PFU per cell. At 18 h 
postinfection, the medium was removed and the cells were washed in 1x PBS, scraped off the 
plate, and pelleted. The cells were lysed in 20% SDS/Proteinase K at 37°C for 4 h.  5M NaCl (80 
µl) was added, and the lysates were extracted 4 times with phenol, followed by 2 times with 
chloroform.  Nucleic acids were precipitated with 1/10 volume 3M sodium acetate plus 2 
volumes 100% ethanol.  Pellets were rinsed in 70% ethanol, dried, and dissolved in 500 µl 
ddH2O with 10µg/ml RNAse A.  The concentration of DNA was determined by 
spectrophotometry. 
4.3.3 Southern blots and hybridization analysis 
To assess cleavage of viral DNA, total cell DNA (10µg) was digested with BamHI or HindIII, 
separated by agarose gel electrophoreses, and transferred in alkaline buffer to a positively 
charged nylon membrane. Blots were rinsed in 2X SSC and stored at room temperature. The 
probes for hybridization analysis consisted of the HSV-1 genomic BamHI J, K, Q fragments, 
 112 
which were purified from the plasmid clones pFH218 (BamHI K), pK1-2 (gift from Neal 
DeLuca; BamHI Q), and pSG25 (gift from Sandra Weller; BamHI J) by restriction digest and 
agarose gel electrophoresis.  Double-stranded DNA probes were radiolabeled with 32P-dCTP by 
nick translation reaction (GE Healthcare Nick Translation kit); unincorporated nucleotides were 
removed by gel filtration (Princeton Separations CentriSep column). Southern blots were pre-
incubated with hybridization buffer (5X SSC, 5X Denhardt solution, 1% SDS, 100µg/ml 
denatured salmon sperm DNA) at 68°C for 3 h.  Probes were boiled, quick-cooled on ice, added 
to hybridization buffer, and incubated with blots overnight at 68°C.  Blots were washed 2 x 20 
minutes with low stringency buffer (2X SSC/0.1% SDS) and 1 x 10 minutes with high stringency 
buffer (0.1X SSC/0.1% SDS) at 68°C.  Blots were analyzed by autoradiography and phosphor 
screens, which were scanned with a Storm 840 Phosphor Imager.  Specific bands were quantified 
with ImageQuant software. 
4.3.4 Pulsed field gel electrophoresis 
2 x 106 Vero cells were infected at a MOI of 2 and incubated to 24 hpi.  Cells were rinsed in 
PBS, resuspended in 150 µl 2% low melt agarose (BioRad Clean Cut agarose), and molded into 
two wells.  After hardening, the plugs were cut in half, rinsed in TE, and lysed overnight at 37°C 
in 20% Sarkosyl/0.5M EDTA.  Plug slices were rinsed in EDTA treated with Proteinase K (0.5 
mg/ml) overnight at 37°C.  Plugs were rinsed in 1X TBE for 5 x 15 minutes before they were 
sealed into the wells of a 1% agarose/1X TBE gel (BioRad Pulse Field agarose). The gel was 
electrophoresed on BioRad CHEF-DRII module for 25 hrs with the following settings: 6V/cm; 
initial 50s; final 90s. The gel was stained with ethidium bromide to visualize DNA. To recover 
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viral DNA, agarose slices were extracted from the gel and incubated in TE at 50˚C overnight.  
Samples were extracted with phenol/chloroform. Nucleic acids in the aqueous phase were 
precipitated with ethanol and resuspended in ddH2O. The recovered DNA was used in PCR with 
primers 5’-GCAGAAGGTCTCCGGTAATATCACC-3’ and 5’-GGTGATCAGGTACAAC 
AGGCGCTC-3’. PCR products were run on 1% agarose in TAE and stained with ethidium 
bromide.   
4.3.5 In vitro DNA binding assay 
1.5 x 108 Vero cells were infected with wt HSV-1 (KOS strain) at a MOI of 5.  At 24 hpi, cells 
were rinsed in PBS then incubated on ice in lysis buffer (50mM Tris pH 7.4, 1mM EDTA, 
150mM NaCl, 1% NP-40, 0.25% sodium deoxycholate) plus 1X protease inhibitors (Roche) for 
45 min.  Nuclei were pelleted by low-speed centrifugation and then resuspended in a volume of 
low salt buffer (20mM Hepes pH 7.9, 1.5mM MgCl2, 20mM KCl, 0.2mM EDTA, 25% glycerol, 
1X protease inhibitors) equal to half the nuclear pellet volume.  High salt buffer (same as the 
previous buffer with KCl adjusted to 1.6M) was added dropwise to the suspension to 1/3 of the 
final volume.  Extracts were gently rotated at 4°C for 30 minutes.  Nuclei were pelleted in a 
microcentrifuge at max speed for 30 minutes.  The supernatant was collected and dialyzed 
overnight into DNA-binding buffer (20mM Tris-HCl, pH 7.5; 50mM KCl; 1mM EDTA, pH 8; 
2mM β-mercapto-ethanol, 10% glycerol) (165). Dialyzed protein was centrifuged for 30 minutes 
at maximum speed in a microcentrifuge to precipitate any remaining cellular debris or insoluble 
material. Resins containing double-stranded or single-stranded calf thymus DNA conjugated to 
cellulose (Sigma) were equilibrated to DNA-binding buffer overnight. After excess buffer was 
removed from the hydrated DNA-cellulose resins, an approximately equal volume of input 
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protein was added to the resin and incubated with agitation for 30 minutes at 4˚C.  Flow-through 
was recovered by gentle centrifugation after the incubation of the input material and each 
successive wash. Proteins were precipitated from each sample with 16% TCA and resuspended 
in loading buffer (0.4M Tris-base, 2X NuPAGE loading buffer (Invitrogen)). 
4.3.6 Immunoblotting  
Protein extracts were separated on a 5 to 12% SDS–polyacrylamide gel and transferred to 
nitrocellulose. The nitrocellulose was washed in Tris-buffered saline (TBS) and blocked 
overnight or 1 h at room temperature in T-TBS (20 mM Tris, 0.5 M NaCl [pH 7.5] plus 0.5% 
Tween 20) supplemented with 10% nonfat dry milk. The UL25 monoclonal antibody 25E10 was 
diluted to 1:5000 in blocking buffer. The diluted antibody was reacted with the blocked 
nitrocellulose for 1 h at room temperature, washed 6 times in T-TBS, and reacted with 
horseradish peroxidase-conjugated anti-mouse immunoglobulin G (IgG) diluted at 1:5000 in 
blocking buffer. The bound Igs were revealed by enhanced chemiluminescence (Pierce ECL kit).  
4.4 RESULTS 
4.4.1 Isolation of whole viral genomes from infected cells 
HSV-1 DNA replication generates concatemers that are subsequently cleaved into unit-length 
molecules and packaged into virions by the DNA packaging machinery. It was previously shown 
that the UL25-null virus KUL25NS cleaved replicated viral DNA into genomes that were 
 115 
sensitive to DNAse (121). This result indicated that the virus processed viral DNA from the 
concatemer but failed to stably package the cleaved genomes. In a report that conflicted with the 
initial characterization of KUL25NS, unit-length and some smaller than unit-length DNA was 
stably packaged by KUL25NS, and the virus genomes appeared to be truncated from the US 
terminus (205). KUL25NS has a nonsense mutation at UL25 amino acid 104, and the virus has a 
growth defect resulting in a 103 PFU/ml reduction in plating efficiency on Vero cells compared 
to the UL25 complementing cell line 8-1 (121). However, the somewhat leaky null phenotype of 
KUL25NS on Vero cells—coupled with the possible rescue of the null gene by recombination 
with the complementing cell line—hindered efforts to evaluate the function of UL25 provided in 
trans (unpublished observation).  To overcome this complication, the UL25 deletion virus, 
v∆UL25, was generated (see Chapter 2).  In this virus, the entire UL25 ORF was replaced with 
the rpsL-neo antibiotic resistance cassette by BAC recombination. This virus expressed no 
UL25, and its reduction in replication on Vero cells was over 105 PFU/ml compared to the virus 
titer on 8-1 cells. In order to reconcile the reports of both complete and premature cleavage of 
UL25 null virus genomes, whole genomes produced by v∆UL25 were analyzed by pulsed field 
gel electrophoresis (PFGE). Vero or 8-1 cells were infected with wt KOS virus or v∆UL25. At 
24 hours post-infection, the whole cell samples were embedded into agarose plugs, lysed, and 
run on PFGE (Figure 32).  All the lanes retained DNA in the wells; this DNA consisted of highly 
branched concatemers that were not resolved by the gel (189, 190).  Linear wt KOS DNA was 
present as a single band that migrated from the wells into the gel to a position consistent with the 
size of the HSV-1 genome (152 kbp) (Figure 32A).  A similar band of DNA was observed in the 
v∆UL25 infection of 8-1 cells, which stably express UL25 and rescue the replication defect of 
the null virus. Vero cells infected with v∆UL25 contained only a faint band of the full-length 
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DNA, and there was also a faint and diffuse band of DNA that was several kbp smaller than wt.  
These bands were designated the “upper” and “lower” forms of v∆UL25 DNA.  To further 
analyze each of the forms of v∆UL25 DNA, gel slices containing the bands were excised from 
the pulsed-field gel, and DNA was extracted from the gel.  However, attempts to amplify the 
extracted DNA by PCR were unsuccessful (data not shown). 
 
 
 
Figure 32. Pulsed Field Gel Electrophoresis. Vero or 8-1 cells were infected at a MOI of 2 and 
incubated to 24 hpi.  Whole cells were embedded into low-melt agarose, lysed, and treated with Proteinase K.  
Agarose plugs were sealed into wells of a 1% agarose/1X TBE gel slab and run on a CHEF-DRII module for 
25 h. The gel was stained with ethidium bromide to visualize DNA. A prominent band representing full-
length genomes was observed in all samples (upper), and a minor band of smaller than unit-length DNA was 
observed in Vero cells infected with the UL25 deletion virus (lower).   
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4.4.2 Replication and cleavage of HSV-1 DNA by UL25 mutant viruses 
Viral DNA cleaved from the concatemer contains free chromosomal termini, and the presence of 
chromosomal ends can be monitored by Southern blot analysis of total infected cell DNA.  To 
better assess the genome processing of v∆UL25 and other UL25 mutant viruses (see Chapter 2), 
total DNA was prepared from Vero cells at 24 hpi and digested with BamHI, which liberated 
both the internal and terminal repeat genome segments (Figure 33).  The BamHI K, S, and Q 
fragments contain the HSV-1 internal repeats (IR), long terminal repeat (TRL), and short terminal 
repeat (TRS), respectively. Only cleaved, genome-length viral DNA with free chromosomal ends 
will give rise to the terminal BamHI Q and S fragments, while cleaved and concatemeric DNA 
contain the joint-spanning BamHI K fragment.  
Digested DNA was transferred to a nylon membrane and hybridized to a probe consisting 
of the BamHI K fragment (Figure 33B(i)). The Q and S terminal fragments were detected in 
Vero cells infected with the wild type virus. The different sizes of the BamHI S and K fragments 
are due to the presence of one to multiple copies of the a sequences, while the Q fragment 
contains only a single copy of the a sequence. An example of a mutant that fails to cleave 
replicated viral DNA is the null mutant GCB, which does not express the product of the HSV-1 
UL28 gene (214). As shown in Figure 33B(i), the terminal Q and S fragments were absent from 
DNA isolated from Vero cells infected with GCB. All of the UL25 linker insertion mutants and 
vΔ1-50 replicated viral DNA when grown on Vero cells, as assessed by the presence of the joint 
K fragments.  However, DNA isolated from Vero cells infected with the replication-defective 
UL25 mutants lacked the terminal Q fragments. 
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Figure 33. Processing of virus DNA. A. Schematic diagram of the HSV-1 genome showing the 
locations of the long and short terminal repeats (TRL and TRS), the joint or internal repeat (IR), and the 
BamHI K, Q and S fragments. The different sizes of the BamHI S fragment are due to the presence of one to 
multiple copies of the a sequence at the UL terminus.  B. Vero cells were infected with the indicated virus at a 
MOI of 5 PFU per cell. At 18 hours post-infection, total infected cell DNA was isolated, digested with BamHI, 
and subjected to Southern blot analysis. The blots were probed with 32P-labeled BamHI K or BamHI Q 
fragments of the HSV-1 genome, which hybridized to TRL, IR, and TRS (i) or IR and TRS (ii), respectively.  
The ratio of the joint K fragment to US-end Q or UL-end S fragments was determined by quantification of the 
hybridizing bands with a Phosphorimager and ImageQuant software. This figure was amended with 
permission from reference (30). 
 
Since the Q and S fragments are similar in size, the blot was probed with a 32P-labeled 
fragment that hybridizes specifically to the US terminus (Figure 33(ii)). The probe detected the Q 
fragment in the digests for the two viruses that replicated on Vero cells—wt KOS and the UL25 
mutant v155i—but not in any of the viruses that did not; the junction fragment K was present in 
all samples. The amounts of radioactivity in the bands corresponding to the joint fragment, the 
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long terminus, and the short terminus (BamHI fragments K, S, and Q, respectively) were 
measured, and the ratio of joint to each terminal fragment was calculated for each lane in Figure 
33. In the case of the BamHI S fragments from the UL terminus, the measurement included both 
the S1 and S2 fragments. For wild-type HSV-1, the ratios of joint to end fragments were similar. 
For the UL25-null virus, v∆UL25, and the other UL25 mutants that do not replicate in Vero 
cells, the UL terminus was present at levels similar to those in the wild-type virus, but the US 
terminus was absent or significantly underrepresented compared to the joint fragment (Figure 33 
(i)). There was a twofold reduction in the US terminus for the 155i linker insertion mutant, v155i. 
This is consistent with the fact that replication of v155i is reduced (see Chapter 2, Table 6) and 
demonstrates a direct correlation of the defect with the cleavage of viral DNA, the production of 
stable C-capsids, and the production of infectious virus.  
The absence of US terminal fragments from the UL25 mutants was surprising because 
previous studies from our laboratory demonstrated that genome-size (152 kbp) HSV-1 DNA is 
present in cells infected with the UL25-null virus, KUL25NS (121). To further examine the US 
terminus generated by the UL25 mutants, total infected cell DNA was digested with HindIII and 
subsequently analyzed by Southern blot analysis using the HSV-1 BamHI J fragment as a probe 
(Figure 34). The probe spanned the HindIII restriction site that links the genome fragments 
containing the 13 kbp fragment from the US terminus (HindIII G fragment) and an internal 5 kbp 
fragment from the US region (HindIII N fragment). The two large hybridizing fragments that are 
present in all of the samples are viral DNA fragments that result from cleavage of the replicated 
DNA concatemers and consist of the joint-spanning fragments HindIII G plus HindIII B or, 
when the UL region is inverted, HindIII G plus HindIII I. The HindIII G fragment was readily 
detected in DNA isolated from Vero cells infected with KOS and v155i, but this fragment was 
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absent from DNA isolated from Vero cells infected with the UL28 mutant, GCB (Figure 34). 
Although the HindIII G fragment was present in the blots of DNA isolated from the five UL25 
mutants (v∆UL25, v143i, v212s, v560s, and v∆1-50) that failed to grow on Vero cells, the 
hybridizing band was diffuse, suggesting that the probe detected multiple US terminal fragments. 
The presence of multiple US terminal fragments would indicate that either the cleavage reaction 
is taking place at several sites to generate HindIII G fragments of different sizes or that the full-
length genomic DNA is not stable and is being degraded. The ratio of HindIII G fragment to the 
internal HindIII N fragment was calculated for each virus and showed that the cleavage at the US 
end is reduced approximately two-fold for the UL25 mutants.  
 
Figure 34. UL25 null viruses produce viral genomes with truncated US ends.  A. Schematic diagram 
of the HSV-1 genome showing the locations of the HindIII G and N fragments. B. Total cell DNA from 
infected Vero cells digested with HindIII and subjected to Southern blot analysis. The blot was probed with 
the 32P-labeled BamHI J fragment of the HSV-1 genome.  The ratio of the internal HindIII N fragment to the 
US end G fragment was determined by quantification of the hybridizing bands with a Phosphorimager and 
ImageQuant software. This figure was amended with permission from reference (30). 
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4.4.3 Characterization of viral genomes in UL25 small deletion and point mutation 
viruses 
UL25 mutant viruses with small deletions within the putative capsid-binding domain (vΔ27-37, 
vΔ27-50) have similar phenotypes to the UL25 linker insertion mutants: they generate A- and B-
capsids containing pUL25 (see Chapter 2).   In contrast, viruses expressing pUL25 with point 
mutations at aa 26, 27, 35, and 36 have a different defect in virus replication.  These viruses 
produce C-capsids that do not escape the nucleus.  To characterize the viral genomes produced 
by these viruses upon infection, total DNA was isolated from Vero cells infected with wild-type 
and mutant viruses and subjected to Southern blot analysis as described in Section 4.4.2.  
 
Figure 35. Processing of virus DNA. A. Schematic diagram of the HSV-1 genome showing the 
locations of the long and short terminal repeats (TRL and TRS), the joint or internal repeat (IR), and the 
BamHI K, Q and S fragments. The different sizes of the BamHI S fragment are due to variable copies of the a 
sequence at the UL terminus. B. Total cell DNA was isolated from Vero cells, digested with BamHI, and 
subjected to Southern blot analysis. The blots were hybridized to probes that detected TRL, IR, and TRS (i) or 
IR and TRS (ii).   
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Wild-type KOS DNA contained all the expected fragments (Figure 35), indicating that 
cleavage of unit-length genomes from the replicated DNA concatemer produced both TRL and 
TRS genome ends.  Like wt, the UL25 mutant v∆40-50 DNA contained each of the genome 
fragments in approximately equimolar amounts. The UL28 null virus GCB was included as a 
negative control because it does not cleave DNA from the concatemer; in GCB DNA, the IR but 
neither TRL nor TRS were detected (Figure 35).  As previously reported, the UL25 deletion 
mutant was negative for TRS but not for TRL. Most UL25 mutants exhibited a phenotype similar 
to v∆UL25, but point mutations that prevented replication on Vero cells—yet did not prevent 
packaging—appeared to carry out secondary cleavage of genomes at TRs, as demonstrated by 
the presence of the Q fragment in DNA from viruses vF26A I27A and vF35A W36A. To clarify 
this result, the identical Southern blot was probed with the BamHI Q fragment, which selectively 
hybridized to the IR and TRS but not TRL.  Prominent Q bands—representing TRS—were 
observed in KOS, v∆40-50, and vF35A W36A DNA, while fainter bands were present in vF26A 
I27A DNA.  Thus, point mutations at aa 26, 27, and 35, 36 allowed completion of genome 
cleavage from the concatemer, but to a reduced extent compared to wt. This result was consistent 
with the observation of C-capsids in both gradients of purified intranuclear capsids and in the 
nuclei of infected cells. 
4.4.4 pUL25 purified from wt-infected mammalian cells does not bind immobilized DNA 
in vitro 
Ogasawara et al. showed that baculovirus-expressed pUL25 bound to HSV-1 genomic DNA 
when purified DNA and protein were mixed in vitro (148).  We investigated the ability of UL25 
protein present in infected mammalian cell nuclei to bind non-specifically to DNA immobilized 
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on a cellulose resin.  Nuclear extracts were prepared by high salt extraction of cells infected with 
wt HSV-1 (KOS) (see Methods). The nuclear extract was dialyzed overnight into DNA binding 
buffer and was cleared of any remaining debris and aggregates. Double stranded (dsDNA) and 
single-stranded (ssDNA)-conjugated-cellulose resins were swelled overnight in DNA-binding 
buffer and gently pelleted. Clarified nuclear extracts were loaded onto the resins, and the flow-
through supernatant was collected after a 30 minute incubation.  Following an initial wash in 
DNA-binding buffer to remove any residual unattached protein, resins were washed for 30 
minutes each with DNA binding buffers with stepwise increases in salt concentration, in a range 
from 0.1 to 2M KCl.  The supernatant was separated from the resin after each wash by gentle 
centrifugation. After concentration of the protein in each wash by TCA precipitation, Western 
blot was used to detect the HSV-1 ssDNA binding protein ICP8, the major capsid protein pUL19 
(VP5), and pUL25 in the DNA-cellulose eluates (Figure 36).  The majority of ICP8 was eluted 
from the dsDNA and ssDNA at 0.5M KCl at 0.8M KCl, respectively, which is consistent with 
published values (68).  In contrast, pUL25 eluted from the resin at very low concentrations of 
salt.  This result was more similar to the pattern of salt elution for the major capsid protein 
pUL19. These data contradict previous assertions that pUL25 has the ability to bind to DNA 
(148). Instead, these results suggest that pUL25 is not a DNA-binding protein, as previously 
suggested, but more likely plays a structural role in DNA packaging. 
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Figure 36. pUL25 purified from infected cell nuclei does not associate with dsDNA or ssDNA in vitro.  
A.  Nuclear extracts from KOS-infected Vero cells were incubated with dsDNA-cellulose in a batch method in 
order to identify DNA-binding proteins. Increasing concentrations of salt (KCl) were used to elute proteins 
with higher DNA-binding affinity.  (Top) Western blot with Ponceau stain shows the total protein loaded in 
each lane.  Lysate, total infected cell lysate.  Input, dialyzed nuclear extracts after centrifugation to remove 
precipitates.  Flow-through, sample collected after initial incubation with resin. The molarity (M) of KCl of 
the washes is indicated above the lanes. Molecular weight markers are shown in kDa. (Bottom) The blot was 
probed for ICP8, the HSV-1 ssDNA binding protein (positive control (+)), pUL25, and pUL19, the major 
capsid protein.  B.  Nuclear extracts were tested for binding to ssDNA-cellulose.  Labels are the same as 
above.  
4.5 DISCUSSION 
In the absence of the DNA packaging gene UL25, HSV-1 genomes are cleaved from the 
replicated DNA concatemer, but they are not retained in the capsid. In this study, the genomes 
produced by UL25 mutant viruses were examined by pulse field gel electrophoresis (PFGE) and 
by Southern blot.  By PFGE of whole cells infected with the UL25 deletion virus, v∆UL25, two 
forms of v∆UL25 DNA were observed: an upper band corresponding to approximately genome-
length (150kbp) DNA, and a lower band that migrated further into the gel.  Both bands were 
extracted from the gel, but they were not successfully amplified with PCR and primers specific 
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to viral DNA.  Southern blot and hybridization analysis of viral DNA was carried out to detect 
three DNA fragments released by BamHI digest. The joint (BamHI K fragment) is located 
between the UL and US segments, and it is present in both concatemeric and cleaved DNA.  The 
UL and US genome termini correspond to the BamHI S and Q fragments, respectively, and they 
are only present in linear DNA that has been cleaved from the concatemer. K and S fragments 
were observed for each UL25 mutant virus, but the Q fragment was present only in the UL25 
mutants that replicated on Vero cells (Tables 6 and 7). Further analysis with a probe that 
hybridized to a region of DNA 5’ to the Q fragment showed that the UL25 mutants produced a 
diffuse band of US terminal DNA that was reduced in intensity compared to wt. Thus, in UL25 
null mutants, the US terminus was present but truncated.  Because the diffuse band can be 
interpreted as a population of genome fragments that are many different sizes, it appears that in 
the absence of functional UL25, the second DNA cleavage event occurs randomly rather than at 
a distinct packaging sequence.  Because the BamHI Q fragment is absent from all of the UL25-
defective mutants, the US terminus for these mutants appears to be located at least 3,000 bp 5’ to 
the wild-type US terminus. 
DNA translocation into the capsid is mediated by the terminase complex comprised of 
the HSV-1 proteins UL15, UL28, and UL33 (33, 88, 246, 247). The cis-acting HSV-1 packaging 
sequences, designated pac1 and pac2, are found near the genomic ends of viral DNA. At the UL 
end of the genome, the pac2 site defines packaging directionality by mediating initiation, and 
pac1 serves to terminate packaging at the US end after a unit-length genome has entered the 
capsid (20). Terminase cleaves viral DNA at the pac2 site and then docks the free end of DNA at 
the capsid portal vertex. Packaging proceeds from the UL end until a full-length genome has 
entered the capsid; DNA cleavage occurs at a pac1 site at the US end. The packaged genome is 
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then sealed within the capsid. Similar to the dsDNA bacteriophages, DNA cleavage is 
suppressed until a full genome (headfull mechanism) has entered the capsid because otherwise 
shorter packaged genomes would be formed from cleavage at the packaging sequences within 
the HSV-1 genome’s internal repeat sequences. The addition of pUL25 to the capsid at or near 
the end of the packaging process suggests that it may function similarly to λ phage head 
completion proteins, gpD, or the Soc and Hoc proteins of phage T4; these proteins bind to the 
phage capsid surface after DNA has entered and are thought to reinforce the capsid structure (67, 
84, 85, 249). Although most of our UL25 mutant proteins were able to attach to capsids, the 
failure of recombinant viruses to replicate on Vero cells was coincident with premature cleavage 
of the US end of the viral genome, as previously described for the UL25-null mutant KUL25NS 
(121, 168, 205). In CMV, the halogenated benzimidazoles BDCRB (2-bromo-5,6-dichloro-1-D-
riborfuranosyl benzamidazole riboside) and TCRB (2,5,6-trichloro-1-D-riborfuranosyl 
benzimidazole riboside) induce premature cleavage events during DNA packaging such that the 
site of cleavage is located at a similar distance from the end of the genome as was observed with 
the UL25 mutants (146). These compounds are not active against HSV-1, but resistance 
mutations to BDCRB and TCRB map to the human CMV terminase genes UL89 and UL56, 
which are the homologues of HSV-1 UL15 and UL28, respectively (100, 228). While the drugs’ 
mechanism of action is not known, they may relax the cleavage site sequence specificity of the 
terminase without relieving the headfull requirement. By extension, the absence of functional 
pUL25 on the capsid surface may relax the cleavage site specificity and allow aberrant cleavage 
by the terminase. 
Based on the published observation that pUL25 binds HSV-1 DNA, we hypothesized that 
pUL25 could do so to remodel or maintain DNA in an appropriate structure that facilitates 
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terminase subunit assembly or DNA insertion into the capsid.  To test pUL25 interaction with 
DNA, nuclear extracts were prepared from infected cells and incubated with double-stranded 
(ds) or single-stranded (ss) DNA-cellulose. pUL25 eluted from ss- and dsDNA-cellulose resins 
in the flow-through or the first wash of 0.1MKCl.  In contrast, the known HSV-1 ssDNA binding 
protein ICP8 required up to 1M KCl to detach from the resins.  These results suggest that pUL25 
is unable to bind non-specifically to either ds- or ssDNA.  This result conflicts with a previous 
report that pUL25 binds to immobilized DNA (148).  We did not test pUL25 binding to HSV-1 
DNA, so we cannot rule out the possibility that pUL25 does have affinity specifically for viral 
DNA. pUL25 could also require a specific DNA sequence or structure for its attachment to 
DNA; the putative terminase subunit UL28 interacted with packaging sequences only when 
DNA probes were denatured and reformed into single-strand or hairpin DNA (5).  Our assay was 
limited in this aspect, as these variables were not tested.  Future studies could address pUL25 
attachment to the specific sequences by competition assay or electromobility shift assay with 
native and denatured probes, in the manner of (5, 28, 35), or chromatin immunoprecipitation 
could be used to isolate pUL25-DNA complexes from infected cells.   
The UL25 mutants presented here fall into three groups: those that failed to cleave DNA 
at the proper packaging sequence (v∆UL25, v143i, v212s, v560s, v∆1-50, v∆1-36, v∆27-50, 
v∆27-37, v∆1-50), those that cleaved and packaged DNA but did not support virion production 
(vF26A I27A, vF35A W36A), and those that behaved similar to the wt virus (v155i, vΔ40-50). 
In Chapter 2, the pUL25 capsid-binding domain was mapped to amino acids 1-36.  The data 
presented here show that some pUL25 mutations outside of the putative capsid-binding domain 
promote the aberrant cleavage phenotype.  Thus, it is possible that these mutations disrupt 
interactions between capsid-bound pUL25 and other proteins involved in DNA cleavage. It has 
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been hypothesized that undetected forms of the pUL17/pUL25 heterodimer (CCSC), or pUL25 
in different protein complexes, may be present on the capsid at locations other than the 
pentons—specifically, at the vertex containing the portal complex (156, 224). Thus, while it is 
unlikely that pUL25 interacts directly with viral DNA as it is being packaged, if the CCSC or 
other form of pUL25 is near the portal, it could indirectly stabilize the DNA cleavage reaction by 
tethering the packaging machinery to the portal or by sealing off the portal after the second 
cleavage of DNA. 
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5.0  SUMMARY AND CONCLUSIONS 
DNA packaging is a critical step in the lytic replicative cycle of herpes simplex virus type 1 
(HSV-1). During the packaging reaction, replicated DNA is resolved from branched concatemers 
to single, unit-length genomes that are inserted into pre-assembled capsid precursors (46, 189). 
Seven HSV-1 genes have been identified that are required for DNA encapsidation (6, 103, 104, 
121, 157, 186, 214). Null mutations of the UL6, UL15, UL17, UL28, UL32, and UL33 genes 
block cleavage of viral genomes from the replicated concatemer and promote the formation of B-
capsids, which are dead-end products retaining the scaffold protein. In contrast, disruption of the 
UL25 gene results in the accumulation of both B-capsids and empty A-capsids in addition to 
unpackaged, genome-length DNA; packaging of shorter-than-wt genomes has also been reported 
(121, 205). Thus, it is inferred that UL25 is not required for the initial cleavage or insertion of 
DNA into the capsid but rather for termination of packaging and maintenance of the viral 
genome after the packaging event. UL25 protein (pUL25) attaches to the capsid exterior.  Its 
occupancy coincides with capsid maturation, such that copy numbers of pUL25 increase from 
procapsids to B-, A-, C-capsids and virions (137, 192).  Structural analysis of pUL25 indicates 
that it has multiple binding surfaces and flexible loop domains. These features may allow pUL25 
to switch between conformational states in order to participate in dynamic interactions. On the 
capsid exterior, pUL25 has access to the viral proteins that promote capsid nuclear egress, 
tegumentation, and virion assembly. Taken together, the structure and location of pUL25 predict 
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that the capsid-associated protein interacts with multiple binding partners and has important roles 
in events downstream from initiation of the packaging reaction.   
Due to similarities in null mutant phenotypes, UL25 has been likened to both the 
decoration proteins and head completion proteins of the double-stranded DNA bacteriophages. In 
the absence of the λ phage gpD decoration protein, capsids are unable to retain DNA, or shorter 
than unit-length genomes—missing the final 20% of sequence—are packaged (249).  
Furthermore, like pUL25, the gpD decoration protein is only added to the expanded capsid after 
the initiation of packaging. The T4 phage Soc decoration protein is dispensable for packaging, 
but it stabilizes the T4 capsid (86).  The addition of pUL25 during DNA packaging likewise 
stabilizes the HSV-1 capsid (183). A major dissimilarity between pUL25 and these decoration 
proteins is the presence of decoration proteins at the capsid three-fold axes of symmetry.  In 
HSV-1, the triplex proteins occupy these positions, and pUL25 is found around the five-fold axis 
of symmetry (33, 137, 145, 224).   Bacteriophage head completion proteins seal off the portal 
after insertion of DNA (25). Like pUL25, the phage SPP1 head completion proteins gp15 and 
gp16 are required for retention of DNA inside the capsid, but not for DNA cleavage (151). These 
head completion proteins are arranged in rings on the exterior of the capsid portal (107). It has 
been suggested that pUL25 binds the HSV-1 portal protein pUL6 (156), but to date, there is no 
structural evidence for pUL25 at the portal. Therefore, in the distribution of protein on the capsid 
surface, pUL25 is not strictly analogous to either the decoration proteins or head completion 
proteins of the bacteriophage system. 
Several functions of pUL25 have been mapped to regions of the protein.  Figure 37 
represents a summary of the current knowledge of pUL25 functional domains.  pUL25 makes 
contact with the packaging protein pUL17—presumably in a heterodimer at the capsid vertices—
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and this interaction is independent of the pUL25 N- and C-termini  (137, 188, 216, 224).  Two 
regions between amino acids 396 and 425 are important for egress of capsids from the nucleus 
after completion of packaging (147). The three C-terminal amino acids and one internal residue 
at position 233 are required for genome uncoating during viral entry to the cell (4, 147, 169).  In 
this study, important functional regions were identified at the N-terminus, amino acid 143, and 
amino acids 560-580.  While the N-terminus constitutes a capsid-binding domain, the latter two 
regions are important for the secondary cleavage of DNA and stable packaging of full-length 
DNA. 
 
Figure 37. Summary of functional regions of pUL25. White bars represent the folded core of the 
protein, while gray lines are the flexible or unstructured N-terminus and internal loop domains.  Conclusions 
drawn from this study are in red, while other published reports are in blue.  aO’Hara, M. et al. 2010. J Virol.  
bPreston, V.G. et al. 2008. J Virol. cScholtes L. and J.D. Baines. 2009. J Virol.  
 
The pUL25 capsid-binding domain is located in its N-terminus. By mutational 
analysis of the UL25 gene coupled with in vitro and in vivo capsid-binding assays, a capsid-
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this region of pUL25 demonstrated that deletion of amino acids 1-36 was sufficient to eliminate 
capsid attachment, and point mutation of four residues highly conserved within the 
alphaherpesviruses—amino acids 26, 27, 35, 36—significantly reduced attachment. Structural 
analysis of capsids containing pUL25 fusion proteins showed that the pUL25 capsid-binding 
domain makes multiple contacts with the capsid surface.  Its extreme N-terminus is close to the 
hexon adjacent to the penton vertex, and a portion of pUL25 close to amino acid 50 makes 
contact with the adjoining triplex.  The mutant protein deleted of amino acids 1-50 was present 
in the nucleus in infected cells, indicating that deletion of the pUL25 N-terminus does not result 
in sequestering of the protein in the cytoplasm. It has been reported that nuclear localization of 
pUL25 is dependent on expression of the triplex protein, VP19c (148).  While our data suggest 
that some residues between amino acids 1-50 contact VP19c, these contacts are not required for 
pUL25 localization to the nucleus.  Together, these results could suggest that pUL25 has 
additional contacts with the capsid or another chaperone and that this connection directs pUL25 
to the nucleus. 
Capsid attachment is required but not sufficient for completion of packaging. 
Several UL25 mutants were generated that did not support viral replication.  These mutations 
included a 5 amino acid insertion at position 143, C-terminal truncations to amino acids 212 or 
560, and small deletions in the N-terminus between amino acids 27 and 50. These mutations did 
not disrupt the capsid-binding domain of pUL25, as demonstrated by the co-purification of the 
mutant proteins with A- and B-capsids produced by each recombinant virus.  However, the 
mutations did preclude successful cleavage of the viral genome at the US terminus.  Thus, pUL25 
is recruited to the capsid surface via the N-terminal capsid-binding domain, but other functional 
regions are required to complete DNA packaging. In recent preliminary experiments, pUL25 
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copy number on PrV and HSV-1 capsids have been estimated to be greater than expected if 
pUL25 occupies 5 positions around each penton vertex (224).  These data suggest that pUL25 is 
present at other locations on the capsid surface. Based on this suggestion and the data presented 
here, we propose that pUL25 potentially contacts other structural or packaging proteins with its 
amino acids 26-50, 143, and 560-580. 
Thin-section electron microscopy was used to observe the morphology and location of 
capsids in cells infected with UL25 null mutant viruses.  Unlike other UL25 null mutants that 
produced only A- and B-capsids, viruses with point mutations at amino acids 26, 27, 35, and 36 
produced C-capsids that were trapped in the nucleus.  This result was especially surprising for 
the virus vF26A I27A F35A W36A.  This virus had very diminished replication on Vero cells, 
and only A- and B-capsids could be purified out of infected nuclei. The observation of intact C-
capsids in cells infected with vF26A I27A F35A W36A suggests two conclusions: (i) the 
substitution of the four residues severely abrogates the pUL25 connection to the capsid, such that 
is easily disrupted upon capsid manipulation, and (ii) the four residues are important for nuclear 
egress or tegumentation of capsids.  
It is has been established that UL25 is required for release of capsids from the nucleus 
(98, 102, 147) and that pUL25 interacts with the large tegument protein pUL36 (32, 156).  At 
present, it is unclear if pUL36 is added to the capsid in the nucleus, and whether or not the 
pUL25-pUL36 interaction drives capsid nuclear egress.  HSV-1 pUL36 has a functional nuclear 
localization signal in its N-terminus and can be detected in the nucleus, but UL36 is not required 
for egress of HSV-1 capsids (1, 22, 44). In PrV, truncated pUL36 is incorporated into nuclear 
capsid assembly compartments (32, 106), but full-length pUL36 is not detected on capsids until 
they exit the nucleus (64, 129). UL25 mutations that block virion assembly but not DNA 
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packaging could disrupt the pUL25-pUL36 interaction.  pUL36 has two independent pUL25 
binding domains at pUL36 aa 2037-2353 and 3105-3164 (32, 156).  Because capsid trafficking 
defects can be isolated to different regions of pUL25—in this study, the N-terminus, and as 
previously reported (147), at aa 396-402 or aa 417-425—pUL25 potentially has multiple 
independent pUL36-binding domains.  This hypothesis fits well with the suggestion that pUL25 
forms distinct complexes with pUL36 that serve different roles at the vertex for assembly and 
egress and at the portal for genome uncoating (32, 156). On the other hand, the pUL25-pUL36 
interaction may simply promote tegumentation of the capsid after it reaches the cytoplasm, in 
which case the nuclear egress defect observed in UL25 mutants must be attributed to disruption 
of UL25 interaction with proteins that promote primary envelopment of intranuclear capsids. 
pUL25 stabilizes secondary cleavage of the viral genome, but does not appear to 
interact directly with DNA.  The HSV-1 genome has two distinctive ends that are cleaved and 
packaged in a directional manner (46, 133).  The UL end is the first cleaved from the replicated 
concatemer, and the second cleavage frees the US end of DNA.  To characterize changes in DNA 
cleavage due to UL25 mutations, viral DNA produced by UL25 mutants was extracted from 
infected cells for Southern blot and hybridization analysis.  While the UL end of the viral genome 
was present in viral DNA from all recombinant viruses, the US end was apparently missing from 
UL25 mutant viruses that failed to replicate on Vero cells.  Further investigation showed that the 
US ends were present but truncated compared to the wt end fragment, suggesting that UL25 null 
mutations promote aberrant cleavage of the viral genome as it is being packaged.  Virus-
expressed pUL25 was purified and tested for non-specific binding to single-strand or double-
strand DNA in vitro.  In these assays, pUL25 demonstrated very low affinity for DNA, 
suggesting that pUL25 promotes completion of packaging without binding to the viral DNA.  
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Taken together, the data presented in these studies and elsewhere suggest that pUL25 has 
multiple sites of attachment on the capsid-surface and, potentially, distinct roles at these 
locations.  At the five-fold axis of symmetry—the penton vertices—pUL25 forms a putative 
heterodimer with the DNA packaging protein pUL17, and inclusion of the heterodimer around 
the vertices stabilizes these vulnerable regions of the capsid.  Because pUL25 has been shown to 
interact with the DNA packaging protein pUL6, pUL25 may also be present around the DNA 
portal, a twelve-mer ring of pUL6 that is present at a single capsid vertex.  At this structurally 
distinct site, pUL25 may adopt a different conformation or engage in interactions with different 
viral proteins than at the vertex.  These interactions could theoretically support completion of 
DNA packaging in two ways: (i) by stabilizing the terminase complex and the portal while DNA 
is being actively propelled through the portal or (ii) by sealing off the portal after the second 
DNA cleavage, much like a head completion protein function in the dsDNA bacteriophages.     
In conclusion, we propose to integrate our current studies of UL25 into the HSV-1 DNA 
encapsidation model (Figure 38). DNA packaging is an energy-dependent process that requires 
conformational changes in the viral DNA (16, 36, 220). Presumably, ATP hydrolysis by the 
terminase-portal complex supplies the force required to compact DNA within the capsid.  pUL25 
association with the capsid may stabilize this transition. The pUL25 capsid-binding domain is 
responsible for the binding of pUL25 to the capsid surface, but other portions of the protein are 
essential for completion of DNA packaging. These essential functions could include a indirect 
role in the cleavage reaction via pUL25 interaction with the terminase and portal complexes. It is 
also possible that a threshold amount of capsid-associated pUL25 is required for the second 
cleavage event.  Terminase sensing of the fully mature capsid, in combination with its 
recognition of the second packaging signal in the TRS, precipitates cleavage of the US terminus. 
 136 
In the absence of pUL25 capsid attachment or capsid-associated but non-functional pUL25, the 
capsid is unstable, and the equilibrium between the internal pressure of packaged DNA and the 
force exerted by the terminase is breached. The internal pressure may therefore inhibit DNA 
entry or cause DNA extrusion through the portal. When the terminase can no longer propel DNA 
into the nascent capsid, it stalls on the DNA and cleaves in a non-specific manner in order to 
abort packaging, thus forming the truncated genomes observed in replication-deficient UL25 
mutants (30, 205). Ejection of the truncated genome leaves the empty A-capsid that is 
characteristic of UL25 null viruses.  
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Figure 38. Model for the role of UL25 in DNA packaging.  (1)  DNA packaging initiates on 
concatemers when the terminase complex consisting of UL15, UL28, and UL33 binds (2) to packaging 
sequences and cleaves (3) the concatemer to generate a UL end with the terminase still bound.  The 
terminase/DNA complex then docks at the portal vertex on the procapsid (4) and the terminase initiates DNA 
packaging (5).  As the procapsid is filled (6A) with DNA it angularizes and in the process, UL25 binding sites 
are exposed at the capsid vertexes.  DNA cleavage is suppressed by a head-full mechanism (7A) until a full-
length genome has entered.  Cleavage occurs at a packaging site located at the US end of the genome (8A).  
More UL25 binds to the capsid, and the newly packaged genome is sealed within the C capsid (9A).   In the 
absence of a functional UL25 protein the packaging reaction proceeds (6B) with the capsid filling and 
expanding until close to a genome-length has entered (7B).  Without UL25 to stabilize the capsid against the 
pressure that the packaged genome generates, premature cleavage (8B) occurs just prior to the entry of the 
US end repeat resulting in genomes with truncated US termini.   In the absence of UL25, the capsid is not 
stable and the DNA is released (9B) generating an empty A-capsid and a free viral genome that is truncated 
at the US end. This figure was amended with permission from reference (30). 
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APPENDIX A: PRIMERS USED FOR CLONING PLASMIDS AND BACS  
TABLE 9. Primers used for plasmid cloning. 
Plasmid 
clone 
pUL25 amino 
acids coded Sequence
A  
pFH274  37-580 5’ GGATCCATGTCGCCCGTCTTTAACC 
  5’ GGATCCCTAAACCGCCGACAGGTAC 
pFH284 51-580 5’ GAATTCGGATCCATGGACCCGTACTGCCCATT 
  5’ GGATCCAACCGCCGACAGGTACTGTGGAATG 
pFH368 1-50 5’ GGATCCGAATTCATGGACCCGTACTGCCCATT 
  5’ GGATCCCTCCGCCGCCGTCTCCCG 
pFH379  51-580 5’ GGATCCGAATTCATGCAGGTGGTCGTCCTACAGGCCCA 
  5’ GGATCCAACCGCCGACAGGTACTGTGGAATG 
AUppercase letters represent the template sequence from HSV-1 UL25. 
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TABLE 10. Primers used for generation of recombinant HSV-1-BACs with UL25 insertions 
and point mutations. 
BAC 
clone 
UL25 
mutation RE Sequence 
bFH407  143i PmeI 5’gccgtcgcggagatggaggtccagatcgtgcgcaactgtttaaacagcaacgacccgccg 
TAGGGATAACAGGGTAATCGATTT 
  PmeI 5’ ggaggttggtgtcgtatcgtagcggcgggtcgttgctgtttaaacagttgcgcacgat 
GCCAGTGTTACAACCAATTAACC 
bFH416  
 
212s PmeI 5’ actttcgggacggccggatgtccaagaccttcatgactgtttaaacaatgacggcgctggt 
TAGGGATAACAGGGTAATCGATTT 
  PmeI 5’ gccgcacgactgcagggacaggaccagcgccgtcattgtttaaacagtcatgaaggtct 
GCCAGTGTTACAACCAATTAACC 
bFH418  
 
560s PmeI 5’ gctccaacaccaagcgtttctccgcgttcaacgttagtgtttaaacagttagcagcgacta 
TAGGGATAACAGGGTAATCGATTT 
  PmeI 5’ gacataaaaagtacaacatgtcgtagtcgctgctaactgtttaaacactaacgttgaacg 
GCCAGTGTTACAACCAATTAACC 
bFH422  
 
GFP 
insertion 
 5’ gacttttggatgtcgcccgtctttaacctcccccgggagacggcggcggag 
ATGGTGAGCAAGGGCGAGGA 
   5’ ctccagggcagcggcagccgctgtgcgctgggcctgcaggacgaccacctg 
CTTGTACAGCTCGTCCATGCCG 
bFH423  
 
155i PmeI 5’ cgacccgccgctacgatacgacaccaacctccccgtggtgtttaaacacgtggatctgc 
TAGGGATAACAGGGTAATCGATTT 
  PmeI 5’ ccgcggcccgcgtacaccatatgtagcagatccacgtgtttaaacaccacggggaggttg 
GCCAGTGTTACAACCAATTAACC 
bFH469 NTAP  5’ cgaccgcagttctcgtgtgttattttcgctctccgcctctcgcag 
ATGAAGCGACGATGGAAAAAG 
   5’ gtgttcccagacgtccagagcgtcaaatgggcagtacgggtccat 
GCCCAGCTTGCAGCCGCCGGA 
bFH480 F26A I27A XbaI 5’ aggcgcttcatagtcgccgattctagaaacgccgccacc 
TAGGGATAACAGGGTAATCGATTT 
  XbaI 5’ gtcccgggggaactcgggggtggcggcgtttctagaatc 
GCCAGTGTTACAACCAATTAACC 
bFH481 F35A W36A BcgI 5’ gaaacttcatcacccccgagttcccccgggacgcagcgatgtcgccc 
TAGGGATAACAGGGTAATCGATTT 
  BcgI 5’ aggttaaagacgggcgacatcgctgcgtcccgggggaactcgggggtg 
GCCAGTGTTACAACCAATTAACC 
bFH482 F26A I27A 
F35A W36A 
BsmI 5’ cttcatagtcgccgattcccggaatgccgccacccccgagttcccccggga 
TAGGGATAACAGGGTAATCGATTT 
  BsmI 5’ tccaaaagtcccgggggaactcgggggtggcggcattccgggaatc 
GCCAGTGTTACAACCAATTAACC 
  BcgI 5’ gaaacttcatcacccccgagttcccccgggacgcagcgatgtcgccc 
TAGGGATAACAGGGTAATCGATTT 
  BcgI 5’ aggttaaagacgggcgacatcgctgcgtcccgggggaactcgggggtg 
GCCAGTGTTACAACCAATTAACC 
RE, restriction enzyme.  Underlined, restriction site. Italic, conservative substitution.   Bold, mutation.  
Uppercase letters represent the template sequence (pEP-Kan-S; pEGFP-in; p-EP-TAP-in). Lowercase 
letters represent HSV-1 UL25 gene sequences. 
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TABLE 11. Primers used for generation of recombinant HSV-1-BACs with UL25 
deletions. 
BAC clone UL25 deletion RE Sequence 
bFH439  
 
ORF replaced 
with rpsL-neo  BglII 
5’ gacaacgaccgcagttctcgtgtgttattttcgctctccgcctctcgcagagatct 
GGCCTGGTGATGATGGCGGGATCG 
  BglII 5’ ggctcttgttttttctccctaatgccccctcccccctcgcccaccacccaagatct TCAGAAGAACTCGTCAAGAAGGCG 
bFH421  
 
∆1-50  5’ accgcagttctcgtgtgttattttcgctctccgcctctcgatgcaggtggtcgtcctgcag TAGGGATAACAGGGTAATCGATTT 
  
 
5’ 
cggcagccgctgtgcgctgggcctgcaggacgaccacctgcatcgagaggcggagagcga 
GCCAGTGTTACAACCAATTAACC 
bFH472 ∆1-36  5’ tgtgttattttcgctctccgcctctcgcagacccccgagttcccccgg TAGGGATAACAGGGTAATCGATTT 
   5’ atccaaaagtcccgggggaactcgggggtctgcgagaggcggagagc GCCAGTGTTACAACCAATTAACC 
bFH471 ∆27-37  5’gaacacaggcgcttcatagtcgccgattcccgaaacttctcgcccgtctttaacctcccc TAGGGATAACAGGGTAATCGATTT 
   5’cgccgccgtctcccgggggaggttaaagacgggcgagaagtttcgggaatcggc GCCAGTGTTACAACCAATTAACC 
bFH473 ∆40-50  5’ gagttcccccgggacttttggatgtcgccccaggtggtcgtcctacag TAGGGATAACAGGGTAATCGATTT 
   5’ tgtgcgctgggcctgtaggacgaccacctggggcgacatccaaaagtc GCCAGTGTTACAACCAATTAACC 
bFH468 ∆27-50  5’gaacacaggcgcttcatagtcgccgattcccgaaacttccaggtggtcgtcctacaggcc TAGGGATAACAGGGTAATCGATTT 
   5’ggcagccgctgtgcgctgggcctgtaggacgaccacctggaagtttcgggaatcggc GCCAGTGTTACAACCAATTAACC 
RE, restriction enzyme.  Underlined, restriction site. Italic, conservative substitution.   Bold, mutation.  
Uppercase letters represent the template sequence (pEP-Kan-S). Lowercase letters represent HSV-1 
sequences.  
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APPENDIX B: COPYRIGHTS AND PERMISSIONS 
The text and figures included in chapters 2, 3, 4, and 5 and referencing viruses v∆UL25, v143i, 
v155i, v212s, v560s, v∆1-50, and vGFP-UL25 are copyright © American Society for 
Microbiology, Journal of Virology, Volume 83, 2009, pages 47-57, DOI: 10.1128/JVI.01889-08 
(“Role of the UL25 Protein in Herpes Simplex Virus DNA Encapsidation”) and have been 
reproduced and amended with permission from the American Society for Microbiology (license 
number 2423801313520). 
The text and figures included in chapter 4 referencing characterization and structural 
determination of the vGFP-UL25 virus are copyright © 2010 Elsevier Ltd, Journal of Molecular 
Biology, Volume 397, 2010, pages 575-586, DOI: 10.1016/J.JMB.2010.01.043 (“Labeling and 
Localization of the Herpes Simplex Virus Capsid Protein UL25 and Its Interaction with the Two 
Triplexes Closest to the Penton”) and have been reproduced and amended with permission from 
Elsevier Ltd (license number 2433130182856). 
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